US20070010474A1 - NF-kappaB oligonucleotide decoy molecules - Google Patents
NF-kappaB oligonucleotide decoy molecules Download PDFInfo
- Publication number
- US20070010474A1 US20070010474A1 US11/521,714 US52171406A US2007010474A1 US 20070010474 A1 US20070010474 A1 US 20070010474A1 US 52171406 A US52171406 A US 52171406A US 2007010474 A1 US2007010474 A1 US 2007010474A1
- Authority
- US
- United States
- Prior art keywords
- decoy
- dsodn
- treatment
- molecule
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010057466 NF-kappa B Proteins 0.000 title claims abstract description 479
- 102000003945 NF-kappa B Human genes 0.000 title claims abstract description 479
- 108091034117 Oligonucleotide Proteins 0.000 title description 51
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims abstract description 66
- 238000011282 treatment Methods 0.000 claims description 149
- 238000000034 method Methods 0.000 claims description 58
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 13
- 230000001404 mediated effect Effects 0.000 claims description 11
- 238000001890 transfection Methods 0.000 claims description 10
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 9
- 150000004713 phosphodiesters Chemical group 0.000 claims description 9
- 230000000692 anti-sense effect Effects 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 5
- 108091081021 Sense strand Proteins 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 abstract description 172
- 230000027455 binding Effects 0.000 abstract description 103
- 230000009870 specific binding Effects 0.000 abstract description 3
- 102100035100 Transcription factor p65 Human genes 0.000 description 83
- 241000699670 Mus sp. Species 0.000 description 78
- 230000000699 topical effect Effects 0.000 description 72
- 239000003981 vehicle Substances 0.000 description 69
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 68
- 229960004311 betamethasone valerate Drugs 0.000 description 68
- 210000004027 cell Anatomy 0.000 description 60
- 206010061218 Inflammation Diseases 0.000 description 56
- 230000004054 inflammatory process Effects 0.000 description 56
- 210000001519 tissue Anatomy 0.000 description 55
- 108090000623 proteins and genes Proteins 0.000 description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 50
- 210000005069 ears Anatomy 0.000 description 50
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 49
- 230000000694 effects Effects 0.000 description 44
- 206010009887 colitis Diseases 0.000 description 43
- 238000002474 experimental method Methods 0.000 description 42
- 210000003491 skin Anatomy 0.000 description 41
- 201000010099 disease Diseases 0.000 description 40
- 238000003556 assay Methods 0.000 description 39
- 210000001072 colon Anatomy 0.000 description 39
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 35
- 239000000284 extract Substances 0.000 description 33
- 102000040945 Transcription factor Human genes 0.000 description 30
- 108091023040 Transcription factor Proteins 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 26
- 201000004624 Dermatitis Diseases 0.000 description 25
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 22
- 239000000499 gel Substances 0.000 description 22
- 102000004127 Cytokines Human genes 0.000 description 21
- 108090000695 Cytokines Proteins 0.000 description 21
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- -1 nucleotide triphosphates Chemical class 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 21
- 230000007423 decrease Effects 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 206010012438 Dermatitis atopic Diseases 0.000 description 19
- 208000009386 Experimental Arthritis Diseases 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 201000008937 atopic dermatitis Diseases 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 230000006698 induction Effects 0.000 description 19
- 230000008595 infiltration Effects 0.000 description 19
- 238000001764 infiltration Methods 0.000 description 19
- 239000011780 sodium chloride Substances 0.000 description 19
- 206010003246 arthritis Diseases 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 18
- 102000039446 nucleic acids Human genes 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 18
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 17
- 230000002757 inflammatory effect Effects 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 210000003630 histaminocyte Anatomy 0.000 description 16
- 206010039073 rheumatoid arthritis Diseases 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 230000000770 proinflammatory effect Effects 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 13
- 206010014025 Ear swelling Diseases 0.000 description 13
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 229960004436 budesonide Drugs 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000001684 chronic effect Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- 230000008961 swelling Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 230000004580 weight loss Effects 0.000 description 13
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 12
- 102000003896 Myeloperoxidases Human genes 0.000 description 12
- 108090000235 Myeloperoxidases Proteins 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 230000036572 transepidermal water loss Effects 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 102100040247 Tumor necrosis factor Human genes 0.000 description 11
- 239000000833 heterodimer Substances 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- 208000011231 Crohn disease Diseases 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 101710163270 Nuclease Proteins 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 10
- 238000010171 animal model Methods 0.000 description 10
- 230000004888 barrier function Effects 0.000 description 10
- 229960002537 betamethasone Drugs 0.000 description 10
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- 210000004969 inflammatory cell Anatomy 0.000 description 10
- 208000027866 inflammatory disease Diseases 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 210000000981 epithelium Anatomy 0.000 description 9
- 210000002175 goblet cell Anatomy 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 206010009900 Colitis ulcerative Diseases 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 102000044159 Ubiquitin Human genes 0.000 description 8
- 108090000848 Ubiquitin Proteins 0.000 description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000000112 colonic effect Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 210000004207 dermis Anatomy 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 230000004807 localization Effects 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 210000004400 mucous membrane Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 description 7
- 102100023059 Nuclear factor NF-kappa-B p100 subunit Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000009266 disease activity Effects 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 239000000710 homodimer Substances 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 6
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 6
- 206010063837 Reperfusion injury Diseases 0.000 description 6
- 102000014456 Trefoil Factor-3 Human genes 0.000 description 6
- 108010078184 Trefoil Factor-3 Proteins 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 230000001640 apoptogenic effect Effects 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000008045 co-localization Effects 0.000 description 6
- 210000004953 colonic tissue Anatomy 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229960002725 isoflurane Drugs 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- 239000003068 molecular probe Substances 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 239000002751 oligonucleotide probe Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 108091035707 Consensus sequence Proteins 0.000 description 5
- 206010012442 Dermatitis contact Diseases 0.000 description 5
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 5
- 206010040799 Skin atrophy Diseases 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000002917 arthritic effect Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 208000010247 contact dermatitis Diseases 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 5
- 210000003979 eosinophil Anatomy 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000000394 mitotic effect Effects 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 235000001508 sulfur Nutrition 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 description 4
- 206010042953 Systemic sclerosis Diseases 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 210000003423 ankle Anatomy 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 210000003855 cell nucleus Anatomy 0.000 description 4
- 230000004700 cellular uptake Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 238000012875 competitive assay Methods 0.000 description 4
- 230000001010 compromised effect Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 4
- 238000002695 general anesthesia Methods 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 229960005205 prednisolone Drugs 0.000 description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 125000004354 sulfur functional group Chemical group 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 208000009137 Behcet syndrome Diseases 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- 108010014414 Chemokine CXCL2 Proteins 0.000 description 3
- 102000016951 Chemokine CXCL2 Human genes 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 239000012807 PCR reagent Substances 0.000 description 3
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 3
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000036566 epidermal hyperplasia Effects 0.000 description 3
- 230000006882 induction of apoptosis Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 108010068698 spleen exonuclease Proteins 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229950003937 tolonium Drugs 0.000 description 3
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 3
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010001889 Alveolitis Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010051392 Diapedesis Diseases 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021138 Hypovolaemic shock Diseases 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102100040441 Keratin, type I cytoskeletal 16 Human genes 0.000 description 2
- 102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 description 2
- 108010066364 Keratin-16 Proteins 0.000 description 2
- 108010066325 Keratin-17 Proteins 0.000 description 2
- 102000005706 Keratin-6 Human genes 0.000 description 2
- 108010070557 Keratin-6 Proteins 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 2
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 2
- 102000007641 Trefoil Factors Human genes 0.000 description 2
- 108010007389 Trefoil Factors Proteins 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000010398 acute inflammatory response Effects 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 201000009267 bronchiectasis Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 230000003475 colitic effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 206010062952 diffuse panbronchiolitis Diseases 0.000 description 2
- 210000004921 distal colon Anatomy 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 230000002497 edematous effect Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000002134 immunopathologic effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000005004 lymphoid follicle Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 208000037890 multiple organ injury Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 150000002972 pentoses Chemical group 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 125000005642 phosphothioate group Chemical group 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 206010040560 shock Diseases 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KXJQNQWYMAXZEV-BXXZVTAOSA-N (2r,3r,4r)-2,3,4,5-tetrahydroxypentanoyl azide Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)N=[N+]=[N-] KXJQNQWYMAXZEV-BXXZVTAOSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- HXVKEKIORVUWDR-FDDDBJFASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(methylaminomethyl)-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(CNC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HXVKEKIORVUWDR-FDDDBJFASA-N 0.000 description 1
- UTAIYTHAJQNQDW-KQYNXXCUSA-N 1-methylguanosine Chemical compound C1=NC=2C(=O)N(C)C(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UTAIYTHAJQNQDW-KQYNXXCUSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 1
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 description 1
- FXEDIXLHKQINFP-UHFFFAOYSA-N 12-O-tetradecanoylphorbol-13-acetate Natural products CCCCCCCCCCCCCC(=O)OC1CC2(O)C(C=C(CO)CC3(O)C2C=C(C)C3=O)C4C(C)(C)C14OC(=O)C FXEDIXLHKQINFP-UHFFFAOYSA-N 0.000 description 1
- RFCQJGFZUQFYRF-UHFFFAOYSA-N 2'-O-Methylcytidine Natural products COC1C(O)C(CO)OC1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-UHFFFAOYSA-N 0.000 description 1
- OVYNGSFVYRPRCG-UHFFFAOYSA-N 2'-O-Methylguanosine Natural products COC1C(O)C(CO)OC1N1C(NC(N)=NC2=O)=C2N=C1 OVYNGSFVYRPRCG-UHFFFAOYSA-N 0.000 description 1
- YHRRPHCORALGKQ-FDDDBJFASA-N 2'-O-methyl-5-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C)=C1 YHRRPHCORALGKQ-FDDDBJFASA-N 0.000 description 1
- RFCQJGFZUQFYRF-ZOQUXTDFSA-N 2'-O-methylcytidine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-ZOQUXTDFSA-N 0.000 description 1
- OVYNGSFVYRPRCG-KQYNXXCUSA-N 2'-O-methylguanosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 OVYNGSFVYRPRCG-KQYNXXCUSA-N 0.000 description 1
- WGNUTGFETAXDTJ-OOJXKGFFSA-N 2'-O-methylpseudouridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O WGNUTGFETAXDTJ-OOJXKGFFSA-N 0.000 description 1
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 description 1
- IQZWKGWOBPJWMX-UHFFFAOYSA-N 2-Methyladenosine Natural products C12=NC(C)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O IQZWKGWOBPJWMX-UHFFFAOYSA-N 0.000 description 1
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- IQZWKGWOBPJWMX-IOSLPCCCSA-N 2-methyladenosine Chemical compound C12=NC(C)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O IQZWKGWOBPJWMX-IOSLPCCCSA-N 0.000 description 1
- VZQXUWKZDSEQRR-SDBHATRESA-N 2-methylthio-N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C12=NC(SC)=NC(NCC=C(C)C)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VZQXUWKZDSEQRR-SDBHATRESA-N 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 1
- UXTIAFYTYOEQHV-UHFFFAOYSA-N 4-(4-amino-3-methoxyphenyl)-2-methoxyaniline;hydron;dichloride Chemical compound [Cl-].[Cl-].C1=C([NH3+])C(OC)=CC(C=2C=C(OC)C([NH3+])=CC=2)=C1 UXTIAFYTYOEQHV-UHFFFAOYSA-N 0.000 description 1
- PQQIIAHYPFFGDK-UHFFFAOYSA-N 4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one;3h-1,3-oxazol-2-one Chemical compound O=C1NC=CO1.O1C(=O)C(=COCC)N=C1C1=CC=CC=C1 PQQIIAHYPFFGDK-UHFFFAOYSA-N 0.000 description 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
- BCZUPRDAAVVBSO-MJXNYTJMSA-N 4-acetylcytidine Chemical compound C1=CC(C(=O)C)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 BCZUPRDAAVVBSO-MJXNYTJMSA-N 0.000 description 1
- LNZCGEMAKACSNT-JRLIAIAZSA-N 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-imino-3-methylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1.O=C1N(C)C(=N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LNZCGEMAKACSNT-JRLIAIAZSA-N 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- 101710118202 43 kDa protein Proteins 0.000 description 1
- UVGCZRPOXXYZKH-QADQDURISA-N 5-(carboxyhydroxymethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(O)C(O)=O)=C1 UVGCZRPOXXYZKH-QADQDURISA-N 0.000 description 1
- VSCNRXVDHRNJOA-PNHWDRBUSA-N 5-(carboxymethylaminomethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCC(O)=O)=C1 VSCNRXVDHRNJOA-PNHWDRBUSA-N 0.000 description 1
- VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
- HLZXTFWTDIBXDF-PNHWDRBUSA-N 5-methoxycarbonylmethyl-2-thiouridine Chemical compound S=C1NC(=O)C(CC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HLZXTFWTDIBXDF-PNHWDRBUSA-N 0.000 description 1
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 1
- SNNBPMAXGYBMHM-JXOAFFINSA-N 5-methyl-2-thiouridine Chemical compound S=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SNNBPMAXGYBMHM-JXOAFFINSA-N 0.000 description 1
- HXVKEKIORVUWDR-UHFFFAOYSA-N 5-methylaminomethyl-2-thiouridine Natural products S=C1NC(=O)C(CNC)=CN1C1C(O)C(O)C(CO)O1 HXVKEKIORVUWDR-UHFFFAOYSA-N 0.000 description 1
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101710125298 Beta-defensin 2 Proteins 0.000 description 1
- 102100038326 Beta-defensin 4A Human genes 0.000 description 1
- 101710176951 Beta-defensin 4A Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- WRBQHANLJJQOQB-BTTZPJNMSA-N CN1C(C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2N=C1)=N.C(CC(=C)C)NC=1C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2N=CN1 Chemical compound CN1C(C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2N=C1)=N.C(CC(=C)C)NC=1C=2N=CN([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C2N=CN1 WRBQHANLJJQOQB-BTTZPJNMSA-N 0.000 description 1
- 108010061300 CXCR3 Receptors Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 101710102044 Envelope protein F13 homolog Proteins 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101001006892 Homo sapiens Krueppel-like factor 10 Proteins 0.000 description 1
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101000830568 Homo sapiens Tumor necrosis factor alpha-induced protein 2 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 101150083678 IL2 gene Proteins 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 101150026829 JUNB gene Proteins 0.000 description 1
- 102100027798 Krueppel-like factor 10 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 102000003959 Lymphotoxin-beta Human genes 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100400865 Mus musculus Abcb1b gene Proteins 0.000 description 1
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 description 1
- 101100444898 Mus musculus Egr1 gene Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- RSPURTUNRHNVGF-IOSLPCCCSA-N N(2),N(2)-dimethylguanosine Chemical compound C1=NC=2C(=O)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RSPURTUNRHNVGF-IOSLPCCCSA-N 0.000 description 1
- SLEHROROQDYRAW-KQYNXXCUSA-N N(2)-methylguanosine Chemical compound C1=NC=2C(=O)NC(NC)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SLEHROROQDYRAW-KQYNXXCUSA-N 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- 108010006401 NF-kappa B p50 Subunit Proteins 0.000 description 1
- 102000005395 NF-kappa B p50 Subunit Human genes 0.000 description 1
- VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 1
- VZQXUWKZDSEQRR-UHFFFAOYSA-N Nucleosid Natural products C12=NC(SC)=NC(NCC=C(C)C)=C2N=CN1C1OC(CO)C(O)C1O VZQXUWKZDSEQRR-UHFFFAOYSA-N 0.000 description 1
- 231100000264 OECD 451 Carcinogenicity Study Toxicity 0.000 description 1
- 102000002491 Octamer Transcription Factor-1 Human genes 0.000 description 1
- 108010068098 Octamer Transcription Factor-1 Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101100271190 Plasmodium falciparum (isolate 3D7) ATAT gene Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 1
- 108700012411 TNFSF10 Proteins 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 102100028082 Tapasin Human genes 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 108010031154 Transcription Factor RelA Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 244000291414 Vaccinium oxycoccus Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 201000005180 acute myocarditis Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000008951 colonic inflammation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000010393 epithelial cell migration Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005205 gut mucosa Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 150000002671 lyxoses Chemical class 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- HLZXTFWTDIBXDF-UHFFFAOYSA-N mcm5sU Natural products COC(=O)Cc1cn(C2OC(CO)C(O)C2O)c(=S)[nH]c1=O HLZXTFWTDIBXDF-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WZRYXYRWFAPPBJ-PNHWDRBUSA-N methyl uridin-5-yloxyacetate Chemical compound O=C1NC(=O)C(OCC(=O)OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 WZRYXYRWFAPPBJ-PNHWDRBUSA-N 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940112971 protopic Drugs 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- QQXQGKSPIMGUIZ-AEZJAUAXSA-N queuosine Chemical compound C1=2C(=O)NC(N)=NC=2N([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=C1CN[C@H]1C=C[C@H](O)[C@@H]1O QQXQGKSPIMGUIZ-AEZJAUAXSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 150000003341 sedoheptuloses Chemical class 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 108010059434 tapasin Proteins 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- RVCNQQGZJWVLIP-VPCXQMTMSA-N uridin-5-yloxyacetic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(OCC(O)=O)=C1 RVCNQQGZJWVLIP-VPCXQMTMSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
- QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
- WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
- 150000003742 xyloses Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Definitions
- the present invention concerns NF- ⁇ B oligonucleotide decoy molecules, and their use in the treatment of various NF- ⁇ B related diseases and pathological conditions.
- NF- ⁇ B is a family of inducible dimeric transcription factors composed of members of the Rel family of DNA-binding proteins that recognize a common sequence motif.
- NF- ⁇ B is a heterogeneous collection of dimers, composed of various combinations of members of the NF- ⁇ B/Rel family. At present, this family is composed of 5 members, termed p52, p50, p65, cRel and Rel B.
- the homology between the members of the Rel family is through the Rel homology domain, which is about 300 amino acids in size and constitutes the DNA-binding domain of these proteins.
- NF- ⁇ B dimers exhibit different binding affinities for NF- ⁇ B sites bearing the consensus sequence GGGRNNYYCC (SEQ ID NO: 1) where R is purine, Y is pyrimidine and N is any base.
- the Rel proteins differ in their abilities to activate transcription, such that only p65/RelA and c-Rel were found to contain potent transcriptional-activation domains among the mammalian family members.
- NF- ⁇ B is found in its inactive form in the cytoplasm, where it is bound to the 43-kDa protein IKB that covers the nuclear localization signal region of the p65/p50 dimer.
- NF- ⁇ B Activation of NF- ⁇ B starts with the proteolytic destruction of IKB followed by the transport of the RelA/p50 complex into the nucleus, where it binds to its recognition site on the DNA and activates transcription of target genes.
- NF ⁇ B family see, for example, Gomez et al., Frontiers in Bioscience 2:49-60 (1997).
- p52 and p50 do not contain transactivation domains. Dimers composed solely of p52 and/or p50 proteins that lack transcriptional activation domains are generally not activators of transcription and can mediate transcriptional repression.
- NF- ⁇ B The transcription factors of the Rel/NF- ⁇ B family are key regulators of immune and inflammatory responses, and contribute to lymphocyte proliferation, survival and oncogenesis.
- NF- ⁇ B plays a key role in the expression of several genes involved in the inflammation, cell proliferation and immune responses.
- NF- ⁇ B NF- ⁇ B regulated by NF- ⁇ B are many which play critical roles in various diseases and conditions, such as rheumatoid arthritis, systemic lupus erythematosus, restenosis, myocardial infarction, ischemia reperfusion injury, glomerulonephritis, atopic dermatitis, saphenous vein graft, Alzheimer's disease, to name a few. See, e.g. Khaled et al.
- NF- ⁇ B decoys have been proposed for the inhibition of neointimal hyperplasia after angioplasty, restenosis and myocardial infarction (Yoshimura et al., Gene Therapy 8: 1635-1642 (2001); Morishita et al., Nature Medicine 3(8): 894-899 (1997)).
- the greater inhibition of reperfusion injury, acute, and chronic rejection after transplantation results in a prolongation of allograft survival and decrease in graft coronary artery disease.
- In vivo transfection of an NF- ⁇ B decoy provides a novel strategy for treatment of acute myocarditis. (Yokoseki et al., supra). Ueno et al., supra reported that blocking NF ⁇ B by NF ⁇ B decoy prevented ischemia reperfusion injury in the heart.
- NF- ⁇ B-dependent HIV-1 LTR reporter gene constructs were transfected into Mono Mac 6 cells, followed by pre-culture with and without LPS, and luciferase activity was measured.
- LPS-tolerant cells were tested, LPS stimulation did not increase transactivation of the NF- ⁇ B-dependent HIV-1 LTR reporter gene. This indicates that the NF- ⁇ B complexes present in LPS-tolerant cells are functionally inactive. This also was applicable to the transcription of the NF- ⁇ B-controlled TNF gene.
- TNF promoter-controlled luciferase reporter construct LPS-tolerant cells showed only a minimal response to LPS stimulation. Therefore, it was concluded that the p50 homodimers induced by LPS tolerance lack transactivation activity. These p50 homodimers instead occupy the cognate NF- ⁇ B-binding sites and prevent transactivation and therefore transcription by the p50/p65 complex.
- the present invention concerns double-stranded NF- ⁇ B decoy oligodeoxynucleotide (NF- ⁇ B dsODN) molecules that contain a core sequence capable of specific binding to an NF- ⁇ B transcription factor.
- the invention concerns NF- ⁇ B decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers when p50/p50 homodimers are present.
- the selective decoy molecules of the invention by not blocking p50/p50 homodimers, allow these homodimers to block the promoters of NF- ⁇ B regulated genes, which provides an additional level of negative regulation of gene transcription.
- the selective NF- ⁇ B decoy molecules are particularly potent inhibitors of NF- ⁇ B activity both in vitro and in vivo.
- the invention provides NF- ⁇ B decoy molecules with high binding affinity for p65.
- the invention concerns double-stranded NF- ⁇ B decoy oligodeoxynucleotide (NF- ⁇ B dsODN) molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers relative to p50/p50 homodimers.
- NF- ⁇ B dsODN double-stranded NF- ⁇ B decoy oligodeoxynucleotide
- the invention concerns an NF- ⁇ B double-stranded decoy oligodeoxynucleotide (dsODN) molecule, comprising a sense and an antisense strand, which preferentially binds p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers when p50/p50 homodimers are present and/or exhibits a p65 binding affinity of 45 or less, as determined by measuring the molar excess required to compete at least 50% of binding of p65/p50 in an electromobility shift assay to the non-mammalian NF- ⁇ B promoter from HIV (sequence 113/114).
- dsODN NF- ⁇ B double-stranded decoy oligodeoxynucleotide
- S p50/p50 equals the molar excess of said dsODN molecule required to compete 50% of the binding of p50/p50 to the non-mammalian NF- ⁇ B promoter from HIV (sequence 113/114) and S p65/p50 equals the molar excess of said dsODN molecule required to compete 50% of the binding of p65/p50 to the non-mammalian NF- ⁇ B promoter from HIV (sequence 113/114), and wherein the score (S) is assigned as 100 if the decoy is unable to compete at least 50% of the binding at any molar ratio tested.
- the present invention concerns NF- ⁇ B dsODN molecules that have a specificity/affinity factor of at least about 25, or at least about 30, or at least about 35, or at least about 40, or at least about 50 or at least about 60, or at least about 70, or at least about 80.
- the decoy molecules of the invention additionally show increased binding affinity to the p50/p65 heterodimers and/or have improved stability in vivo.
- the invention concerns a dsODN molecule comprising in its first strand, in 5′ to 3′ direction, a sequence of the formula FLANK1-CORE-FLANK2, wherein
- CORE is selected from the group consisting of GGGATTTCC (SEQ ID NO: 11); GGACTTTCC (SEQ ID NO: 13); GGATTTCC (SEQ ID NO: 19); GGATTTCCC (SEQ ID NO: 21); and GGACTTTCCC (SEQ ID NO: 25);
- FLANK1 is selected from the group consisting of AT; TC; CTC; AGTTGA (SEQ ID NO: 79), and TTGA (SEQ ID NO: 80);
- FLANK2 is selected from the group consisting of GT; TC; TGT; AGGC (SEQ ID NO: 88); and AG.
- CORE is selected from the group consisting of GGGATTTCC (SEQ ID NO: 11); GGACTTTCC (SEQ ID NO: 13); and GGATTTCC (SEQ ID NO: 19); FLANK1 is AT and FLANK2 is GT; or FLANK1 is TC and FLANK2 is TC; or FLANK1 is CTC and FLANK2 is TGT; or FLANK1 is AGTTGA (SEQ ID NO: 79) and FLANK 2 is AGGC (SEQ ID NO: 88); or FLANK1 is TTGA and FLANK2 is AG.
- CORE is GGGATTTCC (SEQ ID NO: 11); or GGACTTTCC (SEQ ID NO: 13), FLANK1 is AGTTGA (SEQ ID NO: 79) and FLANK 2 is AGGC (SEQ ID NO: 88).
- the NF- ⁇ B dsODN molecules include a second strand that is at least partially complementary to said first strand, and may have a phosphodiesterate, phosphorothioate, mixed phosphodiesterate-phosphorothioate, or any other modified backbone.
- the two strands may be connected to each other solely by Watson-Crick base pairing and/or by covalent bonds.
- the invention concerns an NF- ⁇ B dsODN molecule comprising a sequence, in 5′ to 3′ direction, selected from the group consisting of SEQ ID NOs 26 through 77 and 10.
- the invention concerns an NF- ⁇ B dsODN molecule comprising a sequence, in 5′ to 3′ direction, selected from the group consisting of SEQ ID NOs: 26 through 34.
- the invention concerns an NF- ⁇ B dsODN molecule comprising a sequence, in 5′ to 3′ direction, selected from the group consisting of SEQ ID NOs: 26 through 31.
- the invention concerns an NF- ⁇ B dsODN molecule comprising the sequence of SEQ ID NO: 30.
- the NF- ⁇ B dsODN molecule is 12 to 28, or 14 to 24, or 14 to 22 base pairs long, and may comprise modified or unusual nucleotides.
- the invention concerns an NF- ⁇ B dsODN molecule which exhibits a p65 competitive binding affinity of 45 or less.
- the dsODN with good p65 binding affinity comprises in its sense strand, in 5′ to 3′ direction, a sequence of the formula FLANK1-CORE-FLANK2, wherein
- CORE is selected from the group consisting of GGGGACTTTCCC (SEQ ID NO: 9); GGGACTTTCC (SEQ ID NO: 5); GGACTTTCCC (SEQ ID NO: 25); GGGATTTCC (SEQ ID NO: 11); and GGACTTTCC (SEQ ID NO: 13);
- FLANK1 is selected from the group consisting of AGTTGA (SEQ ID NO: 79); CTC; TC; CT; CCTTGAA (SEQ ID NO: 6); and CT; and
- FLANK 2 is selected from the group consisting of AGGC (SEQ ID NO: 88); TGT; TC; AGG; TCC; and TCA.
- the latter dsODN molecules may have hybrid or otherwise modified backbones, strands that are partially or fully complementary, and connected to each other, completely or partially, by Watson-Crick base pairing and/or by other covalent or non-covalent means.
- the invention concerns a composition
- a composition comprising an NF- ⁇ B double-stranded decoy oligodeoxynucleotide (dsODN) as described above.
- the composition may, for example, be a pharmaceutical composition.
- the invention concerns a method for the treatment of an inflammatory, immune or autoimmune disease, comprising administering to a mammalian subject in need an effective amount of an NF- ⁇ B double-stranded decoy oligodeoxynucleotide (dsODN) molecule described above.
- dsODN NF- ⁇ B double-stranded decoy oligodeoxynucleotide
- the invention further concerns a method for the treatment of cancer, comprising administering to a mammalian subject in need an effective amount of an NF- ⁇ B double-stranded decoy oligodeoxynucleotide (dsODN) molecule herein.
- dsODN NF- ⁇ B double-stranded decoy oligodeoxynucleotide
- the invention concerns a method for the treatment of reperfusion injury or restenosis, comprising administering to a mammalian subject in need an effective amount of an NF- ⁇ B double-stranded decoy oligodeoxynucleotide (dsODN) molecule herein.
- dsODN NF- ⁇ B double-stranded decoy oligodeoxynucleotide
- the mammalian subject is preferably human.
- FIG. 1 is a graph showing the p65/p50 binding of certain NF- ⁇ B decoy molecules.
- FIG. 2 is a graph showing the p50/p50 binding of certain NF- ⁇ B decoy molecules.
- FIG. 3 shows an electrophoretic mobility-shift assay (EMSA) analysis that identifies the NF- ⁇ B proteins contained in complexes bound to a radiolabeled oligonucleotide probe with the NF- ⁇ B transcription factor binding site.
- ESA electrophoretic mobility-shift assay
- FIG. 4 shows that topical application of NF- ⁇ B decoy suppresses inflammation in a dose dependent manner in a mouse model of atopic dermatitis.
- FIG. 5 shows that cessation of the betamethasone, but not NF- ⁇ B decoy treatment results in a rebound of ear swelling and inflammation in the Dp injected ear.
- FIG. 6 shows that topical NF- ⁇ B decoy treatment decreases the expression of pro-inflammatory cytokines (IL-1B and IL-6) in Dp induced murine atopic dermatitis.
- FIG. 7 shows that topical application of NF- ⁇ B decoy suppresses inflammation and the infiltration of inflammatory cells responsible for atopic dermatitis, and decreases epidermal hyperproliferation, cellular infiltration and degranulation of mast cells.
- FIG. 8 shows that administration of NF- ⁇ B decoy into the arthritic joints of rats with collagen induced arthritis (CIA) leads to amelioration of arthritis.
- FIG. 9 shows that administration of NF- ⁇ B decoy into the arthritic joints of rats with adjuvant induced arthritis (AIA) leads to amelioration of arthritis.
- AIA adjuvant induced arthritis
- FIG. 10 shows that NF- ⁇ B decoy reverses weight loss in a murine model of TNBS-induced colitis.
- FIG. 11 shows that NF- ⁇ B decoy reduces inflammation in a murine model of TNBS-induced colitis.
- FIG. 12 shows that NF- ⁇ B decoy reverses weight loss in oxazolone-induced colitis.
- FIG. 13 shows that NF- ⁇ B decoy increases survival in oxazolone-induced colitis.
- FIG. 14 shows the relationship of NF- ⁇ B affinity of various decoy molecules as predicted by bioinformatics versus the specificity/affinity factor experimentally generated.
- FIG. 15 is a scatter plot of bioinformatics matrix binding score versus competition score when binding to p65/p50. Lower competition scores imply higher binding affinity.
- FIG. 16 is a scatter plot of the difference of competition scores between binding with p50/p50 and binding with p65/p50, versus the ratio of the competition scores (p50/p50 versus p65/p50).
- the plots within the smaller square represent the decoys with the best specificity for p65/p50 vs. p50/p50, whereas the plots outside the smaller and larger square have poor specificity, and the plots between (outside the smaller square and inside the larger square) have intermediate specificity.
- FIG. 17 shows that a phosphorothioated NF- ⁇ B decoy is stable to nucleases contained in mouse serum as compared to a corresponding decoy having a phosphodiester backbone.
- FIG. 18 shows quantitated results from a competitive Electrophoretic Mobility-Shift Assay (EMSA) which indicates the ability of the NF- ⁇ B decoy to specifically bind to NF- ⁇ B subunits as compared to a scramble ODN. Identification of the complexes is shown by antibody supershift.
- ESA Electrophoretic Mobility-Shift Assay
- FIG. 19 shows NF- ⁇ B decoy efficacy in a chronic murine inflammation model.
- NC/Nga mice injected intradermally with Dp-extract showed ear swelling.
- Treatments initiated on day 11 include 1% scramble ODN, 0.25% and 1% NF- ⁇ B decoy and 0.1% betamethasone valerate (BMV).
- FIG. 20 shows NF- ⁇ B decoy efficacy in an acute murine inflammation model.
- TPA phorbol 12-tetradecanoate 13-acetate
- Treatments include 1% scramble ODN, 0.1% 0.25% and 0.5% NF- ⁇ B decoy and 0.1% betamethasone valerate (BMV).
- BMV betamethasone valerate
- FIG. 21 shows EMSA analysis that was performed using 32 P-labeled probe and nuclear extracts prepared from control, inflamed, 1% scramble ODN, 1% NF- ⁇ B decoy or BMV treated NC/Nga ears.
- the identities of the NF- ⁇ B proteins contained in complexes bound to the radiolabeled oligonucleotide probe were determined by pre-incubating extracts with antibodies specific for each family member of the NF- ⁇ B proteins.
- the complexes indicated in the brackets contain p65 and p50 homo and heterodimers.
- Antibody/NF- ⁇ B protein complexes of slower mobility are indicated by the asterisk (right panel; *).
- FIG. 22 shows the results of a quantitation gel shift analysis that was performed by normalizing the NF- ⁇ B specific band intensities to the values obtained from a TransAM assay performed with the same nuclear extracts for the ubiquitously expressed transcription factor, NF-YA.
- the y-axis represents normalized values to inflamed tissue, following which ratios were obtained with values for NF- ⁇ B band intensities to NF-YA absorbance readings.
- Each data point is representative of 4 independent ear samples.
- FIG. 23 shows that the tested NF- ⁇ B decoy suppresses inflammation.
- H&E Hematoxylin and Eosin
- FIG. 24 shows quantitative representation of the decrease in mast cells (*P ⁇ 0.02 for 0.25% NF- ⁇ B decoy and P ⁇ 0.04 for BMV), eosinophils (*P ⁇ 0.01 for 0.25% NF- ⁇ B decoy and BMV) and CD4 + T cells upon topical NF- ⁇ B decoy and BMV treatment.
- FIG. 25 shows NF- ⁇ B decoy localization in inflamed tissue using 1% biotinylated NF- ⁇ B decoy.
- 1% NF- ⁇ B decoy-treated ears were stained for CD207 + LC, CD4 + cells, CD117 + mast cells and MCP-1 + macrophages.
- Laser scanning confocal microscopy images show that the NF- ⁇ B decoy is co-localized with cell markers. Sections were observed at a magnification of 60 ⁇ , scale bar is 200 ⁇ m. Lower panel is a higher magnification of images taken at 60 ⁇ .
- FIG. 26 shows NF- ⁇ B decoy delivery in normal porcine skin. Co-localization of 0.5% NF- ⁇ B decoy and nuclei is shown in the left panel. Non-treated skin as a negative control for avidin staining shows minimum background staining on the right panel. Sections were observed at a magnification of 40 ⁇ , scale bar is 25 ⁇ m.
- FIG. 27 shows the results of pharmacokinetic-PCR assay that was performed on a pig skin to detect NF- ⁇ B decoy in ng levels. Increased uptake of the tested NF- ⁇ B decoy is shown in tape stripped samples. These results are representative of 2 independent experiments.
- FIG. 28 shows that NF- ⁇ B decoy inhibits proinflammatory regulators.
- 1% NF- ⁇ B decoy and BMV suppressed cytokine production.
- Inflamed ears after 14 days of treatment twice-a-day (BID) were stained with anti-IL-1 ⁇ , anti-TNF- ⁇ , anti-MIP2 ⁇ and anti-ICAM antibodies. Sections were observed at a magnification of 40 ⁇ , scale bar is 25 ⁇ m.
- FIG. 29 shows that an NF- ⁇ B decoy suppresses key proinflammatory mRNA levels.
- FIG. 30 shows that NF- ⁇ B decoy induces apoptosis. Dustmite induced inflammed ears were analyzed for apoptosis by tunnel assay (upper panel) and for proliferation using Ki67staining (lower panel) after 2 days of treatment with BMV and 1% NF- ⁇ B decoy. Sections were observed at a magnification of 20 ⁇ , scale bar is 100 ⁇ m.
- FIG. 31 shows the apoptotic and mitotic index. Quantitative representation as mitotic and apoptotic index as percent positive cells in epidermis and dermis is shown. Cells were quantitated from 6 independent fields from 3 independent samples. For apoptotic index: compare to inflamed sample P ⁇ 0.0001 for NF- ⁇ B decoy and P ⁇ 0.000 1 for BMV. For mitotic index: compare to inflamed sample P ⁇ 0.006 for NF- ⁇ B decoy and P ⁇ 0.0003 for BMV. The error is expressed as SEM. These results are representative of 3 independent experiments.
- FIG. 32 shows that NF- ⁇ B decoy does not cause skin atrophy.
- FIG. 33 shows picro sirus red stained sections. Dermal thickness of normal treated ears was 93 ⁇ 12 ⁇ m, 1% NF- ⁇ B decoy treated ear was 89 ⁇ 10 ⁇ m and BMV treated ear was 66 ⁇ 7 ⁇ m. Sections were observed at a magnification of 40 ⁇ , scale bar is 25 ⁇ m.
- FIG. 34 shows ubiquitin normalized mRNA levels of extracellular matrix genes.
- Collagen I Col I
- Collagen III Col III
- Tenacin C and elastin are represented on the y-axis
- treatments include 1% NF- ⁇ B decoy and BMV.
- FIG. 35 shows NF- ⁇ B decoy withdrawal does not cause rebound of swelling and inflammation.
- FIG. 36 shows Dp-Ag recall response after withdrawl of NF- ⁇ B decoy treatment.
- NC/Nga mice injected intradermally with Dp-extract showed ear swelling.
- FIG. 37 shows that NF- ⁇ B decoy restores normal levels of transepidermal water loss (TEWL).
- TEWL measures of inflamed ears treated with BMV or 1% topical NF- ⁇ B decoy for 14 days BID show lack of normal restoration in BMV treated samples (marked with *), while 1% NF- ⁇ B decoy treated ears indicated normal TEWL.
- FIG. 38 also shows that NF- ⁇ B decoy restores normal levels of TEWL.
- FIG. 39 shows that NF- ⁇ B decoy treatment does not increase expression of inflammation-associated stratum comeum genes.
- FIG. 40 shows that NF- ⁇ B decoy treatment restores goblet cell function.
- TNF trefoil factor family
- B, D, F mucopolysaccharide staining in the colon assessing goblet cell function from vehicle
- B, D, F 1.5 mg/kg NF- ⁇ B decoy
- FIG. 41 shows that NF- ⁇ B decoy reverses trinitrobenzesulfonic acid (TNBS)-induced colonic inflammation.
- Mice were treated intrarectally with saline vehicle (A), 1.5 mg/kg NF- ⁇ B decoy (B), 0.3 mg/kg budesonide (C), or 1.5 mg/kg scramble ODN (D) on days 2 and 4 post TNBS induction. Mice were sacrificed on day 7, fixed in formalin, and stained with hematoxylin and eosin. Shown are representative sections from each treatment group.
- FIG. 42 shows that NF- ⁇ B decoy treatment restores colonic tissue homeostasis. Ki67 staining of colonic sections from inflamed vehicle treated mice and mice receiving 2 doses of 1.5 mg/kg Decoy at day 2 and 4 post TNBS induction. Colons were harvested at day 7 and processed for analysis. Proliferation in the mucosal epithelium is clearly reduced and restricted to normal zones of the intestinal crypts in the NF- ⁇ B decoy-treated mice (B) as compared to inflamed vehicle controls (A). Elevated proliferation in the inflamed colons was also evident in the lamina limba and muscularis layers (C).
- FIG. 43 shows that NF- ⁇ B decoy is effectively delivered to inflamed regions of the colon.
- NF- ⁇ B decoy (2.5 mg/kg) labeled with a HEX flourophore was intrarectally applied to the colon at the day 4 post TNBS-induction time point and harvested 6 hr after administration.
- Sytox green nuclear counterstaining overlayed with the red Hex-labeled NF- ⁇ B decoy indicates the absence of NF- ⁇ B decoy in relatively normal colonic regions (A) and a very concentrated localization within inflamed lesions (B) throughout the colon.
- A relatively normal colonic regions
- B very concentrated localization within inflamed lesions
- FIG. 45 shows that NF- ⁇ B decoy inhibits p65/p50 complex in the colon.
- Colons from TNBS-induced mice were analyzed for tissue NF- ⁇ B levels by electrophoretic mobility shift assay using 32 P-labeled probe and nuclear extracts prepared from inflamed vehicle controls and NF- ⁇ B decoy treated mice.
- FIG. 46 shows quantitation of transcription factor levels over an eight day timecourse that was graphed with trend line for regression analysis.
- FIG. 47 shows that NF- ⁇ B decoy reduces inflammatory cell infiltration and neutrophil activity.
- Immunohistochemistry for CD45+ cells indicates a reduction in the number of leukocytes after NF- ⁇ B decoy treatment (1.5 mg/kg) as compared to vehicle controls (A versus B).
- Neutrophil infiltration was specifically determined using a cell type specific antibody and by measuring myeloperoxidase levels in the TNBS-induced colons. The number of neutrophils is clearly reduced in histological sections from the distal colon after NF- ⁇ B decoy treatment (C versus D).
- FIG. 48 shows a significant decrease in MPO activity that was observed as a result of NF- ⁇ B decoy treatment at the day 7 time point. Results are expressed as units of MPO activity per mg protein in colons from 5-8 animals per group. Bars represent the mean ⁇ S.E.M from two independent experiments. Asterisk indicates significant difference compared with saline-treated group (p ⁇ 0.05).
- FIG. 49 shows that NF- ⁇ B decoy reduces tissue cytokine mRNA levels.
- FIG. 51 shows representative H&E stained sections from various treatment groups.
- DAI mean disease activity index
- FIG. 54 shows representative H&E stained sections from treatment groups in FIG. 53 .
- FIG. 56 shows the mean disease activity index (DAI) 10 days after the start of the second DSS cycle.
- double-stranded is used to refer to a nucleic acid molecule comprising two complementary nucleotide strands connected to each other solely by Watson-Crick base pairing.
- the term specifically includes molecules which, in addition to the double-stranded region formed by the two complementary strands, comprise single-stranded overhang(s).
- oligonucleotide decoy double-stranded oligonucleotide decoy
- oligodeoxynucleotide decoy oligodeoxynucleotide decoy
- double-stranded oligodeoxynucleotide decoy refers to short nucleic acid molecules comprising a double-stranded region, which bind to and interfere with a biological function of a targeted transcription factor.
- NF- ⁇ B oligonucleotide decoy double-stranded NF- ⁇ B oligonucleotide decoy
- NF- ⁇ B oligodeoxynucleotide decoy double-stranded NF- ⁇ B oligodeoxynucleotide decoy
- double-stranded is used to refer to a nucleic acid molecule comprising two complementary nucleotide strands connected to each other by Watson-Crick base pairing.
- the term specifically includes NF- ⁇ B oligodeoxynucleotide decoy molecules which, in addition to the double-stranded region formed by the two complementary strands, comprise single-stranded overhang(s).
- the term specifically includes NF- ⁇ B oligodeoxynucleotide decoy molecules in which, in addition to the double-stranded region, the two strands are covalently linked to each other at their 3′ and/or 5′ end.
- NF- ⁇ B is used herein in the broadest sense and includes all naturally occurring NF- ⁇ B molecules of any animal species, including all combinations of members of the NF- ⁇ B/Rel family, e.g. p52, p50, p65, cRel and Rel B.
- transcription factor binding sequence is a short nucleotide sequence to which a transcription factor binds.
- the term specifically includes naturally occurring binding sequences typically found in the regulatory regions of genes the transcription of which is regulated by one or more transcription factors.
- the term further includes artificial (synthetic) sequences, which do not occur in nature but are capable of competitively inhibiting the binding of the transcription factor to a binding site in an endogenous gene.
- modified nucleotide refers to nucleotides or nucleotide triphosphates that differ in composition and/or structure from natural nucleotides and nucleotide triphosphates.
- nucleic acids have a distinct chemical orientation such that their two ends are distinguished as either five-prime (5′) or three-prime (3′).
- the 3′ end of a nucleic acid contains a free hydroxyl group attached to the 3′ carbon of the terminal pentose sugar.
- the 5′ end of a nucleic acid contains a free hydroxyl or phosphate group attached to the 5′ carbon of the terminal pentose sugar.
- the term “overhang” refers to a double-stranded nucleic acid molecule, which does not have blunt ends, such that the ends of the two strands are not coextensive, and such that the 5′ end of one strand extends beyond the 3′ end of the opposing complementary strand. It is possible for a linear nucleic acid molecule to have zero, one, or two, 5′ overhangs.
- binding affinity refers to how tightly a given transcription factor will bind to a corresponding oligonucleotide decoy, which can be measured by various experimental approaches, including electromobility shift assays (EMSA) or TransAM assays.
- ESA electromobility shift assays
- TransAM TransAM assays
- reaction ratio describes the ability of a test decoy sequence to compete with a defined sequence for binding and retention of the transcription factor when compared to the defined sequence competing with itself in the TransAm assay. A smaller ratio refer to a higher competition ability to bind the transcription factor.
- inflammatory disease refers to pathological states resulting in inflammation, typically caused by neutrophil chemotaxis.
- disorders include inflammatory skin diseases including psoriasis, eczema and atopic dermatitis; systemic scleroderma and sclerosis; responses associated with inflammatory bowel disease (IBD) (such as Crohn's disease and ulcerative colitis); ischemic reperfusion disorders including surgical tissue reperfusion injury, myocardial ischemic conditions such as myocardial infarction, cardiac arrest, reperfusion after cardiac surgery and constriction after percutaneous transluminal coronary angioplasty, stroke, and abdominal aortic aneurysms; cerebral edema secondary to stroke; cranial trauma, hypovolemic shock; asphyxia; adult respiratory distress syndrome; acute-lung injury; Behcet's Disease; dermatomyositis; polymyositis; multiple sclerosis (MS); meningitis; ence
- IBD inflammatory bowel disease
- the preferred indications include, without limitation, inflammatory skin conditions, such as dermatitis, eczema, rheumatoid arthritis (RA), rheumatoid spondylitis, gouty arthritis and other arthritic conditions, chronic inflammation, autoimmune diabetes, multiple sclerosis (MS), asthma, systhemic lupus erythrematosus, adult respiratory distress syndrome, Behcet's disease, psoriasis, chronic pulmonary inflammatory disease, graft versus host reaction, Crohn's Disease, ulcerative colitis, inflammatory bowel disease (IBD), Alzheimer's disease, and pyresis, along with any disease or disorder that relates to inflammation and related disorders.
- inflammatory skin conditions such as dermatitis, eczema, rheumatoid arthritis (RA), rheumatoid spondylitis, gouty arthritis and other arthritic conditions, chronic inflammation, autoimmune diabetes, multiple sclerosis
- apoptosis and “apoptotic activity” are used in a broad sense and refer to the orderly or controlled form of cell death in mammals that is typically accompanied by one or more characteristic cell changes, including condensation of cytoplasm, loss of plasma membrane microvilli, segmentation of the nucleus, degradation of chromosomal DNA or loss of mitochondrial function. This activity can be determined and measured, for instance, by cell viability assays, FACS analysis or DNA electrophoresis.
- cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
- examples of cancer include, without limitation, carcinoma, lymphoma, leukemia, blastoma, and sarcoma.
- Specific examples of such cancers include squamous cell carcinoma, small-cell lung cancer, non-small cell lung cancer, breast cancer, pancreatic cancer, glioblastoma multiforme, cervical cancer, stomach cancer, bladder cancer, hepatoma, colon carcinoma, and head and neck cancer.
- the cancer includes breast cancer, ovarian cancer, prostate cancer, and lung cancer.
- treatment refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder.
- beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
- Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.
- a therapeutic agent may directly decrease the pathology of tumor cells, or render the tumor cells more susceptible to treatment by other therapeutic agents, e.g., radiation and/or chemotherapy.
- a “subject” is a vertebrate, preferably a mammal, more preferably a human.
- mammal is used herein to refer to any animal classified as a mammal, including, without limitation, humans, higher primates, rodents, domestic and farm animals, and zoo, sports, or pet animals, such as sheep, dogs, horses, cats, cows, etc.
- the mammal herein is human.
- p50/p50 homodimer blocks activation of pro-inflammatory genes, while the p65/p50 heterodimer acts by turning on pro-inflammatory genes, and as a result, is a major component in the pathogenesis of inflammation.
- One idea underlying the present invention is that by designing decoy molecules which could bind p65/p50 and/or cRel/p50 heterodimers and not p50/p50 homodimers, or which would preferentially bind p65/p50 and/or cRel/p50 heterodimers, one could provide extra blockade of NF- ⁇ B driven promoters by leaving p50/p50 homodimers behind to occupy these sites.
- selective decoy molecules have the potential to block NF- ⁇ B activity, such a pro-inflammatory activity associated with the NF- ⁇ B pathway, more efficiently than NF- ⁇ B decoys known in the art.
- Another objective of the present invention is to provide NF- ⁇ B decoy molecules with improved binding affinity for p65.
- This class of NF- ⁇ B dsODN molecules is particularly useful in situations where p50/p50 homodimers are present in small concentrations only, like in the case of dermatitis, and therefore p65/p50 specificity is not critical.
- the oligonucleotide decoys of the present invention have been designed taking advantage of the crystal structure of the p50/p65 heterodimer bound to the immunoglobulin light-chain gene (Chen et al, Nature 391(6665):410-3 (1998)) which contains the consensus sequence of 5′-GGGACTTTCC-3′ (SEQ ID NO: 2).
- the authors showed that p50 contacts the 5-base-pair subsite 5′-GGGAC-3′ (SEQ ID NO: 3) and that p65 contacts the 4-base-pair subsite 5′TTCC-3′ (SEQ ID NO: 4).
- the DNA contacts by the p50/p65 heterodimer are similar to those in the homodimer structures (Ghosh et al, Nature 373(6512):303-10 (1995); Muller et al, FEBS Lett. 369(1):113-7 (1995)).
- each dsODN sequence was analyzed, using bioinformatics methods which give a score of how well a decoy is predicted to bind to NF- ⁇ B.
- the specificity/affinity factor was experimentally generated using traditional binding assays (e.g. competitive binding assay), but could easily be derived from alternative binding assays, including the TransAMTM method (Active Motif, Carlsbad, Calif.), which is an ELISA-based method for detecting and quantifying transcription factor activation.
- the predicted binding affinity was derived using a conventional approach to assess the TF binding affinity, using the TF binding sites matrix system that statistically summarized the experimental TF-DNA binding data.
- TRANSFAC collects position-weight-matrices for DNA-TF binding.
- the tool Match (Kel et al., Nucleic Acids Res. 31:3576-9 (2003)) was used to assess the binding affinity of decoys using the matrices of TRANSFAC, and actual specificity/affinity factors were compared. The data are illustrated in FIGS. 14 and 15 , and discussed below. The exact scores will be assay dependent, however, the relative affinity would remain valid, regardless of the specific assay used.
- the NF- ⁇ B dsODN molecules of the present invention consist of two oligonucleotide strands which are attached to each other by Watson-Crick base pairing. While typically all nucleotides in the two strands participate in the base pairing, this is not a requirement. Oligonucleotide decoy molecules, where one or more, such as 1-3 or 1 or 2 nucleotides are not involved in base pairing are also included. In addition, the double stranded decoys may contain 3′ and/or 5′ single stranded overhangs.
- the NF- ⁇ B dsODN molecules of the present invention comprise two oligonucleotide strands which are attached to each other by Watson-Crick base pairing, and are additionally covalently attached to each other at either the 3′ or the 5′ end, or both, resulting in a dumbell structure, or a circular molecule.
- the covalent linkage may be provided, for example, by phosphodiester linkages or other linking groups, such as, for example, phosphothioate, phosphodithioate, or phosphoamidate linkages.
- the dsODN molecules of the invention comprise a core sequence that is capable of specific binding to an NF- ⁇ B transcription factor, flanked by 5′ and/or 3′ sequences, wherein the core sequence typically consists of about 5 to 14, or about 6 to 12, or about 7 to about 10 base pairs; and the flanking sequences are about 2 to 8, or about 2 to 6, or about 2 to 4, or about 4 to 8, or about 4 to 6 base pairs long.
- the molecule typically comprises an about 12 to 28, preferably about 14 to 24 base-pair long double-stranded region composed of two fully or partially complementary strands (including the core and flaking sequences).
- the core sequence including its length, sequence, base modifications and backbone structure
- the NF- ⁇ B dsODN molecules of the present invention which bind the p65/p50 and/or cRel/p50 heterodimers with high affinity and exhibit no or only low affinity binding for the p50/p50 homodimers, were designed by deleting or changing targeted residues in the binding site (core) of a consensus oligonucleotide decoy, based on the crystal structure of the p65/p50 heterodimer binding to DNA, and follow up testing.
- changes in the flanking sequence have a genuine impact on and can significantly increase the in vivo stability of the NF- ⁇ B decoy molecule, and may affect binding affinity and/or specificity.
- the shape/structure of the NF- ⁇ B decoy molecule can be changed by changing the sequences flaking the core binding sequence, which can result in improved stability and/or binding affinity.
- the shape and structure of the DNA are influenced by the base pair sequence, length of the DNA, backbone and nature of the nucleotide (i.e. native DNA vs. modified sugars or bases).
- the shape and/or structure of the molecule can also be changed by other approaches, such as, for example, by changing the total length, the length of the fully complementary, double-stranded region within the molecule, by alterations within the core and flanking sequences, by changing the backbone structure and by base modifications.
- nucleotide sequences present in the decoy molecules of the present invention may comprise modified or unusual nucleotides, and may have alternative backbone chemistries.
- Synthetic nucleotides may be modified in a variety of ways, see, e.g. Bielinska et al. Science 250:997-1000 (1990).
- oxygens may be substituted with nitrogen, sulfur or carbon; phosphorus substituted with carbon; deoxyribose substituted with other sugars, or individual bases substituted with an unnatural base.
- any change will be evaluated as to the effect of the modification on the binding ability and affinity of the oligonucleotide decoy to the NF- ⁇ B transcription factor, effect on melting temperature and in vivo stability, as well as any deleterious physiological effects.
- modifications are well known in the art and have found wide application for anti-sense oligonucleotide, therefore, their safety and retention of binding affinity are well established (see, e.g. Wagner et al. Science 260:1510-1513 (1993)).
- modified nucleotides are: 4-acetylcytidin, 5-(carboxyhydroxymethyl)uridine, 2′-O-methylcytidine, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluridine, dihydrouridine, 2′-O-methylpseudouridine, ⁇ ,D-galactosylqueuosine, 2′-O-methylguanosine, inosine, N6-isopentenyladenosine 1-metyladenosine, 1-methylpseudouridine, 1-methylguanosine, 1-methylinosine, 2,2-dimethylguanosine, 2-methyladenosine, 2-methylguanosine 3-methylcytidine 5-methylcytidine, N6-methyladenosine, 7-methylguanosine, 5-methylaminomethyl-2-thiouridine, ⁇ ,D-mannosylqueosine, 5-methoxycarbony
- nucleotides can be linked to each other, for example, by a phosphoramidate linkage.
- This linkage is an analog of the natural phosphodiester linkage such that a bridging oxygen (—O—) is replaced with an amino group (—NR—), wherein R typically is hydrogen or a lower alkyl group, such as, for example, methyl or ethyl.
- R typically is hydrogen or a lower alkyl group, such as, for example, methyl or ethyl.
- Other likages, such as phosphothioate, phosphodithioate, etc. are also possible.
- the decoys of the present invention can also contain modified or analogous forms of the ribose or deoxyribose sugars generally present in polynucleotide structures.
- modifications include, without limitation, 2′-substituted sugars, such as 2′-O-methyl-, 2′-O-allyl, 2′-fluoro- and 2′azido-ribose, carboxylic sugar analogs, ⁇ -anomeric sugars, epimeric sugars, such as arabinose, xyloses, lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs, such as methyl riboside.
- the oligonucleotide decoys of the present invention are preferably comprised of greater than about 50%, more preferably greater than about 80%, most preferably greater than about 90% conventional deoxyribose nucleotides.
- the NF- ⁇ B dsODN decoys of the present invention can be further modified to facilitate their localization, purification, or improve certain properties thereof.
- a nuclear localization signal (NLS) can be attached to the decoy molecules, in order to improve their delivery to the cell nucleus.
- the NF- ⁇ B/Rel proteins include a common Rel homology domain, which encompasses the NLS. In a preferred embodiment such naturally occurring NLS, or a variant thereof, is used in the decoy molecules of the present invention.
- NF- ⁇ B decoy molecules of the invention may be conjugated with carrier molecules, such as peptides, proteins or other types of molecules, as described, for example, in the following references: Avrameas et al., J Autoimmun 16, 383-391 (2001); Avrameas et al., Bioconjug. Chem. 10: 87-93 (1999); Gallazzi et al., Bioconjug. Chem. 14, 1083-1095 (2003); Ritter, W. et al., J. Mol. Med. 81, 708-717 (2003).
- carrier molecules such as peptides, proteins or other types of molecules
- the NF- ⁇ B decoy molecules of the invention may further be derivatized to include delivery vehicles which improve delivery, distribution, target specific cell types or facilitate transit through cellular barriers.
- delivery vehicles include, without limitation, cell penetration enhancers, liposomes, lipofectin, dendrimers, DNA intercalators, and nanoparticles.
- the NF- ⁇ B sdODN decoy molecules of the present invention can be synthesized by standard phosphodiester or phosphoramidate chemistry, using commercially available automatic synthesizers.
- the specific dsODN molecules described in the Examples have been synthesized using an automated DNA synthesizer (Model 380B; Applied Biosystems, Inc., Foster City, Calif.).
- the decoys were purified by column chromatography, lyophilized, and dissolved in culture medium. Concentrations of each decoy were determined spectrophotometrically.
- the NF- ⁇ B decoy molecules of the present invention can be conveniently tested and characterized in a gel shift, or electrophoretic mobility shift (EMSA) assay.
- ESA electrophoretic mobility shift
- This assay provides a rapid and sensitive method for detecting the binding of transcription factors to DNA.
- the assay is based on the observation that complexes of protein and DNA migrate through a non-denaturing polyacryamide gel more slowly than free double-stranded oligonucleotides.
- the gel shift assay is performed by incubating a purified protein, or a complex mixture of proteins (such as nuclear extracts), with a 32 P end-labeled DNA fragment containing a transcription factor-binding site. The reaction products are then analyzed on a non-denaturing polyacrylamide gel.
- the specificity of the transcription factor for the binding site is established by competition experiments, using excess amounts of oligonucleotides either containing a binding site for the protein of interest or a scrambled DNA sequence.
- the identity of proteins contained within a complex is established by using an antibody which recognizes the protein and then looking for either reduced mobility of the DNA-protein-antibody complex or disruption of the binding of this complex to the radiolabeled oligonucleotide probe.
- a NF- ⁇ B decoy to bind to and block the activity of an NF- ⁇ B transcription factor can be determined in traditional binding assays (e.g. competitive binding assay), including the TransAMTM method (Active Motif, Carlsbad, Calif.), which is an ELISA-based method for detecting and quantifying transcription factor activation.
- a target sequence in this case a natural NF- ⁇ B binding site, is immobilized on the plate, and a nuclear extract containing NF- ⁇ B is incubated in the wells, in the presence or absence of decoy at various concentrations calculated as the molar ration of decoy:plate bound sequence.
- Positive control wells include decoy with the same sequence as the target DNA on the plate. The data obtained are presented as the ratio of the absorbance of the test decoys and the absorbance of the positive control decoy. Accordingly, lower ratios represent better binding.
- NF- ⁇ B decoys based on the crystal structure of p65/p50 heterodimer binding to DNA, targeted residues in the binding site (core) of the consensus oligonucleotide decoy were deleted.
- the ultimate goal was to design a double-stranded oligonucleotide which was able to bind p65/p50 and/or cRel/p50 heterodimers, preferably both the p65/p50 and cRel/p50 heterodimers, with high affinity and exhibited low affinity for p50/p50 homodimers.
- a variety of NF- ⁇ B decoys were tested for their ability to bind the different NF- ⁇ B proteins in a gel shift assay as described in the following Example 1.
- NF- ⁇ B is involved in the regulation of the transcription of numerous genes.
- a representative grouping and listing of genes transcriptionally activated by NF- ⁇ B is provided below.
- Cytokines/chemokines and their modulators such as, for example, interferon- ⁇ (IFN- ⁇ ), interferon- ⁇ (IFN- ⁇ ), interleukins, such as, IL-1, Il-2, IL-6, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, lymphotoxin- ⁇ , lymphotoxin- ⁇ , TNF- ⁇ , MIP-1, MIP-2, MIP-3, RANTES, TNF- ⁇ , TRAIL.
- IFN- ⁇ interferon- ⁇
- IFN- ⁇ interferon- ⁇
- interleukins such as, IL-1, Il-2, IL-6, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, lymphotoxin- ⁇ , lymphotoxin- ⁇ , TNF- ⁇ , MIP-1, MIP-2, MIP-3, RANTES, TNF- ⁇ , TRAIL.
- Immunoregulators such as, for example, BRL-1, CCR5, CCR7, CD137, CD154, CD40 and CD40 ligand, CD48, CD83, CD23, IL-2 receptor ⁇ chain, certain immunoglobulin heavy and light chains, MHC Class I antigen, T cell receptor subunits, TNF-receptor (p75/80).
- Proteins involved in antigen presentation such as, for example, Complement B, Complement component 3, TAP1, and tapasin.
- Cell adhesion molecules such as, for example, E- and P-selectin, ICAM-1, MadCAM-1, VCAM-1, and Tenascin-C.
- Acute phase proteins such as, for example, angiotensinogen, ⁇ -defensin-2, complement factors, tissue factor-1 (TF-1), urokinase-type plasminogen activator.
- Stress response genes such as, for example, angiotensin-2, COX-2, MAP4K1, Phospholipase A2.
- Cell surface receptors such as, for example, CD23, CD69, EGF-R, Lox-1, Mdr1.
- Regulators of apoptosis such as, for example, Bf11, Bcl-xL, Caspase-11, CD95 (Fas), TRAF-1, TRAF-2.
- Growth factors and their modulators such as, for example, G-CSF, GM-CSF, EPO, IGFBP-1, IGFBP-2, M-CSF, VEGF-C.
- NF- ⁇ B regulates the transcription of other transcription factors, such as c-myc-, c-myb, A20, junB, p53, WT1, and viruses.
- NF- ⁇ B decoy molecules herein are useful in the prevention and treatment of inflammatory, immune and autoimmune diseases, such as rheumatoid arthritis (RA) (Roshak et al., Current Opinion in Pharmacology 2:316-321 (2002)); Crohn's disease and inflammatory bowel disease (IBD) (Dijkstra et al., Scandinavian J. of Gastroenterology Suppl.
- RA rheumatoid arthritis
- IBD Crohn's disease and inflammatory bowel disease
- a more detailed list of diseases and pathogenic conditions, which are targeted for prevention and/or treatment by the NF- ⁇ B decoys of the present invention includes psoriasis, eczema and atopic dermatitis; systemic scleroderma and sclerosis; responses associated with inflammatory bowel disease (IBD) (such as Crohn's disease and ulcerative colitis); ischemic reperfusion disorders including surgical tissue reperfusion injury, myocardial ischemic conditions such as myocardial infarction, cardiac arrest, reperfusion after cardiac surgery and constriction after percutaneous transluminal coronary angioplasty, stroke, and abdominal aortic aneurysms; cerebral edema secondary to stroke; cranial trauma, hypovolemic shock; asphyxia; adult respiratory distress syndrome; acute-lung injury; Behcet's Disease; dermatomyositis; polymyositis; multiple sclerosis (MS); meningitis; encephalitis; uveitis; osteoarth
- Rheumatoid arthritis is a chronic systemic autoimmune inflammatory disease that mainly involves the synovial membrane of multiple joints with resultant injury to the articular cartilage.
- Efficacy of the NF- ⁇ B decoy molecules of the present invention in the prevention and/or treatment of arthritis can be evaluated in a collagen-induced arthritis (CIA) model (Terato et al. Brit. J. Rheum.
- TNF- ⁇ tumor necrosis factor
- a cytokine which has been implicated in the pathogenesis of human rheumatoid arthritis.
- the expression of TNF- ⁇ in these mice results in severe chronic arthritis of the forepaws and hind paws, and provides a good mouse model for study of inflammatory arthritis.
- a representative NF- ⁇ B decoy molecule of the present invention showed significant efficacy in the collagen-induced and adjuvant-induced arthritis models.
- NF- ⁇ B decoy molecules of the present invention can be tested in various animal models of inflammatory skin conditions.
- Such models are well known in the art and include Dustmite Ag (Dp) induced contact dermatitis in NC/Nga mice (Sasakawa, T et al., Int Arch Allergy Immunol 126:23947 (2001); Sasakawa et al., Int Arch Allergy Immunol 133:55-63 (2004)). Results of testing a representative NF- ⁇ B decoy of the invention in this model are described in Examples 3, 4, and 6.
- the NF- ⁇ B decoy molecules of the present invention can also be tested for efficacy in the treatment of inflammatory skin conditions, such as, for example, dermatitis, and eczema in pig skin inflammatory models.
- the NF- ⁇ B decoy molecules of the present invention effectively block NF- ⁇ B activity in this model, and block expression of key inflammatory genes.
- NF- ⁇ B decoys are devoid of the known side effects of steroid therapy and involve limited systemic exposure.
- Skin is known for its functional role as a protective barrier. It is now clear that skin is also a very dynamic organ that can elicit immunological responses. However, not all immunological reactions in the skin are beneficial, some harmful reaction (inflammation) might result from reacting to invaders, such as allergens (contact dermatitis, atopic dermatitis an other kin inflammatory diseases) that require down-regulation/medication. Other reactions might occur from autoreactive lymphocytes being exposed to skin antigens, such as epithelia base membrane component type VII collage or cell surface components or keratinocytes, or still unknown cell components, which can lead to pemphigus vulgaris (Anhalt et al., N. Engl. J. Med.
- IBD Inflammatory Bowel Disease
- IBD inflammatory bowel disease
- Traditional treatment is based on corticosteroid therapy and the administration of salazopyrine.
- other therapeutics such as an anti-TNF- ⁇ antibody, have been developed.
- new therapies partly due to the known side effects of steroid therapy, and since in a significant subgroup of patients current therapies fail to induce remission. See, e.g. Mee et al., Gut 2:1-5 (1979).
- Mouse models are described by Matsumoto, et al., Gut 43:71-78 (1998); and Strober et al., J Clin Invest 107:667-670 (2001).
- T cells are the main culprit of the inflammation.
- the balance between pro- and anti-inflammatory cytokines secreted by T cells regulates both the initiation and perpetuation of inflammatory bowel disease.
- Most of these secreted factors are regulated directly or indirectly by NF- ⁇ B (Neurath et al., Natl. Med. 8(6):567-73 (2002); Strober et al., J. Gastroenterol. 38 Suppl 15:55-8 (2003)).
- IBS irritable bowel disease
- gastritis Barrett syndrome
- peptide lulcer Barrett syndrome
- reflux disease acute and chronic pancreatitis
- cholecystitis result from similar, albeit more chronic dysregulated mucosal immune systems and thus are expected to be responsive to treated with NF- ⁇ B inhibitors.
- NF- ⁇ B plays a pivotal role in the coordinated transactivation of cytokine and adhesion molecule genes involved in atherosclerosis and lesion formation after vascular injury (Yoshimura et al., Gene Therapy 8: 1635-1642 (2001)); neuronal damage after cerebral ischemia (Ueno et al., J. Thoracic and Cardiovascular Surgery 122(4): 720-727 (2001)); chronic airway inflammation (Griesenbach et al., Gene Therapy 7, 306-313 (2000)); progression of autoimmune myocarditis (Yokoseki et al., Circ. Res.
- NF- ⁇ B decoy molecules also find utility in the treatment of such diseases and conditions.
- NF- ⁇ B and the signaling pathways that are involved in its activation are also important for tumor development. See, e.g. Karin et al., Nat. Rev. Cancer 2(4):301-10 (2002). Therefore, blocking NF- ⁇ B by the decoy molecules of the present invention finds utility in the prevention and treatment of cancer, offering a new anti-cancer strategy, either alone or in combination with other treatment options.
- the route of delivery of the NF- ⁇ B decoys of the present invention depends on the disease or pathological condition the prevention and/or treatment is targeted.
- a preferred mode of delivering the NF- ⁇ B decoys of the present invention is pressure-mediated transfection, as described, for example, in U.S. Pat. Nos. 5,922,687 and 6,395,550, the entire disclosures of which are hereby expressly incorporated by reference.
- the NF- ⁇ B decoy molecules are delivered to cells in a tissue by placing the decoy nucleic acid in an extracellular environment of the cells, and establishing an incubation pressure around the cells and the extracellular environment. The establishment of the incubation pressure facilitates the uptake of the nucleic acid by the cells, and enhances localization to the cell nuclei.
- a sealed enclosure containing the tissue and the extracellular environment is defined, and the incubation pressure is established within the sealed enclosure.
- the boundary of the enclosure is defined substantially by an enclosing means, so that target tissue (tissue comprising the target cell) is subjected to isotropic pressure, and does not distend or experience trauma.
- part of the enclosure boundary is defined by a tissue.
- a protective means such as an inelastic sheath is then placed around the tissue to prevent distension and trauma in the tissue. While the incubation pressure depends on the application, incubation pressures about 300 mmHg-1500 mmHg above atmospheric pressure, or at least about 100 mmHg above atmospheric pressure are generally suitable for many applications.
- the incubation period necessary for achieving maximal transfection efficiency depends on parameters such as the incubation pressure and the target tissue type. For some tissue, such as human vein tissue, an incubation period on the order of minutes (>10 minute) at low pressure (about 0.5 atm) is sufficient for achieving a transfection efficiency of 80-90%. For other tissue, such as rat aorta tissue, an incubation period on the order of hours (>1 hour) at high pressure (about 2 atm) is necessary for achieving a transfection efficiency of 80-90%.
- Suitable mammalian target tissue for this type of delivery includes blood vessel tissue (in particular veins used as grafts in arteries), heart, bone marrow, and normal and tumor connective tissue, liver, genital-urinary system, bones, muscles, gastrointestinal organs, endocrine and exocrine organs, synovial tissue and skin.
- a method of the present invention can be applied to parts of an organ, to a whole organ, or to a whole organism.
- a nucleic acid solution can be perfused into a target region (e.g. a kidney) of a patient, and the patient is subject to pressure in a pressurization chamber.
- the NF- ⁇ B decoys of the present invention can be administered by other conventional techniques.
- retrovial transfection, transfection in the form of liposomes are among the known methods suitable for transfection.
- the decoy concentration in the lumen will generally be in the range of about 0.1 ⁇ M to about 50 ⁇ M per decoy, more usually about 1 ⁇ M to about 10 ⁇ M, most usually about 3 ⁇ M.
- Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved.
- Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides. In general, an effective dose is from 0.01 ⁇ g to 100 g per kg of body weight. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues.
- the effective dose will depend on the target disease, the route of delivery, the formulation used, the severity of the disease, the age, sex, and overall condition of the patient to be treated, and other similar considerations.
- murine experiments typically use about 25-100 ⁇ g decoy in 50 to 100 ⁇ l injectable formulation. Based on these dose regimens, determination of the proper dosage for other species, including humans, can be assisted by mathematical calculations that have been developed for inter-species scaling. See, for example, Mordenti et al., Pharm Res 8:1351-9 (1991).
- the decoys of the present invention are administered in the form of conventional topical formulations, such as, for example, creams, ointments, gels, suspensions, and the like.
- topical formulations will contain one or more penetration enhancers and/or surfactants to assure efficient delivery through the skin.
- Topical formulations for delivery of dsODN molecules are described in co-pending application U.S. Provisional Application Ser. No. 60/612,046, filed on Sep. 21, 2004, the entire disclosure of which is hereby expressly incorporated by reference.
- Topical formulations specifically include aqueous, emulsion-based and liposome formulations.
- a typical formulation may be a topical cream containing about 0.1 to 5% by weight, or about 0.2 to 3% by weight, or about 0.25 to 1% by weight of active ingredient.
- at least one and preferably both strands of the NF- ⁇ B decoy molecules of the present invention are fully phosphorothioated.
- the most suitable concentration can be determined empirically. The determination of the appropriate concentrations and doses is well within the competence of one skilled in the art. Optimal treatment parameters will vary depending on the indication, decoy, clinical status of the patient, etc., and can be determined empirically based on the instructions provided herein and general knowledge in the art.
- the decoys may be administered as compositions comprising individual decoys or mixtures of decoys. Usually, a mixture contains up to 6, more usually up to 4, more usually up to 2 decoy molecules.
- NF- ⁇ B decoy molecules of the present invention can optionally be administered in combination with such drug treatments.
- Combination treatment includes simultaneous administration as well as consecutive administration of two or more drugs in any order.
- the topical anti-inflammatory applications the NF- ⁇ B decoys of the invention can be administered in combination with betamethasone or similar therapeutic agents.
- the administration of the NF- ⁇ B decoy molecules can be combined with other treatment options, including treatment with chemotherapeutic anticancer agents and/or radiation therapy.
- NF- ⁇ B dsODN decoy molecules were designed and tested for their ability to bind and/or compete for binding of NF- ⁇ B.
- the goal of the invention was to design NF- ⁇ B decoy molecules that preferentially bind p65/p50 and/or cRel/p50 heterodimers over p50/p50 homodimers.
- the selective decoy molecules of the invention allow these homodimers to block the promoters of NF- ⁇ B regulated genes, which provides an additional level of negative regulation of gene transcription.
- oligonucleotide decoys were designed, which contained fewer numbers of G's at the 5′ end of the consensus binding site with the aim to prepare decoy molecules that would have lower affinity for the p50/p50 homodimer but still bind the p65/p50 heterodimer.
- These oligonucleotide decoys were assigned “core” and “flank” letter codes for ease of identification and presentation. The cores were assigned letter codes “A” through “L” and the flanks “T” through “Z′”.
- NF- ⁇ B-binding DNA consensus sequences were selected from publications of NF- ⁇ B related DNA-protein interactions, including: Blank et al., EMBO J. 10:4159-4167 (1991); Bours et al. Mol. Cell. Biol. 12:685-695 (1992); Bours et al. U. Cell 72:729-739 (1993); Duckett et al. Mol. Cell. Biol. 13:1315-1322 (1993); Fan C.
- decoys were generated for initial screening. These decoys include a “mutation decoy”, the scrambled decoys, decoys with different length at their 5′ or 3′ end, and decoys with alternative base composition within the core region and/or in the flanking sequences.
- the core binding sites were computationally aligned (forward strand only) with known binding sequences. Based on this alignment, several major groups of decoys with slightly different core binding sites were created.
- TCA (SEQ ID NO:82 and SEQ ID NO:83) F GACTTTCC 15 X CT . . . TC (SEQ ID NO:84 and SEQ ID NO:85) G GACTTTCCC 17 Y TC . . . CA (SEQ ID NO:86 and SEQ ID NO:87) H GGATTTCC 19 Z AGTTGA . . . AGGC (SEQ ID NO:79 and SEQ ID NO:88) I GGATTTCCC 21 Z′ TTGA . . . AGGC (SEQ ID NO:80 and SEQ ID NO:89) J GATTTCC 23 Z-4 TTGA . . . AG (SEQ ID NO:90 and SEQ ID NO:91) K GATTTCCC 24 Z-2 GTTGA . . . AGG (SEQ ID NO:81 and SEQ ID NO:92) L GGACTTTCCC 25
- the sequences of the NF- ⁇ B decoys used in the Examples herein include 5′AGTTGAGGACTTTCCAGGC-3′ (SEQ ID NO: 30) and 5′-GCCTGGAAAGTCCTCAACT-3′ (SEQ ID NO: 95).
- the scrambled ODN sequence was 5′-CAGTAGTATGTGAGCCTGC-3′ (SEQ ID NO: 46) and 5′-GCAGGCTCACATACTACTG-3′ (SEQ ID NO: 96).
- the ODNs were purified using ion exchange chromatography (Avecia Biotechnology). All ODNs used were phosphorothioates and were annealed by combining equal molarities of each strand at room temperature. Concentrations of ODNs were determined by spectrophotometry.
- the EMSA assay was employed to characterize oligonucleotide decoys for the NF- ⁇ B transcription factor.
- a radiolabeled oligonucleotide probe non-mammalian, based on NF- ⁇ B promoter from HIV, sequence 113/114, SEQ ID NO: 48, and its complement
- binding of p65/p50, cRel/p50 and p50/p50 was tested using a nuclear extract from an activated monocyte cell line.
- NF- ⁇ B gel shift assays were performed as follows.
- a double-stranded oligonucleotide containing a consensus NF- ⁇ B binding site (5′ AGTTGAGGGGACTTTCCCAGGC 3′) (SEQ ID NO: 78) was end-labeled with ⁇ 32 P-ATP using T4 Polynucleotide Kinase (Promega).
- a double-stranded ODN containing a consensus NF- ⁇ B binding site from the IL-6 promoter (5′ TGTGGGATTTTCCCATGACTC 3′) (SEQ ID NO: 94) was end-labeled with ⁇ 32 P-ATP using T4 Polynucleotide Kinase (Promega).
- a nuclear extract prepared from LPS stimulated THP-1 cells was incubated with 35 fmol of radiolabeled probe in the presence or absence of competing unlabeled NF- ⁇ B double-stranded oligonucleotides (dsODN) or scrambled dsODN.
- the incubations were carried out at room temperature for 30 minutes in a 20 ⁇ l reaction volume composed of 10 mM Tris-HCl pH 8, 100 mM KCL, 5 mM MgCl2, 2 mM DTT, 10% Glycerol, 0.1% NP-40, 0.025% BSA and 1 ⁇ g Poly-dIdC.
- the reactions were loaded onto a 6% polyacrylamide gel, subjected to electrophoresis and dried.
- the dried gels were imaged and quantitated using a Typhoon 8600 PhosphorImager (Amersham) and ImageQuant software.
- the identity of the NF- ⁇ B proteins contained in complexes bound to the radiolabeled oligonucleotide probe were identified by pre-incubating the reactions for 5 to 10 minutes with individual antibodies specific for each member of the NF- ⁇ B family prior to the addition of the radiolabeled probe. All antibodies were purchased from Active Motif (p65 and p50) or Santa Cruz Biotechnology (p52, RelB, cRel).
- the normal phosphodiester backbone was modified to contain phosphorothioate linkages. Stability enhancement from the phosphorothioate backbone was verified by incubating NF- ⁇ B decoy containing either a phosphodiester or phosphorothioate backbone in serum for different time intervals and assessing degradation by gel electrophoresis.
- Mouse serum (United States Biologicals) was diluted to a final working concentration of 70% using Phosphate Buffered Saline (PBS).
- PBS Phosphate Buffered Saline
- NF- ⁇ B decoy containing either a phoshodiester (PO) or phosphorothioate (PS) backbone was diluted into serum for a final concentration of 4 ⁇ M.
- Gentamycin was included to prevent bacterial growth.
- the reactions were allowed to incubate at 37° C. and 10 ⁇ l aliquots were removed at 0, 30, 75 and 120 minutes. The reactions were stopped by the addition of 1 ⁇ l 0.5M EDTA and quickly frozen on dry ice.
- the samples were loaded onto a 20% polyacrylamide gel and subjected to electrophoresis. The gels were imaged and quantitated using a Typhoon 8600 PhosphorImager (Amersham) and ImageQuant software.
- FIG. 18 shows that nuclear extracts from a human monocytic cell line has 2 strong DNA-protein complexes when incubated with an NF- ⁇ B-containing consensus sequence from the IL-6 promoter. A competitive reduction in the density of these bands was observed with NF- ⁇ B decoy addition that was concentration dependent. The band densities remained unchanged in samples treated with a negative control ODN containing a scrambled sequence (scramble ODN) at up to 10-fold excess over the radiolabeled probe.
- the NF- ⁇ B complexes, identified by antibody supershifts, were shown to either contain a p65/p50 complex (top band) or a combination of p50/cRel/p52 complexes (lower band). This verifies that the NF- ⁇ B decoy binds the proinflammatory NF- ⁇ B heterodimeric complexes in a dose- and sequence-specific manner and has improved stability due to the chemically-modified backbone.
- oligonucleotide decoys are designed, they are modified to enhance their stability. Replacing one of the non-bridging oxygen atoms of the internucleotide linkage with a sulfur group, creating what is referred to as a phosphorothioate (PS) oligodeoxynucleotide, has been highly successful.
- PS phosphorothioate
- the molecules are relatively nuclease resistant; however, they have been shown to exhibit nonspecific protein binding relative to 3′-terminally modified and unmodified oligonucleotide decoys (Brown et al, J. Biol. Chem. 269(43):26801-5 (1994)). Therefore, a set of experiments was performed to determine how many sulfurs were required at the 3′, 5′ or an internal site to provide nuclease resistance to our oligonucleotide decoys while maintaining the achieved specificity.
- NF- ⁇ B oligonucleotide decoy molecules that preferentially bind to the NF- ⁇ B p65/p50 and/or cRel/p50 heterodimer relative to the p50/p50 homodimer.
- the experimental results showed that the binding to p65/p50 and cRel/p50 were generally equivalent, therefore, only the p65/p50 bands were quantitated in our analysis.
- FIG. 1 shows the p65/p50 binding of certain NF- ⁇ B decoy molecules.
- FIG. 2 shows the p50/p50 binding of certain NF- ⁇ B decoy molecules.
- the score (S) is assigned as 100 if the decoy is unable to compete at least 50% of the binding at any molar ratio tested.
- a preferred decoy molecule will have a lower score for the p65/p50 heterodimer and a higher score for the p50/p50 homodimer.
- the specificity of the decoy to p65/p50 heterodimer versus p50/p50 homodimer is proportional to their difference of score (score p50/p50-score p65/50).
- the results of the EMSA competition binding experiments, performed as described above, are summarized in Table 2A, where the decoy molecules are listed starting with the most specific decoys (highest specificity/affinity factor).
- NF- ⁇ B decoys As discussed earlier, for certain uses of the NF- ⁇ B decoys herein specificity is not a requirement. For such applications, it is advantageous to select NF- ⁇ B decoy molecules with high binding affinity for p65.
- Table 2B shows the p65 binding affinity for some NF- ⁇ B decoy molecules tested.
- H3/H3, H5/H5, H6/H6, and H7/H7 were identified as the optimal backbone for the 153/154 decoy.
- Optimal backbone chemistries for other decoys can be tested and determined in an analogous manner.
- decoys with an affinity score below 40, or below 35, or below 30, or below 25, or below 20 are selected. Since this data was generated in a competitive binding assay, smaller scores indicate better binding affinity, as they represent the amount of competing material left binding after the competition.
- the results set forth in Table 3B show that, with a few exceptions, such as H4 on both strands or H5 on one strand, which decreases p65 binding affinity, increasing the level of phosphorothioate substitutions generally increases p65 binding affinity.
- Decoy molecules must also specifically block only the target transcription factor and not non-specifically bind and block unrelated transcription factors. It has also been established that it is possible to design NF- ⁇ B decoy molecules which do not exhibit any non-specific effects on unrelated promoters using EMSA. Specifically, using radiolabeled oligonucleotide probes corresponding to the promoter sequences for the ubiquitous transcription factor Oct-1, it demonstrated that 153/154 (wherein “154” designates the reverse sequence corresponding to the sequence “153”) PO and H3 NF- ⁇ B decoy did not show any binding affinity for the promoter (data not provided). This is important because any non-specific effects of an oligonucleotide to other important proteins in the cell could result in unwanted toxicity of the decoy for the treatment individual.
- oligonucleotide decoys are modified to enhance their stability. Replacing one of the non-bridging oxygen atoms of the internucleotide linkage with a sulfur group, creating what is referred to as a phosphorothioate oligodeoxynucleotide, has been highly successful.
- the molecules are relatively nuclease resistant; however, they have been shown to exhibit non-specific protein binding relative to 3′-terminally modified and unmodified oligonucleotide decoys (Brown et al., J.
- Binding specificity was assessed by the gel shift assay described above. 3′-exonuclease resistance was assessed using a standard snake venom assay (Cummins et al., Nucleic Acids Res. 23:2019-24 (1995)). To assess the resistance of the decoys to more relevant mammalian nuclease activity, as assay was adapted in which cytoplasmic and nuclear extracts were prepared from activated macrophages. (Hoke et al., Nucl. Acids Res. 19(20):5743-8 (1991)). The activity of the extracts was confirmed with positive controls in each assay. It was determined that capping the 3′-ends of each strand of the decoy with a few sulfur groups was sufficient to protect it from nuclease degradation.
- a nuclear localization signal (NLS) containing peptide to improve the entry of an oligonucleotide decoy into the nucleus
- NLS nuclear localization signal
- a peptide with the NLS sequence based on the simian virus 40 large tumor antigen (PKKKRKVEDPYC) was synthesized by Sigma Genosys and conjugated to the NF- ⁇ B 153 H3 oligonucleotide as follows. Briefly, 6.5 nmols of oligonucleotide was first incubated with 40-fold molar excess of the linker Sulfo-SMCC (Pierce) at room temperature for 2 hours.
- the activated oligonucleotide was incubated with 5-fold molar excess of the NLS peptide at room temperature overnight.
- the reaction was analyzed by loading 1 ⁇ l onto a 20% PAGE gel (non-denaturing). The gel was stained with SYBR Gold (Molecular Probes) and visualized on a Typhoon Phosphorimager (Amersham). The concentration of the NLS-peptide conjugated single strand 153 H3 was determined by OD absorbance.
- the conjugate was then annealed to its complemetary strand 154 H3 (in equal molar amounts) containing a biotin molecule at its 5′ end.
- the presence of the biotin molecule on the now double stranded NLS decoy was to enable visualization (via streptavidin) of the localization through the use of microscopy.
- Dp Ag induced dermatitis was induced as previously described (Sasakawa, T et al., Int Arch Allergy Immunol 126:239-47 (2001); Sasakawa et al., Int Arch Allergy Immunol 133:55-63 (2004)). Briefly, Six week old male NC/Nga mice were injected intradermally with 5 ⁇ g of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on days 0, 2, 4, 7, 9, and 11.
- the DP injected ear was topically treated 2 times a day for 10-12 days with 20 ⁇ l of vehicle, vehicle containing 0.25% or 0.1 % NF- ⁇ B decoy or betamethasone as a control.
- the ear thickness was measured with an ear thickness gauge (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment.
- topical 0.25% NF- ⁇ B decoy or betamethasone (BID) treatment resulted in a rapid decrease in ear thickness while the 0.1% NF- ⁇ B decoy treatment group resulted in little to no decrease in ear thickness similar to the vehicle control.
- Topical application of NF- ⁇ B decoy suppresses inflammation in a dose dependent manner in this mouse model of atopic dermatitis.
- the purpose of this experiment was to determine whether or not NF- ⁇ B decoy efficacy is maintained when treatment is stopped.
- Dp Ag-induced dermatitis was induced as previously described (Sasakawa et al, supra). Briefly, six-week old male NC/Nga mice were injected intradermally with 5 ⁇ g of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on days 0, 2, 4, 7, 9, and 11. Starting on day 11, the DP injected ear was topically treated 2 times a day for 10-12 days with 20 ⁇ l of vehicle, vehicle containing 0.25% NF-kB decoy or betamethasone as a control. Topical treatment was then stopped for 2 weeks. The ear thickness was measured with an ear thickness gauge (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment.
- an ear thickness gauge OEMst, Dyer, Inc., Lancaster, Pa.
- NF- ⁇ B decoy treatment The ability of NF- ⁇ B decoy treatment to maintain the decrease in ear thickness after discontinuation of treatment was examined. As shown in FIG. 5 , discontinuation of the NF- ⁇ B decoy treatment resulted in no increase in ear swelling, while the cessation of betamethasone in the Dp injected ears resulted in a significant increase of ear swelling.
- the goal of this study was to evaluate the effect of NF- ⁇ B decoy treatment on elevated pro-inflammatory cytokine expression in Dp injected NC/Nga mice.
- mice Right ears of Dp-injected mice were removed 1 day after the final decoy treatment. Part of the ear was flash frozen in liquid nitrogen and store at ⁇ 80° C. Total RNA was isolated from the ears using Qiazol (Qiagen) according to manufacturer's instruction. The expression of the mouse genes were assayed by real-time quantitative PCR with an ABI PRISM 7900 Sequence Detector System (Applied Biosystems, Foster City, Calif.). All procedures were carried out as previously described (Hurst et al., Immunol 169:443-53 (2002)).
- RNA samples were mixed with random hexamers (Gibco-BRL), Oligo dt (Boehringer), and the first strand cDNAs were synthesized with SurperScript II reverse transcriptase.
- Primers for the respective genes were designed using the primer design software Primer Express (Applied Biosystems). Primers were synthesized by Sigma Genosys (Woodlands, Tex.). The quantitative PCR was performed using TaqMan PCR reagent kits according to the manufacturer's protool (Applied Biosystems). Sample cDNAs equivalent to 25 ng of RNA were examined in each reaction in a 384-well PCR plate. Levels of ubiquitin were measured for each sample, and used as internal standard. Cytokine levels are expressed as relative expression to ubiquitin levels.
- NF- ⁇ B decoy treatment The effects of NF- ⁇ B decoy treatment on pro-inflammatory gene expression in the skin was analyzes by real-time quantitative PCR. As shown in FIG. 6 , vehicle or non treated Dp injected mice showed a marked increase in expression levels of both IL-1 ⁇ and IL-6, while NF- ⁇ B decoy treatment decreased the expression levels of both cytokines similar to that of protopic and betamethasone.
- Topical NF- ⁇ B decoy treatment decreases the expression of pro-inflammatory cytokines (IL-1 ⁇ and IL-6) in Dp induced murine atopic dermatitis.
- mice Right ears of Dp-injected mice were removed 1 day after the final decoy treatment. Part of the ear was fixed in 10% phosphate buffered formalin (pH 7.2) and embedded in paraffin, and 3 micron sections were cut. Then the samples were stained with hematoxylin and eosin for histology and toluidine blue for detection of degranulated mast cells.
- H&E staining showed severe epidermal hyperplasia and cellular infiltration into the dermis of vehicle treated ears injected with Dp, and treatment with NF- ⁇ B decoy or betamethasone produced both a decrease in epidermal hyperplasia and cellular infiltrate.
- FIG. 7 most of the mast cells in the Dp-injected, vehicle treated mice were degranulated while treatment with NF- ⁇ B decoy or betamethasone demonstrated a decrease in degranulated mast cells.
- NF- ⁇ B decoy suppresses inflammation and the infiltration of inflammatory cells (i.e mast cells) responsible for atopic dermatitis. Also, NF- ⁇ B decoy treatment decreased epidermal hyperproliferation, cellular infiltration and degranulation of mast cells.
- the NF- ⁇ B decoy is a 19 base pair (molecular weight of 13 kDa) double-stranded deoxyribonucleic acid comprised of a random mixture of R- and S-chiral forms of oligonucleotides.
- the sequence of the NF- ⁇ B decoy used in this study was: 5′AGTTGAGGACTTTCCAGGC-3′ (SEQ ID NO: 30) and 5′-GCCTGGAAAGTCCTCAACT-3′ (SEQ ID NO: 95).
- the scrambled oligonucleotides (ODN) sequence was 5′-CAGTAGTATGTGAGCCTGC-3′ (SEQ ID NO: 46) and 5′-GCAGGCTCACATACTACTG-3′ (SEQ ID NO: 96). All oligonucleotides used were phosphorothioates and were annealed by combining equal molarities of each strand at room temperature.
- oligonucleotides described above are also used in Examples 8-14 described below.
- the Dp injected ear was topically treated 2 times a day for 11-14 days with 20 ⁇ l of vehicle, vehicle containing 0.25% or 1% NF- ⁇ B decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control.
- the ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment.
- TPA 12-O-tetradecanoylphorbol 13-acetate
- TPA phorbol 12-tetradecanoate 13-acetate
- mice were treated topically with 20 ⁇ l of vehicle, vehicle containing 1% of scramble ODN, 0.1%, 0.25% or 0.5% NF- ⁇ B, or topical 0.1% BMV as the positive control.
- the ear thickness was measured with ear thickness gauge (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after induction.
- FIG. 19 For the chronic atopic dermatitis model, a dose-dependent inhibition of inflammation following NF- ⁇ B Decoy treatment was observed ( FIG. 19 ). The highest topical dose of 1% NF- ⁇ B decoy inhibited inflammation by 74%, similar to topical BMV. Ears treated with scrambled ODN, vehicle only, or ears left untreated maintained severe ear thickness ( FIG. 19 ).
- TPA-induced ear swelling was reduced following application of topical NF- ⁇ B decoy; the highest dose (1%) showed similar efficacy to BMV treatment, with over 70% inhibition of ear swelling ( FIG. 20 )
- Dp Dustmite Ag
- NC/Nga mice Charles River Lab
- Animals were injected intradermally with 5 ⁇ g of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on days 0, 2, 4, 7, 9, and 11.
- the Dp injected ear was topically treated 2 times a day for 11-14 days with 20 ⁇ l of vehicle, vehicle containing 0.25% or 1% NF- ⁇ B decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control.
- the ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment.
- EMSA The NF- ⁇ B gel shift assays were performed as follows. A double-stranded ODN containing a consensus NF- ⁇ B binding site from the IL-6 promoter (5′TGTGGGATTTTCCCATGACTC 3′ (SEQ ID NO: 97)) was end-labeled with ⁇ 32P-ATP using T4 Polynucleotide Kinase (Promega). 5 ⁇ g of a nuclear extract prepared from Dp-Ag injected ears was incubated with 35 fmol of radiolabeled probe in the presence or absence of indicated antibodies.
- NF- ⁇ B proteins contained in complexes bound to the radiolabeled ODN probe were identified by pre-incubating the reactions for 10 minutes with antibodies specific for each member of the NF- ⁇ B family prior to the addition of the radiolabeled probe (all antibodies were purchased from Active Motif (p65 and p50) (Carlsbad, Calif.) or Santa Cruz Biotechnology (p52, RelB, cRel).
- NF-YA TransAM Assay To assess the relative affinities of NF- ⁇ B decoy for a NF-YA/SP1 containing complex, the NF-YA TransAM assay (Active Motif, Carlsbad, Calif.) was utilized. The assay was performed according to manufacturer's instructions. A double-stranded ODN containing the consensus NF-YA binding sequence was immobilized on a 96-well plate. A nuclear extract prepared from NC/Nga ears/activated THP-1 cells were incubated and allowed to bind to the immobilized ODN. The unbound material was washed away and the bound NF-YA/SP 1 detected using an antibody that specifically recognizes NF-YA/SP1.
- the NF-YA/SP1 antibody was detected by a secondary antibody labeled with horseradish peroxidase (HRP), and the amount of HRP in each well was measured using a colorimetric substrate reaction and read using a microplate spectrophotometer.
- HRP horseradish peroxidase
- Nuclear extract quality and equal gel loading was confirmed by normalizing the band intensity from the gel shift analysis to the values obtained from a TransAM assay for the ubiquitously expressed transcription factor, nuclear factor-YA (NF-YA) ( FIG. 22 ).
- the DNA-binding specificity of the NF- ⁇ B decoy was tested through competitive inhibition of NF- ⁇ B protein.
- NF- ⁇ B decoy demonstrates a dose-dependent inhibition of p65-DNA binding activity. Further, NF- ⁇ B decoy failed to block the binding activity of other known ubiquitously expressed transcription factors including SP1 or NF-YA.
- Dp Dustmite Ag
- NC/Nga mice Charles River Lab
- Animals were injected intradermally with 5 ⁇ g of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on days 0, 2, 4, 7, 9, and 11.
- the Dp injected ear was topically treated 2 times a day for 11 -14 days with 20 ⁇ l of vehicle, vehicle containing 0.25% or 1% NF- ⁇ B decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control.
- the ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment.
- Hematoxylin and Eosin Staining Dp injected mice ears were formalin-fixed, paraffin-embedded and 5- ⁇ M sections were then stained with hematoxylin and eosin.
- Mast Cells Staining Deparaffinized and rehydrated sections were stained in toluidine blue working solution (1% Toluidine blue stock solution).
- Eosinophils Staining Formalin-fixed, paraffin-embedded tissue samples were stained with congo red for detection of eosionophiis.
- FIG. 23B Toludine blue stained ear sections of both untreated and scrambled ODN treated lesions showed an increased number of mast cells ( FIG. 23B ), while inflamed skin treated with topical NF- ⁇ B decoy or BMV showed fewer mast cells ( FIG. 23B ).
- congo red staining revealed a decrease in eosinophil infiltration in skin treated with topical NF- ⁇ B decoy or BMV, ( FIG. 23C ).
- CD4 + T cells were also decreased with topical NF- ⁇ B decoy and BMV treatment ( FIG. 23D ). Mice treated with either vehicle control or scrambled-sequence ODN fail to reduce such inflammatory response.
- a quantitative representation of the decrease in mast cells (60%), eosinophils (70%) and CD4 + T cells (60%), upon topical NF- ⁇ B decoy and BMV treatment was performed ( FIG. 24 ).
- Topical application of NF- ⁇ B decoy suppresses inflammation and the infiltration of inflammatory cells (i.e. mast cells) responsible for atopic dermatitis.
- the purpose of this experiment is to examine the specific cellular uptake of topical NF- ⁇ B decoy.
- Dp Dustmite Ag
- NC/Nga mice Charles River Lab
- Animals were injected intradermally with 5 ⁇ g of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on days 0, 2, 4, 7, 9, and 11.
- the Dp injected ear was topically treated 2 times a day for 11-14 days with 20 ⁇ l of vehicle, vehicle containing 0.25% or 1% NF- ⁇ B decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control.
- the ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment.
- NF- ⁇ B Decoy Localization Cryosections were used for co-localization of 1% biotinylated NF- ⁇ B decoy with various cells in inflamed skin. After fixation in 2% paraformaldehyde, sections were blocked with Goat Ig (Sigma, Atlanta, Ga.).
- Primary antibodies include rat anti-mouse CD4 (R&D Systems, Minneapolis, Minn.), rat anti-mouse CD117 (BD, San Diego, Calif.), rabbit anti-mouse CD207-Langerin (Imgenex, San Diego, Calif.), rat anti-mouse MCP-1 (Abcam, Cambridge, UK), rat IgG2b Iso.
- BD rabbit Ig Iso (Sigma 10 mg/ml).
- Secondary antibodies include Alexa 546 SAV (Molecular Probes, Eugene, Oreg.), goat anti-rat Alexa 546, goat anti-rabbit Alexa 546 (Molecular Probes). Images were taken at 60 ⁇ magnification, using laser scanning confocal microscopy.
- NF- ⁇ B decoy was detected in langerin-positive, resident antigen-presenting cells (APC)-Langerhans cells (LC), CD117 positive mast cells, CD4 + T cells and MCP-1 positive macrophages ( FIG. 25 ).
- APC resident antigen-presenting cells
- LC resident antigen-presenting cells
- CD117 positive mast cells CD4 + T cells
- MCP-1 positive macrophages FIG. 25 .
- results show efficient drug delivery to inflamed mouse skin by immunohistological analysis as revealed by the presence of NF- ⁇ B decoy in cells pivotal for disease progression and maintenance, including keratinocytes, resident APC-Langerhans cell LCs, mast cells, CD4 + T cells and macrophages.
- the purpose of this experiment is to demonstrate effective topical NF- ⁇ B decoy delivery into porcine skin tissue.
- biotinylated NF- ⁇ B decoy was applied at 30 ⁇ l/cm 2 area on the back of a light skinned female Yorkshire pig for 24 hrs. Skin was washed thoroughly with PBS to remove any remaining formulation. Duct tape from Intertape Polymer Group (Sarasota, Fla.) was used and the skin was tape-stripped 20 times. The biotinylated-NF- ⁇ B decoy was visualized using AlexaFluor 488 -streptavidin (Molecular Probes) and counterstained with Hoechst stain for nuclear co-localization.
- the purpose of this experiment is to evaluate the anti-inflammatory effects of NF- ⁇ B decoy through the inhibition of essential regulators of inflammation and by induction of apoptosis of key immune cells.
- Dp Dustmite Ag
- NC/Nga mice Charles River Lab
- Animals were injected intradermally with 5 ⁇ g of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on days 0, 2, 4, 7, 9, and 11.
- the Dp injected ear was topically treated 2 times a day for 11-14 days with 20 ⁇ l of vehicle, vehicle containing 0.25% or 1% NF- ⁇ B decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control.
- the ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment.
- Apoptosis and Mitotic Index Formalin-fixed, paraffin-embedded tissue samples were used to identify apoptotic cells by the TUNEL assay. All the reagents were provided in the “In Situ Cell Death Detection Kit” (Roche, Indianapolis, Ind., Cat. No. 1 684 795). Formalin-fixed, paraffin-embedded tissue samples were also used to identify proliferating cells using Ki67 rabbit monoclonal antibody (NeoMarkers Cat. No. RM-9106, Lab Vision Corp., Fremont, Calif.).
- Immunoflourescence Cryosections were used for IL-1 ⁇ , TNF ⁇ , MIP2 ⁇ and ICAM localization.
- Primary antibodies include PE-rat anti-mouse IL-1 ⁇ (R&D Systems, Minneapolis, Minn.), PE-rat anti-mouse TNF (BD), rat anti-mouse MIP2 ⁇ (R&D Systems, Minneapolis, Minn.), rat anti-mouse ICAM (Serotec, Raleigh, N.C.), rat IgG2b isotype control (BD) (Sigma, Atlanta, Ga.).
- Secondary antibodies include goat anti-rat Alexa 546 (Molecular Probes, Eugene, Oreg.).
- RNA Analysis Total RNA was isolated from the ears using Qiazol (Qiagen, Valencia, Calif.). The first strand cDNA was synthesized using Reverse Transcriptase II (Invitrogen, Carlsbad, Calif.). The expression of the mouse genes was assayed by real-time quantitative PCR with an ABI PRISM 7900 Sequence Detector System (Applied Biosystems, Foster City, Calif.). Primers were designed to cross at least one intron based on the most current genome sequences using software Primer3 (Whitehead Institute for Biomedical Research, MIT). The quantitative PCR was performed using TaqMan PCR reagent kits according to the manufacturer's protocol (Applied Biosystems, Foster City, Calif.). ECM genes and cytokine mRNA levels were normalized to ubiquitin mRNA levels and expressed relative to normal untreated samples.
- Immunohistological analysis of skin lesions showed an increase in inflammatory cytokine expression IL-1 ⁇ , TNF- ⁇ , macrophage inflammatory protein 2-alpha precursor (Mip2 ⁇ ) and a key adhesion molecule, intercellular adhesion molecule 1 (ICAM-1) in the inflamed ears ( FIG. 28 ).
- Both topical NF- ⁇ B decoy and BMV treatment decreased the expression of IL-1 ⁇ , TNF- ⁇ Mip2 ⁇ and ICAM-1.
- Tissues treated with the scrambled ODN showed no alteration in the expression of these molecules.
- NF- ⁇ B decoy and BMV treatment inhibits mRNA levels of both Th1 and Th2 related proinflammatory genes including chemokine (C-C motif) receptor 3 (CCR3), IL-4, ICAM, thymic stromal lymphopoietin (TSLP), IL-13, IFN ⁇ , IL-1 ⁇ and TNF- ⁇ ( FIG. 29 ).
- NF- ⁇ B decoy treated Dp Ag-inflamed ears was analyzed by Tunnel assay and by Ki67 staining ( FIG. 30 ).
- Enhanced apoptosis mediated by BMV and topical NF- ⁇ B decoy application on inflammed ears was observed, in both the skin epidermis and dermis ( FIG. 30 ).
- the scramble ODN failed to elicit a similar response.
- Positive Ki67 staining showed increased proliferation in the epidermal and dermal layers of inflamed ears ( FIG. 30 ; lower panel).
- Topical NF- ⁇ B decoy similar to BMV, exerts its anti-inflammatory action by blocking expression of major inflammatory regulators and by inducing apoptosis of inflamed skin cells.
- Dp Dustmite Ag
- NC/Nga mice Charles River Lab
- Animals were injected intradermally with 5 ⁇ g of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on days 0, 2, 4, 7, 9, and 11.
- the Dp injected ear was topically treated 2 times a day for 11 -14 days with 20 ⁇ l of vehicle, vehicle containing 0.25% or 1% NF- ⁇ B decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control.
- the ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment.
- topical NF- ⁇ B decoy did not cause skin atrophy in a 4-week dermal pig and a 21-week mouse carcinogenicity study.
- ECM extra-cellular matrix
- Dp Dustmite Ag
- NC/Nga mice Charles River Lab
- Animals were injected intradermally with 5 ⁇ g of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on days 0, 2, 4, 7, 9, and 11.
- the Dp injected ear was topically treated 2 times a day for 11-14 days with 20 ⁇ l of vehicle, vehicle containing 0.25% or 1% NF- ⁇ B decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control.
- the ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment.
- TEWL Measurements Transepidermal water loss in Dp-induced inflamed ears was measured using a Tewameter water analyzer (Courage and Khazaka, Cologne, Germany). Inflamed ears were treated with scramble ODN, 1% NF- ⁇ B decoy or BMV for 14 days twice-a-day (BID). Ears were analyzed 16-18 hrs after the last application of either scramble ODN, 1% NF- ⁇ B decoy or BMV.
- PCRPK Analysis The amount of NF- ⁇ B decoy in skin tissue was determined by using in-house developed method. Simply, the method is based on real-time quantitative PCR based assay with specific primer design and reagent modifications.
- the skin samples undergo alkaline lysis (using P2 buffer of Qiagen Miniprep Kit). Quantitative measure of NF- ⁇ B decoy in samples is obtained by comparing with the standard curve that is prepared by spiking known amounts of NF- ⁇ B decoy to the same biological matrix (or sample without NF- ⁇ B decoy treatment). The final value of NF- ⁇ B decoy in tissue was normalized to the net tissue weight.
- NF- ⁇ B decoy and steroid treatment were compared. Unlike NF- ⁇ B decoy, cessation of BMV resulted in an immediate and severe rebound of swelling and inflammation.
- PCRPK Polymerase Chain Reaction Pharmacokinetics
- BMV treatment withdrawal causing rebound is known to be associated with barrier disruption; therefore the effects of BMV and topical NF- ⁇ B decoy on integrity of mouse stratum corneum (SC) were determined by measuring the rate of Transepidemal Water Loss (TEWL). Increase of TEWL in inflamed ears was restored to normal levels by topical NF- ⁇ B Decoy application for 14 days (BID) ( FIG. 37 ). In contrast, BMV treatment failed to achieve complete reduction of TEWL, indicative of the lack of normal restoration of epidermal permeability. Next, the likelihood of topical NF- ⁇ B decoy or BMV application (BID for 14 days) on normal ears to exert adverse effects on SC function was assessed.
- TEWL Transepidemal Water Loss
- BMV nor NF- ⁇ B decoy produced any changes in basal TEWL.
- BMV treatment showed a significant delay of barrier recovery at 3 hrs, 6 hrs and 24 hrs ( FIG. 38 ).
- NF- ⁇ B decoy treatment does not increase expression of inflammation-associated genes like skin-derived antileucoproteinase (SKALP), cytokeratin 6 (CK6), and cytokeratin 16 (CK16) levels, as observed in inflamed skin ( FIG. 39 ).
- SKALP skin-derived antileucoproteinase
- CK6 cytokeratin 6
- CK16 cytokeratin 16
- BMV treatment further augments this expression ( FIG. 39 ).
- the inflammation-associated cytokeratin 17 (CK17) mRNA levels were not induced in this inflammation model (data not shown).
- topical NF- ⁇ B decoy treatment restored inflammation-induced compromised barrier function and does not induce inflammation-associated cytokeratin genes.
- NF- ⁇ B plays a pivotal role in the development of arthritis.
- Collagen Induced Arthritis was induced using a method previously described by Trentham et al., Arthritis Rheum 25:911-6 (1982). Briefly, 6 week old female DA rats (Charles Rivers) were immunized intradermally with 1 mg of bovine type II collagen (Chondrex) dissolved in 0.5 ml of 0.1M acetic acid at 4° C. and emulsified in 0.5 ml of cold Freund's incomplete adjuvant (Difco, Detroit, Mich.). Onset of arthritis in the ankle joints could be seen between 10 and 12 days. All rats whose onset of arthritis could not be recognized visually by day 13 were excluded from the study.
- the rats were anesthetized with isoflurane.
- 50 ⁇ l of a 100 ⁇ g solution of NF- ⁇ B decoy was injected into the articular space of the hind ankle with a 27 gauge needle.
- 0.5 mg of prednisolone was injected into the articular space of the hind ankle. Footpad swelling was measured with a caliper every other day for the first 2 weeks then 1 ⁇ week there after.
- Hindpaw swelling in CIA rats injected with NF- ⁇ B decoy was measured daily for the first week and then twice a week thereafter. As shown in FIG. 8 , one-time injection of NF- ⁇ B decoy markedly reduced footpad swelling starting on day 23 and continued to resolve at a faster rate while the inflammation in the scramble control gradually decreased over time. Prednisolone treated animals significantly decreased hindpaw swelling almost immediately after injection and continued to suppress swelling throughout the experiment.
- AIA adjuvant induced arthritis
- AIA was induced using a method previously described by Taurog et al. ( Cell Immunol 75:271-82 (1983); Cell Immunol 80:198-204 (1983)). Briefly, 7-8 -week old female Lewis rats (Charles Rivers) were immunized intradermally at the base of the tail with 0.2 ml of a 10 mg/ml solution of Freund's adjuvant containing heat-killed mycobacterium tuberculosus H37Ra (Difco, Detroi, Mich.). Onset of arthritis in the ankle joints could be seen between 10 and 12 days. All rats whose unset of arthritis could not be recognized visually by day 12 were excluded from the study.
- the rats were anesthetized with isoflurane.
- 50 ⁇ l of a 100 ⁇ g solution of NF- ⁇ B decoy was injected into the articular space of the hind ankle with a 27 gauge needle.
- 0.5 mg of prednisolone was injected into the articular space of the hind ankle. Footpad swelling was measured with a caliper daily for the first week and 2 times a week thereafter.
- Trinitrobenzene sulfonic acid (TNBS)-induced colitis in the mouse is one of the most relevant animal models that resembles the etiology of Crohn's disease (CD) in humans.
- intestinal inflammation develops as a result of the covalent binding of the haptenizing agent to autologous host proteins with subsequent stimulation of a delayed-type hypersensitivity to TNBS-modified self antigens.
- the hapten-induced colitis displays CD-like features, notably transmural mononuclear inflammation and predominant Th-1 activity of the resident mucosal leukocytes. Inflammation and cytokine production in TNBS-treated mice, as well as in CD patients, is associated with activation of transcription factors such as nuclear factor NF- ⁇ B.
- colitis is induced in SJL/J mice by intrarectal administration of 2 mg TNBS in a 45% ethanol solution.
- Intrarectal injection is administered with a 3.5F polyurethane umbilical catheter equipped with a 1 -ml syringe. The catheter is inserted so that the tip is 3 cm proximal to the anal verge and the TNBS was injected with a total volume of 100 ⁇ l.
- mice are held in a vertical position for 30 s after the injection.
- mice Changes in body weight are monitored daily, which typically amount to weight losses of 15-30% occurring over a period of approximately 1-4 weeks after TNBS administration.
- the mice are treated with decoy in the same intrarectal manner with a single administration either prior to TNBS (prophylactic) or at various time points post TNBS induction (therapeutic). In some instances a second decoy treatment may be administered to prolong therapeutic effects if deemed necessary.
- animals are sacrificed at different time points to harvest tissues for mRNA and/or protein expression and histological analysis.
- NF- ⁇ B decoy The efficacy of NF- ⁇ B decoy was corroborated at the histopathological level in colons harvested from mice in both treatment groups at the day 7 post induction time point ( FIG. 11 ).
- the TNBS-induced animals treated with vehicle alone showed localized inflammation, loss of the mucosal epithelium, an increase in crypt depth (with some sign of crypt branching), dissolution of the muscularis mucosae, and thickening of the muscularis layer (localized to the site of the inflammation). All these features are consistent with human inflammatory bowel disease (IBD) and the animal models presented in the literature.
- IBD human inflammatory bowel disease
- Oxazolone induced colitis in the mouse is a relevant model for studying disease pathology related to ulcerative colitis (UC) in humans.
- UC ulcerative colitis
- intestinal inflammation develops as a result of covalent binding of the haptenizing agent to autologous host proteins with subsequent stimulation of a delayed-type hypersensitivity to oxazolone-mediated self antigens.
- oxazolone elicits an inflammatory bowel disease involving the distal half of the colon, and has histologic features resembling UC rather than Crohn's disease.
- oxazolone colitis is driven by a Th2 as opposed to Th1 response.
- NF- ⁇ B regulates many of the cytokines, chemokines, and cell adhesion molecules contributing to this response.
- mice were presensitized by applying 200 ⁇ l of a 3% (w/v) solution of oxazolone (ethoxymethylene-2-phenyl-2-oxazolin-5-one) in 100% ethanol to a 2 ⁇ 2 cm field of shaved abdominal skin.
- mice were rechallenged intrarectally with 150 ⁇ l of 1.5% oxazolone in 50% ethanol or only 50% ethanol, again under general anesthesia with isoflurane.
- Intrarectal injection was administered with a 3.5F polyurethane umbilical catheter equipped with a 1-ml syringe.
- mice were held in a vertical position for 30 seconds after the injection. Changes in body weight were monitored daily. Typically 15-20% weight losses were observed over a period of approximately 5-7 days after oxazolone administration.
- the oxazolone colitis model has an accurate disease progression from which the animals fully recover within 7-10 days.
- mice were treated with the NF- ⁇ B decoy in the same intrarectal manner with a single administration either prior to intrarectal oxazolone challenge (prophylactic) or at various time points post oxazolone challenge (therapeutic). In some instances, a second decoy treatment may be administered to prolong therapeutic effects if deemed necessary. In addition to body weight measurements, in certain experiments animals were sacrificed at various time points to harvest tissues for mRNA expression and histological analysis.
- Examples 19, 20 and 21 show additional studies in three different mouse models of acute colitis that display unique features related to human IBD.
- the NF- ⁇ B decoy used in the experiments described in Examples 19, 20 and 21 was a 19 base pair (molecular weight of 13 kDa) double-stranded deoxyribonucleic acid comprised of a random mixture of R- and S-chiral forms of oligonucleotides.
- the sequence of the NF- ⁇ B decoy used in this study was: 5′AGTTGAGGACTTTCCAGGC-3′ (SEQ ID NO: 30) and 5′-GCCTGGAAAGTCCTCAACT-3′ (SEQ ID NO: 95).
- the scrambled oligonucleotides (ODN) sequence was 5′-CAGTAGTATGTGAGCCTGC-3′ (SEQ ID NO: 46) and 5′-GCAGGCTCACATACTACTG-3′ (SEQ ID NO: 96). All oligonucleotides used were phosphorothioates and were annealed by combining equal molarities of each strand at room temperature.
- Trinitrobenzene sulfonic acid (TNBS) colitis was induced in 5-6 week old male SJL/J mice.
- 2.5 mg TNBS (Sigma, Atlanta, Ga.) dissolved in 45% ethanol was administered intrarectally on day 0 with a 3.5F polyurethane umbilical catheter (Supplier) equipped with a 1-ml syringe. The catheter is inserted so that the tip is 4 cm proximal to the anal verge and the TNBS is injected with a total volume of 150 ⁇ l.
- mice are held in a vertical position for 30 s after the injection. Changes in body weight are monitored daily.
- the animals are treated in the same intrarectal manner with 150 ⁇ l of vehicle, vehicle containing specified dose of NF- ⁇ B decoy or scramble ODN (negative control ODN), or 0.3 mg/kg budesonide (Sigma, St. Louis, Mo.) as the steroid control.
- vehicle containing specified dose of NF- ⁇ B decoy or scramble ODN (negative control ODN), or 0.3 mg/kg budesonide (Sigma, St. Louis, Mo.) as the steroid control.
- ODN negative control ODN
- 0.3 mg/kg budesonide Sigma, St. Louis, Mo.
- NF- ⁇ B decoy treatment In addition to assessing the ability of NF- ⁇ B decoy treatment to mitigate pro-inflammatory responses in colitis discussed below, the ability of NF- ⁇ B decoy treatment to affect mucosal repair processes was evaluated. Mucosal healing in the gastrointestinal tract requires both restitution and regeneration of the epithelium. (See Okamoto and Watanabe, Dig Dis Sci, 50 Suppl 1:S34-8 (2005); Taupin and Podolsky, Nat Rev Mol Cell Biol, 4:721-32 (2003)). Restitution promotes epithelial-cell migration to reseal lesions and re-establish surface-cell continuity.
- the trefoil factor family of secreted peptides play an essential role in protecting the mucosal epithelium from a range of insults and contribute to restitution and repair.
- NF- ⁇ B activation has been specifically associated with decreased intestinal trefoil factor (ITF) expression in inflamed epithelium.
- ITF intestinal trefoil factor
- the immunohistochemical staining was carried out with Autostainer (DAKO, Carpinteria, Calif.) using rabbit monoclonal anti-Ki67 (LabVision, Freemont, Calif.), peroxidase-conjugated mouse anti-smooth muscle actin, EPOS-SMA (DAKO, Carpinteria, Calif.), goat anti ITF (intestinal trefoil factor) (Santa Cruz Biotechnologies, Inc., Santa Cruz Calif.).
- the primary antibodies were localized by anti-rabbit SuperPicture-HRP reagent (ZYMED, South San Francisco, Calif.), biotinylated anti-goat IgG, biotinylated anti-rat IgG and ABC-HRP (Vector Laboratories, Inc., Burlingame, Calif.). Peroxidase activity was revealed using DAB substrate. The sections were counterstained with hematoxylin before coverslipping.
- fluorescently labeled decoy (HEX-NF ⁇ B decoy) was intrarectally administered into mice with TNBS-induced colitis as discussed below.
- HEX-NF ⁇ B decoy succinimidyl ester labeled NF- ⁇ B decoy
- TNBS-treated mice Colon harvested after 6 hours was embedded and frozen in Tissue-Tek OTC following formalin fixation.
- the whole colon of HEX-NF ⁇ B decoy treated animals was embedded and frozen in Tissue-Tek OTC following formalin fixation.
- the frozen sections were photographed using a NIKON laser scanning confocal microscope (NIKON USA, NJ).
- NIKON USA NIKON USA, NJ.
- a NIKON Eclipse E800 light microscope was fitted with the PCM 2000 confocal system.
- the fluorochromes were sequentially excited with a HeNe laser followed by an Argon laser (using the 488 line for excitation).
- the confocal images were captured with Simple PCI software, v. 4.0.6 (Compix Inc., Cranberry Township, Pa.).
- the HEX-NF ⁇ B decoy concentrated specifically at sites of inflammation, with little to no decoy accumulation observed in non-inflamed areas where the mucosal epithelium is intact.
- HEX-NF ⁇ B decoy uptake and /or accumulation were not seen in the cells of intact mucosal epithelium or in cells in the underlying lamina basement ( FIG. 43A ).
- HEX-NF ⁇ B decoy accumulation was detected not only in the luminal inflammatory cells but also in cells throughout the lamina basement all the way to the muscularis mucosae ( FIG. 43B ).
- NF- ⁇ B decoy in tissue was determined using an in-house developed pharmacokinetic-PCR (PCRPK) method based on a real-time quantitative PCR assay with specifically designed primers and modified reaction mixture.
- PCRPK pharmacokinetic-PCR
- colons from TNBS-induced mice were analyzed for tissue NF- ⁇ B levels at various time points post treatment using an electrophoretic mobility shift assay.
- Nuclear extracts prepared from colon tissue were evaluated for transcription factor levels using the NF- ⁇ B TransAM assay (Active Motif, Carlsbad, Calif.) according to manufacturer's instructions.
- p65 binding in the vehicle treated animals increased through day 6 reaching a peak level of 0.82 ⁇ 0.02 A450 units and remaining elevated through day 8 ( FIG. 46 ).
- the amount of p65 available for binding was mitigated upon treatment with 1.5 mg/kg NF- ⁇ B decoy beginning on day 2, and after a second dose at day 4 p65 levels remained substantially lower than vehicle controls through day 7 (0.61 ⁇ 0.09 A450 units).
- Myeloperoxidase (MPO) activity can be used as a quantitative measure of the extent of neutrophil infiltration into inflamed tissue.
- MPO myeloperoxidase
- MPO activity was measured by adding 50 ml of supernatant to 250 ml of an assay reaction mixture containing 0.5% hexadecyltrimethylammonium bromide (in 50 mM potassium phosphate, pH 6.4), 0.17 mg/ml o-dianisidine dihydrochloride, and 0.0015% hydrogen peroxide. After a 30 min incubation period at room temperature, absorbance at 450 nm was measured. Absolute MPO activity was determined based on the generation of a standard curve and normalized with protein concentration as determined by BCA assay (Pierce, Rockford, Ill.).
- Colitis induction with TNBS followed by vehicle treatment resulted in substantially increased MPO activity levels that peaked at post induction day 2 but remained elevated at the day 7 endpoint.
- Treatment with 1.5 mg/kg NF- ⁇ B decoy on days 2 and 4 post disease induction significantly decreased the colonic MPO activity by 52% at day 7 (p ⁇ 0.05) ( FIG. 48 ).
- the scramble ODN had no protective effect, ruling out non-specific inhibitory mechanisms.
- this data indicates the ability of NF- ⁇ B decoy to reduce infiltration and activity of inflammatory cells in colonic tissue and that the effectiveness of NF- ⁇ B decoy was sequence dependent and superior to budesonide.
- TNBS-induced inflammation resulted in upregulation of TNF ⁇ , IL-1 ⁇ , IL-6, IL-12 and MCP-1 mRNA levels ( FIG. 49 ).
- Treatment with 1.5 mg/kg NF- ⁇ B decoy resulted in a 5-fold reduction in TNF ⁇ levels as compared to vehicle controls at the day 7 endpoint (1.1 ⁇ 0.4 versus 5.1 ⁇ 1.3, respectively; p ⁇ 0.05).
- the highly expressed cytokines IL-6 and IL-1 ⁇ were reduced by NF- ⁇ B decoy treatment 2- and 4-fold (P ⁇ 0.05); respectively.
- IL-12 a key Th1-inducing cytokine, was down-regulated nearly 4-fold in NF- ⁇ B decoy treated mice (data not shown).
- These important mediators of the inflammatory response are all controlled by NF- ⁇ B and affect the differentiation and activation of key immune cells, including macrophages, lymphocytes and polymorphonuclear neutrophils. The ability of NF- ⁇ B decoy to down-regulate these important inflammatory mediators indicates one of the mechanisms by which efficacy is achieved in ameloriating colitis.
- the purpose of this experiment was to determine the therapeutic potential of our NF- ⁇ B decoy to treat a Th2 cytokine-mediated colitis model.
- Oxazolone-induced colitis was initiated by presensitizing C57BL/10 mice with a 3% (w/v) solution of oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one; Sigma, Atlanta, Ga.) in 100% ethanol applied topically to a 2 ⁇ 2 cm field of shaved abdominal skin. 5-7 days after presensitization mice are rechallenged intrarectally with 150 ul of 1.5% oxazolone in 50% ethanol or 50% ethanol alone under general anesthesia with isoflurane.
- mice are treated with 1.5 or 5 mg/kg NF- ⁇ B decoy or 0.3 mg/kg budesonide in the same intrarectal manner with a single administration either prior to intrarectal oxazolone challenge (prophylactic) or at various time points post oxazolone challenge (therapeutic).
- NF- ⁇ B decoy Animals receiving NF- ⁇ B decoy treatment showed greater improvement than those given budesonide in a majority of the pathological parameters evaluated; including mucoid crypt cysts and abscesses, goblet cell depletion, edema, mononuclear cell infiltration and transmural inflammation. Overall, this data shows that topical delivery of naked NF- ⁇ B decoy has a better efficacy profile than budesonide in a Th2-mediated disease model.
- DSS dextran sodium sulphate
- DSS dextran sodium sulfate
- NF- ⁇ B decoy 35-45 kDa
- scramble ODN negative control ODN
- vehicle every other day by intrarectal administration from day 0 to day 9.
- a disease activity index (DAI) was calculated on day 10 based on the summation of scores evaluating weight loss, blood in stool, and stool consistency. Each parameter was graded on a scale of 0 to 4, and the combined scores were divided by 3 to obtain the final disease activity index. The presence of blood in the stool was evaluated with Hemoccult test strips (Supplier).
- Colon lengths were also measured when mice were sacrificed. Chronic colitis was induced by giving the mice 4% DSS in their drinking water for two cycles. The first cycle of DSS administration was followed by 14 days of plain drinking water. The second cycle of DSS was followed by 3 days of plain drinking water, after which the mice were sacrificed. NF- ⁇ B decoy (5 mg/kg) was intrarectally administered every other day for a total of 5 treatments beginning the first day of each DSS cycle.
- a repeated inflammation cycle protocol for the DSS model was used to assess the effectiveness of NF- ⁇ B decoy treatment under more clinically-related chronic inflammatory conditions. Treatment in this model was given therapeutically, beginning at the start of the 2 nd cycle. Ten days into the second DSS cycle, the NF- ⁇ B decoy treated group had a significantly lower DAI score as compared to the vehicle control ( FIG. 56 ) (p ⁇ 0.0015).
- the decreased DAI score in the NF- ⁇ B decoy treated mice comprised reductions of over 30% in weight loss (1.9 ⁇ 0.3 versus 2.9 ⁇ 0.2) and stool consistency scores (1.6 ⁇ 0.2 versus 2.4 ⁇ 0.2), and a reduction of over 80% in the amount of fecal occult blood (0.1 ⁇ 0.1 versus 0.6 ⁇ 0.2) observed in this group. No effect was observed with the scramble ODN.
- the NF- ⁇ B decoy treated colons still displayed some intermittent areas of inflammation but overall the colitic damage was substantially reduced compared to vehicle treated controls which had very high levels of infiltrates, lamina intestinal edema, disrupted crypt morphology, loss of goblet cells, and large well-developed lymphoid aggregates (data not shown).
- the amelioration of disease in the DSS induced colitis model shows the therapeutic potential of NF- ⁇ B decoy in a mixed Th1/Th2 mediated disease.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
Abstract
The present invention concerns double-stranded NF-κB decoy oligodeoxynucleotide (NF-κB dsODN) molecules that contain a core sequence capable of specific binding to an NF-κB transcription factor. In a particular aspect, the invention concerns NF-κB decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention concerns NF-κB decoy molecules with improved binding affinity to p65.
Description
- This application is a continuation application of copending U.S. application Ser. No. 11/368,060 filed on Mar. 3, 2006, which is a continuation-in-part of U.S. application Ser. No. 11/004,512 filed on Dec. 2, 2004, which claims priority under 35 U.S.C. § 119(e)(1) of U.S. provisional patent application Ser. No. 60/526,623, filed on Dec. 2, 2003, and U.S. Provisional patent application Ser. No. 60/612,029, filed on Sep. 21, 2004, the entire disclosures of which are hereby expressly incorporated by reference.
- 1. Field of the Invention
- The present invention concerns NF-κB oligonucleotide decoy molecules, and their use in the treatment of various NF-κB related diseases and pathological conditions.
- 2. Description of the Related Art
- NF-κB is a family of inducible dimeric transcription factors composed of members of the Rel family of DNA-binding proteins that recognize a common sequence motif. In its active DNA-binding form, NF-κB is a heterogeneous collection of dimers, composed of various combinations of members of the NF-κB/Rel family. At present, this family is composed of 5 members, termed p52, p50, p65, cRel and Rel B. The homology between the members of the Rel family is through the Rel homology domain, which is about 300 amino acids in size and constitutes the DNA-binding domain of these proteins.
- Different NF-κB dimers exhibit different binding affinities for NF-κB sites bearing the consensus sequence GGGRNNYYCC (SEQ ID NO: 1) where R is purine, Y is pyrimidine and N is any base. The Rel proteins differ in their abilities to activate transcription, such that only p65/RelA and c-Rel were found to contain potent transcriptional-activation domains among the mammalian family members. NF-κB is found in its inactive form in the cytoplasm, where it is bound to the 43-kDa protein IKB that covers the nuclear localization signal region of the p65/p50 dimer. Activation of NF-κB starts with the proteolytic destruction of IKB followed by the transport of the RelA/p50 complex into the nucleus, where it binds to its recognition site on the DNA and activates transcription of target genes. For further review of the NFκB family see, for example, Gomez et al., Frontiers in Bioscience 2:49-60 (1997).
- p52 and p50 do not contain transactivation domains. Dimers composed solely of p52 and/or p50 proteins that lack transcriptional activation domains are generally not activators of transcription and can mediate transcriptional repression.
- The transcription factors of the Rel/NF-κB family are key regulators of immune and inflammatory responses, and contribute to lymphocyte proliferation, survival and oncogenesis. Thus, NF-κB plays a key role in the expression of several genes involved in the inflammation, cell proliferation and immune responses. (D'Acquisto et al., Gene Therapy 7: 1731-1737 (2000); Griesenbach et al., Gene Therapy 7, 306-313 (2000); Morishita et al., Gene Therapy 7: 1847-1852 (2000)). Among the genes regulated by NF-κB are many which play critical roles in various diseases and conditions, such as rheumatoid arthritis, systemic lupus erythematosus, restenosis, myocardial infarction, ischemia reperfusion injury, glomerulonephritis, atopic dermatitis, saphenous vein graft, Alzheimer's disease, to name a few. See, e.g. Khaled et al. Clinical Immunology and Immunopathology 86(2): 170-179 (1998); Morishita et al., Nature Medicine 3(8): 894-899 (1997); Cho-Chung et al., Current Opinion in Molecular Therapeutics 1(3): 386-392 (1999); Nakamura et al., Gene Therapy 9: 1221-1229 (2002); Shintani et al., Ann. Thorac. Surg. 74: 1132-1138 (2002); and Li et al., J. Neurochem. 74(1): 143-150 (2000).
- NF-κB decoys have been proposed for the inhibition of neointimal hyperplasia after angioplasty, restenosis and myocardial infarction (Yoshimura et al., Gene Therapy 8: 1635-1642 (2001); Morishita et al., Nature Medicine 3(8): 894-899 (1997)). The greater inhibition of reperfusion injury, acute, and chronic rejection after transplantation results in a prolongation of allograft survival and decrease in graft coronary artery disease. (Feeley et al., Transplantation 70(11): 1560-1568 (2000)). In vivo transfection of an NF-κB decoy provides a novel strategy for treatment of acute myocarditis. (Yokoseki et al., supra). Ueno et al., supra reported that blocking NFκB by NFκB decoy prevented ischemia reperfusion injury in the heart.
- It has been shown (Ziegler-Heitbrock et al, J. Leukoc. Biol. 55(10:73-80 (1994); Kastenbauer and Ziegler-Heitbrock, Infect. Immunol. 67(4):1553-9 (1999)) that when a human monocyte cell line, Mono Mac 6, was pre-treated for two days with low doses of lipopolysaccharide (LPS), the response to subsequent LPS stimulation was strongly reduced. Upon stimulation of these LPS-tolerant cells with LPS, these cells exhibited a predominance of the p50 homodimer as shown by the gel shift assay. The authors then tested the effect of the altered NF-κB complexes on gene expression via reporter gene analysis. NF-κB-dependent HIV-1 LTR reporter gene constructs were transfected into
Mono Mac 6 cells, followed by pre-culture with and without LPS, and luciferase activity was measured. When LPS-tolerant cells were tested, LPS stimulation did not increase transactivation of the NF-κB-dependent HIV-1 LTR reporter gene. This indicates that the NF-κB complexes present in LPS-tolerant cells are functionally inactive. This also was applicable to the transcription of the NF-κB-controlled TNF gene. Using a TNF promoter-controlled luciferase reporter construct, LPS-tolerant cells showed only a minimal response to LPS stimulation. Therefore, it was concluded that the p50 homodimers induced by LPS tolerance lack transactivation activity. These p50 homodimers instead occupy the cognate NF-κB-binding sites and prevent transactivation and therefore transcription by the p50/p65 complex. - The present invention concerns double-stranded NF-κB decoy oligodeoxynucleotide (NF-κB dsODN) molecules that contain a core sequence capable of specific binding to an NF-κB transcription factor. In a particular aspect, the invention concerns NF-κB decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers when p50/p50 homodimers are present. The selective decoy molecules of the invention, by not blocking p50/p50 homodimers, allow these homodimers to block the promoters of NF-κB regulated genes, which provides an additional level of negative regulation of gene transcription. As a result, the selective NF-κB decoy molecules are particularly potent inhibitors of NF-κB activity both in vitro and in vivo.
- If p50/p50 homodimers are not present, are present only in small amounts, or do not play a significant role in the disease state, the invention provides NF-κB decoy molecules with high binding affinity for p65.
- In one aspect, the invention concerns double-stranded NF-κB decoy oligodeoxynucleotide (NF-κB dsODN) molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers relative to p50/p50 homodimers.
- In another aspect, the invention concerns an NF-κB double-stranded decoy oligodeoxynucleotide (dsODN) molecule, comprising a sense and an antisense strand, which preferentially binds p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers when p50/p50 homodimers are present and/or exhibits a p65 binding affinity of 45 or less, as determined by measuring the molar excess required to compete at least 50% of binding of p65/p50 in an electromobility shift assay to the non-mammalian NF-κB promoter from HIV (sequence 113/114).
- In yet another aspect, the invention concerns The dsODN molecule of
claim 1 characterized by a specificity/affinity factor of at least about 20, where the specificity/affinity factor is determined in a competitive binding assay, and is defined as follows:
Specificity/affinity factor=(S p50/p50 −S p65/p50)×S p50/p50 /S p65/p50 - where Sp50/p50 equals the molar excess of said dsODN molecule required to compete 50% of the binding of p50/p50 to the non-mammalian NF-κB promoter from HIV (sequence 113/114) and Sp65/p50 equals the molar excess of said dsODN molecule required to compete 50% of the binding of p65/p50 to the non-mammalian NF-κB promoter from HIV (sequence 113/114), and wherein the score (S) is assigned as 100 if the decoy is unable to compete at least 50% of the binding at any molar ratio tested.
- In another aspect, the present invention concerns NF-κB dsODN molecules that have a specificity/affinity factor of at least about 25, or at least about 30, or at least about 35, or at least about 40, or at least about 50 or at least about 60, or at least about 70, or at least about 80. In a preferred embodiment, the decoy molecules of the invention additionally show increased binding affinity to the p50/p65 heterodimers and/or have improved stability in vivo.
- In a further aspect, the invention concerns a dsODN molecule comprising in its first strand, in 5′ to 3′ direction, a sequence of the formula FLANK1-CORE-FLANK2, wherein
- CORE is selected from the group consisting of GGGATTTCC (SEQ ID NO: 11); GGACTTTCC (SEQ ID NO: 13); GGATTTCC (SEQ ID NO: 19); GGATTTCCC (SEQ ID NO: 21); and GGACTTTCCC (SEQ ID NO: 25);
- FLANK1 is selected from the group consisting of AT; TC; CTC; AGTTGA (SEQ ID NO: 79), and TTGA (SEQ ID NO: 80);
- FLANK2 is selected from the group consisting of GT; TC; TGT; AGGC (SEQ ID NO: 88); and AG.
- In a specific embodiment, CORE is selected from the group consisting of GGGATTTCC (SEQ ID NO: 11); GGACTTTCC (SEQ ID NO: 13); and GGATTTCC (SEQ ID NO: 19); FLANK1 is AT and FLANK2 is GT; or FLANK1 is TC and FLANK2 is TC; or FLANK1 is CTC and FLANK2 is TGT; or FLANK1 is AGTTGA (SEQ ID NO: 79) and
FLANK 2 is AGGC (SEQ ID NO: 88); or FLANK1 is TTGA and FLANK2 is AG. - In another specific embodiment, CORE is GGGATTTCC (SEQ ID NO: 11); or GGACTTTCC (SEQ ID NO: 13), FLANK1 is AGTTGA (SEQ ID NO: 79) and
FLANK 2 is AGGC (SEQ ID NO: 88). - In yet another specific embodiment, The dsODN molecule of
claim 14 wherein CORE is GGACTTTCC (SEQ ID NO: 13), FLANK1 is AGTTGA (SEQ ID NO: 79) andFLANK 2 is AGGC (SEQ ID NO: 88). - The NF-κB dsODN molecules include a second strand that is at least partially complementary to said first strand, and may have a phosphodiesterate, phosphorothioate, mixed phosphodiesterate-phosphorothioate, or any other modified backbone.
- The two strands may be connected to each other solely by Watson-Crick base pairing and/or by covalent bonds.
- In a further aspect, the invention concerns an NF-κB dsODN molecule comprising a sequence, in 5′ to 3′ direction, selected from the group consisting of
SEQ ID NOs 26 through 77 and 10. - In a still further aspect, the invention concerns an NF-κB dsODN molecule comprising a sequence, in 5′ to 3′ direction, selected from the group consisting of SEQ ID NOs: 26 through 34.
- In another aspect, the invention concerns an NF-κB dsODN molecule comprising a sequence, in 5′ to 3′ direction, selected from the group consisting of SEQ ID NOs: 26 through 31.
- In yet another aspect, the invention concerns an NF-κB dsODN molecule comprising the sequence of SEQ ID NO: 30.
- In a particular embodiment, the NF-κB dsODN molecule is 12 to 28, or 14 to 24, or 14 to 22 base pairs long, and may comprise modified or unusual nucleotides.
- In a further aspect, the invention concerns an NF-κB dsODN molecule which exhibits a p65 competitive binding affinity of 45 or less.
- In a particular embodiment, the dsODN with good p65 binding affinity comprises in its sense strand, in 5′ to 3′ direction, a sequence of the formula FLANK1-CORE-FLANK2, wherein
- CORE is selected from the group consisting of GGGGACTTTCCC (SEQ ID NO: 9); GGGACTTTCC (SEQ ID NO: 5); GGACTTTCCC (SEQ ID NO: 25); GGGATTTCC (SEQ ID NO: 11); and GGACTTTCC (SEQ ID NO: 13);
- FLANK1 is selected from the group consisting of AGTTGA (SEQ ID NO: 79); CTC; TC; CT; CCTTGAA (SEQ ID NO: 6); and CT; and
-
FLANK 2 is selected from the group consisting of AGGC (SEQ ID NO: 88); TGT; TC; AGG; TCC; and TCA. - Just as in other aspects of the invention, the latter dsODN molecules may have hybrid or otherwise modified backbones, strands that are partially or fully complementary, and connected to each other, completely or partially, by Watson-Crick base pairing and/or by other covalent or non-covalent means.
- In another aspect, the invention concerns a composition comprising an NF-κB double-stranded decoy oligodeoxynucleotide (dsODN) as described above. The composition may, for example, be a pharmaceutical composition.
- In yet another aspect, the invention concerns a method for the treatment of an inflammatory, immune or autoimmune disease, comprising administering to a mammalian subject in need an effective amount of an NF-κB double-stranded decoy oligodeoxynucleotide (dsODN) molecule described above.
- The invention further concerns a method for the treatment of cancer, comprising administering to a mammalian subject in need an effective amount of an NF-κB double-stranded decoy oligodeoxynucleotide (dsODN) molecule herein.
- In a further aspect, the invention concerns a method for the treatment of reperfusion injury or restenosis, comprising administering to a mammalian subject in need an effective amount of an NF-κB double-stranded decoy oligodeoxynucleotide (dsODN) molecule herein.
- In all aspects, the mammalian subject is preferably human.
-
FIG. 1 is a graph showing the p65/p50 binding of certain NF-κB decoy molecules. -
FIG. 2 is a graph showing the p50/p50 binding of certain NF-κB decoy molecules. -
FIG. 3 shows an electrophoretic mobility-shift assay (EMSA) analysis that identifies the NF-κB proteins contained in complexes bound to a radiolabeled oligonucleotide probe with the NF-κB transcription factor binding site. -
FIG. 4 shows that topical application of NF-κB decoy suppresses inflammation in a dose dependent manner in a mouse model of atopic dermatitis. -
FIG. 5 shows that cessation of the betamethasone, but not NF-κB decoy treatment results in a rebound of ear swelling and inflammation in the Dp injected ear. -
FIG. 6 shows that topical NF-κB decoy treatment decreases the expression of pro-inflammatory cytokines (IL-1B and IL-6) in Dp induced murine atopic dermatitis. -
FIG. 7 shows that topical application of NF-κB decoy suppresses inflammation and the infiltration of inflammatory cells responsible for atopic dermatitis, and decreases epidermal hyperproliferation, cellular infiltration and degranulation of mast cells. -
FIG. 8 shows that administration of NF-κB decoy into the arthritic joints of rats with collagen induced arthritis (CIA) leads to amelioration of arthritis. -
FIG. 9 shows that administration of NF-κB decoy into the arthritic joints of rats with adjuvant induced arthritis (AIA) leads to amelioration of arthritis. -
FIG. 10 shows that NF-κB decoy reverses weight loss in a murine model of TNBS-induced colitis. -
FIG. 11 shows that NF-κB decoy reduces inflammation in a murine model of TNBS-induced colitis. -
FIG. 12 shows that NF-κB decoy reverses weight loss in oxazolone-induced colitis. -
FIG. 13 shows that NF-κB decoy increases survival in oxazolone-induced colitis. -
FIG. 14 shows the relationship of NF-κB affinity of various decoy molecules as predicted by bioinformatics versus the specificity/affinity factor experimentally generated. -
FIG. 15 is a scatter plot of bioinformatics matrix binding score versus competition score when binding to p65/p50. Lower competition scores imply higher binding affinity. -
FIG. 16 is a scatter plot of the difference of competition scores between binding with p50/p50 and binding with p65/p50, versus the ratio of the competition scores (p50/p50 versus p65/p50). The plots within the smaller square represent the decoys with the best specificity for p65/p50 vs. p50/p50, whereas the plots outside the smaller and larger square have poor specificity, and the plots between (outside the smaller square and inside the larger square) have intermediate specificity. -
FIG. 17 shows that a phosphorothioated NF-κB decoy is stable to nucleases contained in mouse serum as compared to a corresponding decoy having a phosphodiester backbone. -
FIG. 18 shows quantitated results from a competitive Electrophoretic Mobility-Shift Assay (EMSA) which indicates the ability of the NF-κB decoy to specifically bind to NF-κB subunits as compared to a scramble ODN. Identification of the complexes is shown by antibody supershift. -
FIG. 19 shows NF-κB decoy efficacy in a chronic murine inflammation model. NC/Nga mice injected intradermally with Dp-extract showed ear swelling. Treatments initiated on day 11 (indicated by the arrow) include 1% scramble ODN, 0.25% and 1% NF-κB decoy and 0.1% betamethasone valerate (BMV). The error is expressed as standard error of the mean (SEM) (n=8, P<0.001). These results are representative of 10 independent experiments. -
FIG. 20 shows NF-κB decoy efficacy in an acute murine inflammation model. A single application of 2 μg/ml phorbol 12-tetradecanoate 13-acetate (TPA) induced an acute inflammatory response as noted by a dramatic increasee in ear thickness. Treatments include 1% scramble ODN, 0.1% 0.25% and 0.5% NF-κB decoy and 0.1% betamethasone valerate (BMV). The error is expressed as SEM (n=8, *P<0.002). These results are representative of 5 independent experiments. -
FIG. 21 shows EMSA analysis that was performed using 32P-labeled probe and nuclear extracts prepared from control, inflamed, 1% scramble ODN, 1% NF-κB decoy or BMV treated NC/Nga ears. The identities of the NF-κB proteins contained in complexes bound to the radiolabeled oligonucleotide probe were determined by pre-incubating extracts with antibodies specific for each family member of the NF-κB proteins. The complexes indicated in the brackets contain p65 and p50 homo and heterodimers. Antibody/NF-κB protein complexes of slower mobility are indicated by the asterisk (right panel; *). These results are representative of 3 independent experiments. -
FIG. 22 shows the results of a quantitation gel shift analysis that was performed by normalizing the NF-κB specific band intensities to the values obtained from a TransAM assay performed with the same nuclear extracts for the ubiquitously expressed transcription factor, NF-YA. The y-axis represents normalized values to inflamed tissue, following which ratios were obtained with values for NF-κB band intensities to NF-YA absorbance readings. Each data point is representative of 4 independent ear samples. -
FIG. 23 shows that the tested NF-κB decoy suppresses inflammation. (A) Hematoxylin and Eosin (H&E)-stained sections showed Dp-induced hyperproliferated epidermis and edematous dermis, with massive increase in lymphocyte infiltrations. Sections were observed at a magnification of 10×, scale bar is 100 μm. (B) Toludine blue stained skin sections showing the number of mast cells (indicated by arrows). (C) Sections were stained with congo red to quantitate eosinophils (indicated by arrows). (D) CD4+ T cells were detected by immunoflouresence microscopy (indicated by arrows). Sections were observed at a magnification of 40×, scale bar in B, C, and D is 25 μm. -
FIG. 24 shows quantitative representation of the decrease in mast cells (*P<0.02 for 0.25% NF-κB decoy and P<0.04 for BMV), eosinophils (*P<0.01 for 0.25% NF-κB decoy and BMV) and CD4+ T cells upon topical NF-κB decoy and BMV treatment. -
FIG. 25 shows NF-κB decoy localization in inflamed tissue using 1% biotinylated NF-κB decoy. 1% NF-κB decoy-treated ears were stained for CD207+ LC, CD4+ cells, CD117+ mast cells and MCP-1+ macrophages. Laser scanning confocal microscopy images show that the NF-κB decoy is co-localized with cell markers. Sections were observed at a magnification of 60×, scale bar is 200 μm. Lower panel is a higher magnification of images taken at 60×. -
FIG. 26 shows NF-κB decoy delivery in normal porcine skin. Co-localization of 0.5% NF-κB decoy and nuclei is shown in the left panel. Non-treated skin as a negative control for avidin staining shows minimum background staining on the right panel. Sections were observed at a magnification of 40×, scale bar is 25 μm. -
FIG. 27 shows the results of pharmacokinetic-PCR assay that was performed on a pig skin to detect NF-κB decoy in ng levels. Increased uptake of the tested NF-κB decoy is shown in tape stripped samples. These results are representative of 2 independent experiments. -
FIG. 28 shows that NF-κB decoy inhibits proinflammatory regulators. 1% NF-κB decoy and BMV suppressed cytokine production. Inflamed ears after 14 days of treatment twice-a-day (BID) were stained with anti-IL-1β, anti-TNF-α, anti-MIP2α and anti-ICAM antibodies. Sections were observed at a magnification of 40×, scale bar is 25 μm. -
FIG. 29 shows that an NF-κB decoy suppresses key proinflammatory mRNA levels. Ubiquitin normalized mRNA levels of key proinflammatory genes from inflamed ears treated with 1% Scramble ODN, 1% topical NF-κB decoy and betamethasone valerate (BMV) for 7 days BID is represented on y-axis. The error is expressed as SEM (n=4). These results are representative of 3 independent experiments. -
FIG. 30 shows that NF-κB decoy induces apoptosis. Dustmite induced inflammed ears were analyzed for apoptosis by tunnel assay (upper panel) and for proliferation using Ki67staining (lower panel) after 2 days of treatment with BMV and 1% NF-κB decoy. Sections were observed at a magnification of 20×, scale bar is 100 μm. -
FIG. 31 shows the apoptotic and mitotic index. Quantitative representation as mitotic and apoptotic index as percent positive cells in epidermis and dermis is shown. Cells were quantitated from 6 independent fields from 3 independent samples. For apoptotic index: compare to inflamed sample P<0.0001 for NF-κB decoy and P<0.000 1 for BMV. For mitotic index: compare to inflamed sample P<0.006 for NF-κB decoy and P<0.0003 for BMV. The error is expressed as SEM. These results are representative of 3 independent experiments. -
FIG. 32 shows that NF-κB decoy does not cause skin atrophy. Normal mouse ears were treated with BMV and 1% NF-κB decoy for 14 days twice-a-day (BID). The error is expressed as SEM (n=8, P<0.0001). These results are representative of 5 independent experiments. -
FIG. 33 shows picro sirus red stained sections. Dermal thickness of normal treated ears was 93±12 μm, 1% NF-κB decoy treated ear was 89±10 μm and BMV treated ear was 66±7 μm. Sections were observed at a magnification of 40×, scale bar is 25 μm. -
FIG. 34 shows ubiquitin normalized mRNA levels of extracellular matrix genes. Collagen I (Col I), Collagen III (Col III), Tenacin C and elastin are represented on the y-axis, treatments include 1% NF-κB decoy and BMV. The error is expressed as SEM (n=4, BMV samples were compared to normal samples P<0.001 for Col I and Col III, P<0.03 for tenacin C and P<0.002 for elastin. These results are representative of 3 independent experiments -
FIG. 35 shows NF-κB decoy withdrawal does not cause rebound of swelling and inflammation. Pharmacokinetic-PCR analysis shows decreased 1% NF-κB decoy after 3 days. Ears were analyzed by real-time quantitative PCR. The error is expressed as SEM (n=8). These results are representative of 2 independent experiments. -
FIG. 36 shows Dp-Ag recall response after withdrawl of NF-κB decoy treatment. NC/Nga mice injected intradermally with Dp-extract showed ear swelling. BMV and 1% topical NF-κB decoy treatment was initiated on day 13 (indicated by the arrow). Ears were treated for 14 days twice-a-day (BID). Topical treatment was then stopped on day 28 (*). Following which a single intradermal injection of Dp-extract was performed in all groups. Ear swelling was measured for the next 2 weeks. Data is plotted as SEM (n=8). -
FIG. 37 shows that NF-κB decoy restores normal levels of transepidermal water loss (TEWL). TEWL measures of inflamed ears treated with BMV or 1% topical NF-κB decoy for 14 days BID show lack of normal restoration in BMV treated samples (marked with *), while 1% NF-κB decoy treated ears indicated normal TEWL. The error is expressed as SEM (n=8, P<0.005). These results are representative of 3 independent experiments. -
FIG. 38 also shows that NF-κB decoy restores normal levels of TEWL. Topical BMV and 1% topical NF-κB decoy treatment was performed on normal BALB/c ears for 14 days BID, followed by acetone treatment. Barrier recovery was determined at 3, 6, 24 hrs. The 100% value is from the untreated normal control animals. Results are plotted as % recovery and the error is expressed as SEM (n=8, P<0.005). These results are representative of 3 independent experiments. -
FIG. 39 shows that NF-κB decoy treatment does not increase expression of inflammation-associated stratum comeum genes. Ubiquitin normalized mRNA levels of inflammation associated stratum comeum genes from inflamed ears treated with BMV and 1% topical NF-κB decoy for 14 days BID are represented on the y-axis. Error is expressed as SEM (n=5, P<0.005). These results are representative of 2 independent experiments. -
FIG. 40 shows that NF-κB decoy treatment restores goblet cell function. Representative sections of trefoil factor family (TFF) and mucopolysaccharide staining in the colon assessing goblet cell function from vehicle (A, C, E) and 1.5 mg/kg NF-κB decoy (B, D, F) treatment groups seven days after induction of TNBS colitis are shown. -
FIG. 41 shows that NF-κB decoy reverses trinitrobenzesulfonic acid (TNBS)-induced colonic inflammation. Mice were treated intrarectally with saline vehicle (A), 1.5 mg/kg NF-κB decoy (B), 0.3 mg/kg budesonide (C), or 1.5 mg/kg scramble ODN (D) ondays day 7, fixed in formalin, and stained with hematoxylin and eosin. Shown are representative sections from each treatment group. -
FIG. 42 shows that NF-κB decoy treatment restores colonic tissue homeostasis. Ki67 staining of colonic sections from inflamed vehicle treated mice and mice receiving 2 doses of 1.5 mg/kg Decoy atday day 7 and processed for analysis. Proliferation in the mucosal epithelium is clearly reduced and restricted to normal zones of the intestinal crypts in the NF-κB decoy-treated mice (B) as compared to inflamed vehicle controls (A). Elevated proliferation in the inflamed colons was also evident in the lamina propria and muscularis layers (C). In NF-κB decoy treated mice, normal levels of proliferation were also observed in the lymphoid follicles (D). Smooth muscle actin staining revealed a very disrupted muscularis in the inflamed vehicle treated mice that was returned to normal after NF-κB decoy treatment (E versus F, respectively). -
FIG. 43 shows that NF-κB decoy is effectively delivered to inflamed regions of the colon. NF-κB decoy (2.5 mg/kg) labeled with a HEX flourophore was intrarectally applied to the colon at theday 4 post TNBS-induction time point and harvested 6 hr after administration. Sytox green nuclear counterstaining overlayed with the red Hex-labeled NF-κB decoy indicates the absence of NF-κB decoy in relatively normal colonic regions (A) and a very concentrated localization within inflamed lesions (B) throughout the colon. At higher magnification it is apparent that the NF-κB decoy co-localizes in the cell nucleus. -
FIG. 44 shows the amount of NF-κB decoy present in the tissue that was quantitated based on the percent of p65/p50 heterodimer remaining and normalized to vehicle control values. Data represent mean±S.E.M. values (n=3-5mice/group). -
FIG. 45 shows that NF-κB decoy inhibits p65/p50 complex in the colon. Colons from TNBS-induced mice were analyzed for tissue NF-κB levels by electrophoretic mobility shift assay using 32P-labeled probe and nuclear extracts prepared from inflamed vehicle controls and NF-κB decoy treated mice. -
FIG. 46 shows quantitation of transcription factor levels over an eight day timecourse that was graphed with trend line for regression analysis. -
FIG. 47 shows that NF-κB decoy reduces inflammatory cell infiltration and neutrophil activity. Immunohistochemistry for CD45+ cells indicates a reduction in the number of leukocytes after NF-κB decoy treatment (1.5 mg/kg) as compared to vehicle controls (A versus B). Neutrophil infiltration was specifically determined using a cell type specific antibody and by measuring myeloperoxidase levels in the TNBS-induced colons. The number of neutrophils is clearly reduced in histological sections from the distal colon after NF-κB decoy treatment (C versus D). -
FIG. 48 shows a significant decrease in MPO activity that was observed as a result of NF-κB decoy treatment at theday 7 time point. Results are expressed as units of MPO activity per mg protein in colons from 5-8 animals per group. Bars represent the mean±S.E.M from two independent experiments. Asterisk indicates significant difference compared with saline-treated group (p<0.05). -
FIG. 49 shows that NF-κB decoy reduces tissue cytokine mRNA levels. Ubiquitin normalized mRNA levels of TNFα (A), IL-6 (B), IL-1β (C) and MCP-1 (D) from inflamed colons after two intrarectal treatments with vehicle, 1.5 mg/kg NF-κB decoy, 0.3 mg/kg budesonide or 1.5 mg/kg scramble ODN. Data is plotted as mean±S.E.M. (n=5-8 mice/group) from two independent experiments. Asterisk indicates significant difference compared with saline-treated group (p<0.05). -
FIG. 50 shows that NF-κB decoy reverses disease activity in the oxazolone colitis model. Mean percent body weight of 3 independent experiments (n=25-35 mice per group). Asterisk indicates a significant difference between NF-κB decoy and vehicle treated groups at theday -
FIG. 51 shows representative H&E stained sections from various treatment groups. -
FIG. 52 shows colonic sections from a representative experiment that were assessed by a blinded pathologist and quantitated in the histological colitis score. Bars represent the mean±S.E.M (n=5/group). Asterisk indicates significant difference compared with saline-treated group (p<0.05). -
FIG. 53 shows the mean disease activity index (DAI) atday 10. Colitis was induced with 5% DSS in the drinking water for 10 days and mice were intrarectally treated with saline vehicle, 2.5 mg/kg NF-κB decoy, budesonide, or scramble ODN every other day for a total of 5 treatments. Data represent mean±S.E.M. (n=15-25 mice/group) from 3 independent experiments. Asterisk indicates significant difference compared with saline-treated group (p<0.05). -
FIG. 54 shows representative H&E stained sections from treatment groups inFIG. 53 . -
FIG. 55 shows the histological colitis score. Bars represent the mean±S.E.M (n=6-14/group). -
FIG. 56 shows the mean disease activity index (DAI) 10 days after the start of the second DSS cycle. Data represent mean±S.E.M. (n=15-25 mice/group) from 3 independent experiments. Asterisk indicates significant difference compared with saline-treated group (p<0.05). - A. Definitions
- Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, N.Y. 1994), and March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 4th ed., John Wiley & Sons (New York, N.Y. 1992), provide one skilled in the art with a general guide to many of the terms used in the present application.
- The term “double-stranded” is used to refer to a nucleic acid molecule comprising two complementary nucleotide strands connected to each other solely by Watson-Crick base pairing. The term specifically includes molecules which, in addition to the double-stranded region formed by the two complementary strands, comprise single-stranded overhang(s).
- The terms “oligonucleotide decoy,” “double-stranded oligonucleotide decoy,” “oligodeoxynucleotide decoy,” and “double-stranded oligodeoxynucleotide decoy” are used interchangeably, and refer to short nucleic acid molecules comprising a double-stranded region, which bind to and interfere with a biological function of a targeted transcription factor. Accordingly, the terms “NF-κB oligonucleotide decoy,” “double-stranded NF-κB oligonucleotide decoy,” “NF-κB oligodeoxynucleotide decoy,” and “double-stranded NF-κB oligodeoxynucleotide decoy” are used interchangeably, and refer to short nucleic acid molecules comprising a double-stranded region, which bind to and interfere with a biological function of an NF-κB transcription factor. The term “double-stranded” is used to refer to a nucleic acid molecule comprising two complementary nucleotide strands connected to each other by Watson-Crick base pairing. The term specifically includes NF-κB oligodeoxynucleotide decoy molecules which, in addition to the double-stranded region formed by the two complementary strands, comprise single-stranded overhang(s). In addition, the term specifically includes NF-κB oligodeoxynucleotide decoy molecules in which, in addition to the double-stranded region, the two strands are covalently linked to each other at their 3′ and/or 5′ end.
- The term “NF-κB” is used herein in the broadest sense and includes all naturally occurring NF-κB molecules of any animal species, including all combinations of members of the NF-κB/Rel family, e.g. p52, p50, p65, cRel and Rel B.
- The term “transcription factor binding sequence” is a short nucleotide sequence to which a transcription factor binds. The term specifically includes naturally occurring binding sequences typically found in the regulatory regions of genes the transcription of which is regulated by one or more transcription factors. The term further includes artificial (synthetic) sequences, which do not occur in nature but are capable of competitively inhibiting the binding of the transcription factor to a binding site in an endogenous gene.
- As used herein, the phrase “modified nucleotide” refers to nucleotides or nucleotide triphosphates that differ in composition and/or structure from natural nucleotides and nucleotide triphosphates.
- As used herein, the terms “five prime” or “5′” and “three-prime” or “3′” refer to a specific orientation as related to a nucleic acid. Nucleic acids have a distinct chemical orientation such that their two ends are distinguished as either five-prime (5′) or three-prime (3′). The 3′ end of a nucleic acid contains a free hydroxyl group attached to the 3′ carbon of the terminal pentose sugar. The 5′ end of a nucleic acid contains a free hydroxyl or phosphate group attached to the 5′ carbon of the terminal pentose sugar.
- As used herein, the term “overhang” refers to a double-stranded nucleic acid molecule, which does not have blunt ends, such that the ends of the two strands are not coextensive, and such that the 5′ end of one strand extends beyond the 3′ end of the opposing complementary strand. It is possible for a linear nucleic acid molecule to have zero, one, or two, 5′ overhangs.
- As used herein, the terms “preferential binding,” “preferentially bind” and their grammatical equivalents are used to mean that the specificity/affinity factor is at least about 20, or at least about 25, or at least about 30, or at least about 35, or at least about 40, where the specificity/affinity ratio is defined as follows:
Specificity/affinity factor=(S p50/p50 −S p65/p50)×S p50/p50 /S p65/p50
where Sp50/p50 equals the molar excess of decoy required to compete 50% of the binding of p50/p50 to the non-mammalian NF-κB promoter from HIV (sequence 113/114, SEQ ID NO: 48, and its complement) and Sp65/p50 equals the molar excess of decoy required to compete 50% of the binding of p65/p50 to the non-mammalian NF-κB promoter from HIV (sequence 113/114). The score (S) is assigned as 100 if the decoy is unable to compete at least 50% of the binding at any molar ratio tested. - The term “binding affinity” refers to how tightly a given transcription factor will bind to a corresponding oligonucleotide decoy, which can be measured by various experimental approaches, including electromobility shift assays (EMSA) or TransAM assays.
- The term “competition ratio” describes the ability of a test decoy sequence to compete with a defined sequence for binding and retention of the transcription factor when compared to the defined sequence competing with itself in the TransAm assay. A smaller ratio refer to a higher competition ability to bind the transcription factor.
- As used herein, the term “inflammatory disease” or “inflammatory disorder” refers to pathological states resulting in inflammation, typically caused by neutrophil chemotaxis. Examples of such disorders include inflammatory skin diseases including psoriasis, eczema and atopic dermatitis; systemic scleroderma and sclerosis; responses associated with inflammatory bowel disease (IBD) (such as Crohn's disease and ulcerative colitis); ischemic reperfusion disorders including surgical tissue reperfusion injury, myocardial ischemic conditions such as myocardial infarction, cardiac arrest, reperfusion after cardiac surgery and constriction after percutaneous transluminal coronary angioplasty, stroke, and abdominal aortic aneurysms; cerebral edema secondary to stroke; cranial trauma, hypovolemic shock; asphyxia; adult respiratory distress syndrome; acute-lung injury; Behcet's Disease; dermatomyositis; polymyositis; multiple sclerosis (MS); meningitis; encephalitis; uveitis; osteoarthritis; lupus nephritis; autoimmune diseases such as rheumatoid arthritis (RA), Sjorgen's syndrome, vasculitis; diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder, multiple organ injury syndrome secondary to septicaemia or trauma; alcoholic hepatitis; bacterial pneumonia; antigen-antibody complex mediated diseases including glomerulonephritis; sepsis; sarcoidosis; immunopathologic responses to tissue/organ transplantation; inflammations of the lung, including pleurisy, alveolitis, vasculitis, pneumonia, chronic bronchitis, bronchiectasis, diffuse panbronchiolitis, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis (IPF), and cystic fibrosis; etc. The preferred indications include, without limitation, inflammatory skin conditions, such as dermatitis, eczema, rheumatoid arthritis (RA), rheumatoid spondylitis, gouty arthritis and other arthritic conditions, chronic inflammation, autoimmune diabetes, multiple sclerosis (MS), asthma, systhemic lupus erythrematosus, adult respiratory distress syndrome, Behcet's disease, psoriasis, chronic pulmonary inflammatory disease, graft versus host reaction, Crohn's Disease, ulcerative colitis, inflammatory bowel disease (IBD), Alzheimer's disease, and pyresis, along with any disease or disorder that relates to inflammation and related disorders.
- The terms “apoptosis” and “apoptotic activity” are used in a broad sense and refer to the orderly or controlled form of cell death in mammals that is typically accompanied by one or more characteristic cell changes, including condensation of cytoplasm, loss of plasma membrane microvilli, segmentation of the nucleus, degradation of chromosomal DNA or loss of mitochondrial function. This activity can be determined and measured, for instance, by cell viability assays, FACS analysis or DNA electrophoresis.
- The terms “cancer” and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, without limitation, carcinoma, lymphoma, leukemia, blastoma, and sarcoma. Specific examples of such cancers include squamous cell carcinoma, small-cell lung cancer, non-small cell lung cancer, breast cancer, pancreatic cancer, glioblastoma multiforme, cervical cancer, stomach cancer, bladder cancer, hepatoma, colon carcinoma, and head and neck cancer. In a preferred embodiment, the cancer includes breast cancer, ovarian cancer, prostate cancer, and lung cancer.
- The term “treatment” refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. In tumor (e.g., cancer) treatment, a therapeutic agent may directly decrease the pathology of tumor cells, or render the tumor cells more susceptible to treatment by other therapeutic agents, e.g., radiation and/or chemotherapy.
- A “subject” is a vertebrate, preferably a mammal, more preferably a human.
- The term “mammal” is used herein to refer to any animal classified as a mammal, including, without limitation, humans, higher primates, rodents, domestic and farm animals, and zoo, sports, or pet animals, such as sheep, dogs, horses, cats, cows, etc. Preferably, the mammal herein is human.
- B. Detailed Description
- It is known that the p50/p50 homodimer blocks activation of pro-inflammatory genes, while the p65/p50 heterodimer acts by turning on pro-inflammatory genes, and as a result, is a major component in the pathogenesis of inflammation. One idea underlying the present invention is that by designing decoy molecules which could bind p65/p50 and/or cRel/p50 heterodimers and not p50/p50 homodimers, or which would preferentially bind p65/p50 and/or cRel/p50 heterodimers, one could provide extra blockade of NF-κB driven promoters by leaving p50/p50 homodimers behind to occupy these sites. As a result, such selective decoy molecules have the potential to block NF-κB activity, such a pro-inflammatory activity associated with the NF-κB pathway, more efficiently than NF-κB decoys known in the art.
- Another objective of the present invention is to provide NF-κB decoy molecules with improved binding affinity for p65. This class of NF-κB dsODN molecules is particularly useful in situations where p50/p50 homodimers are present in small concentrations only, like in the case of dermatitis, and therefore p65/p50 specificity is not critical.
- Design of NF-κB Decoys with Improved Properties
- 1. Design of NF-κB dsODN Molecules
- The oligonucleotide decoys of the present invention have been designed taking advantage of the crystal structure of the p50/p65 heterodimer bound to the immunoglobulin light-chain gene (Chen et al, Nature 391(6665):410-3 (1998)) which contains the consensus sequence of 5′-GGGACTTTCC-3′ (SEQ ID NO: 2). The authors showed that p50 contacts the 5-base-
pair subsite 5′-GGGAC-3′ (SEQ ID NO: 3) and that p65 contacts the 4-base-pair subsite 5′TTCC-3′ (SEQ ID NO: 4). The DNA contacts by the p50/p65 heterodimer are similar to those in the homodimer structures (Ghosh et al, Nature 373(6512):303-10 (1995); Muller et al, FEBS Lett. 369(1):113-7 (1995)). - In addition, each dsODN sequence was analyzed, using bioinformatics methods which give a score of how well a decoy is predicted to bind to NF-κB. Subsequently, the specificity/affinity factor was experimentally generated using traditional binding assays (e.g. competitive binding assay), but could easily be derived from alternative binding assays, including the TransAM™ method (Active Motif, Carlsbad, Calif.), which is an ELISA-based method for detecting and quantifying transcription factor activation. The predicted binding affinity was derived using a conventional approach to assess the TF binding affinity, using the TF binding sites matrix system that statistically summarized the experimental TF-DNA binding data. The analysis was conducted using the most updated version (8.2, June 2004) of the TRANSFAC database (Wingender et al., Nucleic Acids Res 24:238-41 (1996); Wingender et al., Pac Symp Biocomput 477-85 (1997); Wingender et al., Nucleic Acids Res. 25:265-8 (1997)). TRANSFAC collects position-weight-matrices for DNA-TF binding. The tool Match (Kel et al., Nucleic Acids Res. 31:3576-9 (2003)) was used to assess the binding affinity of decoys using the matrices of TRANSFAC, and actual specificity/affinity factors were compared. The data are illustrated in
FIGS. 14 and 15 , and discussed below. The exact scores will be assay dependent, however, the relative affinity would remain valid, regardless of the specific assay used. - In one embodiment, the NF-κB dsODN molecules of the present invention consist of two oligonucleotide strands which are attached to each other by Watson-Crick base pairing. While typically all nucleotides in the two strands participate in the base pairing, this is not a requirement. Oligonucleotide decoy molecules, where one or more, such as 1-3 or 1 or 2 nucleotides are not involved in base pairing are also included. In addition, the double stranded decoys may contain 3′ and/or 5′ single stranded overhangs.
- In another embodiment, the NF-κB dsODN molecules of the present invention comprise two oligonucleotide strands which are attached to each other by Watson-Crick base pairing, and are additionally covalently attached to each other at either the 3′ or the 5′ end, or both, resulting in a dumbell structure, or a circular molecule. The covalent linkage may be provided, for example, by phosphodiester linkages or other linking groups, such as, for example, phosphothioate, phosphodithioate, or phosphoamidate linkages.
- Generally, the dsODN molecules of the invention comprise a core sequence that is capable of specific binding to an NF-κB transcription factor, flanked by 5′ and/or 3′ sequences, wherein the core sequence typically consists of about 5 to 14, or about 6 to 12, or about 7 to about 10 base pairs; and the flanking sequences are about 2 to 8, or about 2 to 6, or about 2 to 4, or about 4 to 8, or about 4 to 6 base pairs long. The molecule typically comprises an about 12 to 28, preferably about 14 to 24 base-pair long double-stranded region composed of two fully or partially complementary strands (including the core and flaking sequences).
- Changing the core sequence (including its length, sequence, base modifications and backbone structure) it is possible to change the binding affinity, the stability and the specificity of the NF-κB decoy molecule. Indeed, the NF-κB dsODN molecules of the present invention, which bind the p65/p50 and/or cRel/p50 heterodimers with high affinity and exhibit no or only low affinity binding for the p50/p50 homodimers, were designed by deleting or changing targeted residues in the binding site (core) of a consensus oligonucleotide decoy, based on the crystal structure of the p65/p50 heterodimer binding to DNA, and follow up testing.
- In addition, changes in the flanking sequence have a genuine impact on and can significantly increase the in vivo stability of the NF-κB decoy molecule, and may affect binding affinity and/or specificity. In particular, the shape/structure of the NF-κB decoy molecule can be changed by changing the sequences flaking the core binding sequence, which can result in improved stability and/or binding affinity. The shape and structure of the DNA are influenced by the base pair sequence, length of the DNA, backbone and nature of the nucleotide (i.e. native DNA vs. modified sugars or bases). Thus, the shape and/or structure of the molecule can also be changed by other approaches, such as, for example, by changing the total length, the length of the fully complementary, double-stranded region within the molecule, by alterations within the core and flanking sequences, by changing the backbone structure and by base modifications.
- The nucleotide sequences present in the decoy molecules of the present invention may comprise modified or unusual nucleotides, and may have alternative backbone chemistries. Synthetic nucleotides may be modified in a variety of ways, see, e.g. Bielinska et al. Science 250:997-1000 (1990). Thus, oxygens may be substituted with nitrogen, sulfur or carbon; phosphorus substituted with carbon; deoxyribose substituted with other sugars, or individual bases substituted with an unnatural base. Thus replacement of non-bridging oxygen atoms of the internucleotide linkage with a sulfur group (to yield a phosphorothioate linkage) has been useful in increasing the nuclease resistance of the dsODN molecule. Experiments determining the relationship between the number of sulfur modifications and stability and specificity of the NF-κB dsODN molecules herein are set forth in the Example below.
- In each case, any change will be evaluated as to the effect of the modification on the binding ability and affinity of the oligonucleotide decoy to the NF-κB transcription factor, effect on melting temperature and in vivo stability, as well as any deleterious physiological effects. Such modifications are well known in the art and have found wide application for anti-sense oligonucleotide, therefore, their safety and retention of binding affinity are well established (see, e.g. Wagner et al. Science 260:1510-1513 (1993)).
- Examples of modified nucleotides, without limitation, are: 4-acetylcytidin, 5-(carboxyhydroxymethyl)uridine, 2′-O-methylcytidine, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluridine, dihydrouridine, 2′-O-methylpseudouridine, β,D-galactosylqueuosine, 2′-O-methylguanosine, inosine, N6-isopentenyladenosine 1-metyladenosine, 1-methylpseudouridine, 1-methylguanosine, 1-methylinosine, 2,2-dimethylguanosine, 2-methyladenosine, 2-methylguanosine 3-methylcytidine 5-methylcytidine, N6-methyladenosine, 7-methylguanosine, 5-methylaminomethyl-2-thiouridine, β,D-mannosylqueosine, 5-methoxycarbonylmethyl-2-thiouridine, 5-metoxycarbonalmethyluridine, 5-methoxyuridine, 2-methylthio-N6-isopentenyladenosine, N-((9-beta-D-ribofuransyl-2-methylthiopurine-6-yl)carbamoyl)threonine, N-((9-beta-D-ribofuranosyl)purine-6-yl)N-methylcarbamoyl)threonine, uridine-5-oxyacetic acid-methylester uridine-5-oxyacetic acid, wybutoxosine, pseudouridine queuosine, 2-thiocytidine, 5-methyl-2-thiouridine, 2-thiouridine, 4-thiouridine, 5-methyluridine, N-((9-beta-D-ribofuranosylpurine-6-yl)-carbamoylthreonine, 2′-O-methyl-5-methyluridine, 2′-O-methyluridine, 3-(3-3-amino-3-carboxy-propyl)uridine(acp3)u, and wybutosine.
- In addition, the nucleotides can be linked to each other, for example, by a phosphoramidate linkage. This linkage is an analog of the natural phosphodiester linkage such that a bridging oxygen (—O—) is replaced with an amino group (—NR—), wherein R typically is hydrogen or a lower alkyl group, such as, for example, methyl or ethyl. Other likages, such as phosphothioate, phosphodithioate, etc. are also possible.
- The decoys of the present invention can also contain modified or analogous forms of the ribose or deoxyribose sugars generally present in polynucleotide structures. Such modifications include, without limitation, 2′-substituted sugars, such as 2′-O-methyl-, 2′-O-allyl, 2′-fluoro- and 2′azido-ribose, carboxylic sugar analogs, α-anomeric sugars, epimeric sugars, such as arabinose, xyloses, lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs, such as methyl riboside.
- In general, the oligonucleotide decoys of the present invention are preferably comprised of greater than about 50%, more preferably greater than about 80%, most preferably greater than about 90% conventional deoxyribose nucleotides.
- The NF-κB dsODN decoys of the present invention can be further modified to facilitate their localization, purification, or improve certain properties thereof. For example, a nuclear localization signal (NLS) can be attached to the decoy molecules, in order to improve their delivery to the cell nucleus. The NF-κB/Rel proteins include a common Rel homology domain, which encompasses the NLS. In a preferred embodiment such naturally occurring NLS, or a variant thereof, is used in the decoy molecules of the present invention.
- In addition, the NF-κB decoy molecules of the invention may be conjugated with carrier molecules, such as peptides, proteins or other types of molecules, as described, for example, in the following references: Avrameas et al.,
J Autoimmun 16, 383-391 (2001); Avrameas et al., Bioconjug. Chem. 10: 87-93 (1999); Gallazzi et al., Bioconjug. Chem. 14, 1083-1095 (2003); Ritter, W. et al., J. Mol. Med. 81, 708-717 (2003). - The NF-κB decoy molecules of the invention may further be derivatized to include delivery vehicles which improve delivery, distribution, target specific cell types or facilitate transit through cellular barriers. Such delivery vehicles include, without limitation, cell penetration enhancers, liposomes, lipofectin, dendrimers, DNA intercalators, and nanoparticles.
- 2. Synthesis of NF-κB dsODN Molecules
- The NF-κB sdODN decoy molecules of the present invention can be synthesized by standard phosphodiester or phosphoramidate chemistry, using commercially available automatic synthesizers. The specific dsODN molecules described in the Examples have been synthesized using an automated DNA synthesizer (Model 380B; Applied Biosystems, Inc., Foster City, Calif.). The decoys were purified by column chromatography, lyophilized, and dissolved in culture medium. Concentrations of each decoy were determined spectrophotometrically.
- 3. Characterization of NF-κB dsODN Molecules
- The NF-κB decoy molecules of the present invention can be conveniently tested and characterized in a gel shift, or electrophoretic mobility shift (EMSA) assay. This assay provides a rapid and sensitive method for detecting the binding of transcription factors to DNA. The assay is based on the observation that complexes of protein and DNA migrate through a non-denaturing polyacryamide gel more slowly than free double-stranded oligonucleotides. The gel shift assay is performed by incubating a purified protein, or a complex mixture of proteins (such as nuclear extracts), with a 32P end-labeled DNA fragment containing a transcription factor-binding site. The reaction products are then analyzed on a non-denaturing polyacrylamide gel. The specificity of the transcription factor for the binding site is established by competition experiments, using excess amounts of oligonucleotides either containing a binding site for the protein of interest or a scrambled DNA sequence. The identity of proteins contained within a complex is established by using an antibody which recognizes the protein and then looking for either reduced mobility of the DNA-protein-antibody complex or disruption of the binding of this complex to the radiolabeled oligonucleotide probe.
- The ability of a NF-κB decoy to bind to and block the activity of an NF-κB transcription factor can be determined in traditional binding assays (e.g. competitive binding assay), including the TransAM™ method (Active Motif, Carlsbad, Calif.), which is an ELISA-based method for detecting and quantifying transcription factor activation. Briefly, a target sequence, in this case a natural NF-κB binding site, is immobilized on the plate, and a nuclear extract containing NF-κB is incubated in the wells, in the presence or absence of decoy at various concentrations calculated as the molar ration of decoy:plate bound sequence. Positive control wells include decoy with the same sequence as the target DNA on the plate. The data obtained are presented as the ratio of the absorbance of the test decoys and the absorbance of the positive control decoy. Accordingly, lower ratios represent better binding.
- In designing the selective NF-κB decoys herein, based on the crystal structure of p65/p50 heterodimer binding to DNA, targeted residues in the binding site (core) of the consensus oligonucleotide decoy were deleted. The ultimate goal was to design a double-stranded oligonucleotide which was able to bind p65/p50 and/or cRel/p50 heterodimers, preferably both the p65/p50 and cRel/p50 heterodimers, with high affinity and exhibited low affinity for p50/p50 homodimers. To achieve this aim, a variety of NF-κB decoys were tested for their ability to bind the different NF-κB proteins in a gel shift assay as described in the following Example 1.
- 4. Use of NF-κB dsODN Molecules, and Treatment Methods
- NF-κB is involved in the regulation of the transcription of numerous genes. A representative grouping and listing of genes transcriptionally activated by NF-κB is provided below.
- Cytokines/chemokines and their modulators, such as, for example, interferon-γ (IFN-γ), interferon-β (IFN-β), interleukins, such as, IL-1, Il-2, IL-6, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, lymphotoxin-α, lymphotoxin-β, TNF-α, MIP-1, MIP-2, MIP-3, RANTES, TNF-α, TRAIL.
- Immunoregulators, such as, for example, BRL-1, CCR5, CCR7, CD137, CD154, CD40 and CD40 ligand, CD48, CD83, CD23, IL-2 receptor α chain, certain immunoglobulin heavy and light chains, MHC Class I antigen, T cell receptor subunits, TNF-receptor (p75/80).
- Proteins involved in antigen presentation, such as, for example, Complement B,
Complement component 3, TAP1, and tapasin. - Cell adhesion molecules, such as, for example, E- and P-selectin, ICAM-1, MadCAM-1, VCAM-1, and Tenascin-C.
- Acute phase proteins, such as, for example, angiotensinogen, β-defensin-2, complement factors, tissue factor-1 (TF-1), urokinase-type plasminogen activator.
- Stress response genes, such as, for example, angiotensin-2, COX-2, MAP4K1, Phospholipase A2.
- Cell surface receptors, such as, for example, CD23, CD69, EGF-R, Lox-1, Mdr1.
- Regulators of apoptosis, such as, for example, Bf11, Bcl-xL, Caspase-11, CD95 (Fas), TRAF-1, TRAF-2.
- Growth factors and their modulators, such as, for example, G-CSF, GM-CSF, EPO, IGFBP-1, IGFBP-2, M-CSF, VEGF-C.
- Early response genes, such as, for example, TIEG, B94, Egr-1. In addition, NF-κB regulates the transcription of other transcription factors, such as c-myc-, c-myb, A20, junB, p53, WT1, and viruses.
- Thus, inhibition of NF-κB induced gene expression, including expression of pro-inflammatory cytokines, such as IL-1 and TNF-α, and immune modulators, by the NF-κB decoy molecules herein is useful in the prevention and treatment of inflammatory, immune and autoimmune diseases, such as rheumatoid arthritis (RA) (Roshak et al., Current Opinion in Pharmacology 2:316-321 (2002)); Crohn's disease and inflammatory bowel disease (IBD) (Dijkstra et al., Scandinavian J. of Gastroenterology Suppl. 236:3741 (2002)); colitis; pancreatitis (Eeber and Adler, Pancreatology 1:356-362 (2001)), periodonitis (Nichols et al., Annals of Periodontology 6:20-29 (2001)); lupus (Kammer and Tsokos, Current Directions in Autoimmunity 5:131-150 (2002)); asthma (Pahl and Szelenyi, Inflammation Research 51:273-282 (2002)); and ocular allergy (Bielory et al., Opinion in Allergy and Clinical Immunology 2:435-445 (2003)), inflammatory skin diseases, such as atopic dermatitis/eczema, psoriasis, and the like.
- A more detailed list of diseases and pathogenic conditions, which are targeted for prevention and/or treatment by the NF-κB decoys of the present invention includes psoriasis, eczema and atopic dermatitis; systemic scleroderma and sclerosis; responses associated with inflammatory bowel disease (IBD) (such as Crohn's disease and ulcerative colitis); ischemic reperfusion disorders including surgical tissue reperfusion injury, myocardial ischemic conditions such as myocardial infarction, cardiac arrest, reperfusion after cardiac surgery and constriction after percutaneous transluminal coronary angioplasty, stroke, and abdominal aortic aneurysms; cerebral edema secondary to stroke; cranial trauma, hypovolemic shock; asphyxia; adult respiratory distress syndrome; acute-lung injury; Behcet's Disease; dermatomyositis; polymyositis; multiple sclerosis (MS); meningitis; encephalitis; uveitis; osteoarthritis; lupus nephritis; autoimmune diseases such as rheumatoid arthritis (RA), Sjorgen's syndrome, vasculitis; diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder, multiple organ injury syndrome secondary to septicaemia or trauma; alcoholic hepatitis; bacterial pneumonia; antigen-antibody complex mediated diseases including glomerulonephritis; sepsis; sarcoidosis; immunopathologic responses to tissue/organ transplantation; inflammations of the lung, including pleurisy, alveolitis, vasculitis, pneumonia, chronic bronchitis, bronchiectasis, diffuse panbronchiolitis, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, and the like.
- Rheumatoid Arthritis
- Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease that mainly involves the synovial membrane of multiple joints with resultant injury to the articular cartilage. Efficacy of the NF-κB decoy molecules of the present invention in the prevention and/or treatment of arthritis can be evaluated in a collagen-induced arthritis (CIA) model (Terato et al. Brit. J. Rheum. 35:828-838 (1966)), in the adjuvant-induced arthritis model (Taurog et al., Cell Immunol 75:271-82 (1983); Taurog et al., Cell Immunol 80:198-204 (1983)), or a model of antibody-mediated arthritis induced by the intravenous injection of a cocktail of four monoclonal antibodies, as described by Terato et al., J. Immunol. 148:2103-8 (1992); Terato et al., Autoimmunity 22:137-47 (1995). Candidates for the prevention and/or treatment of arthritis can also be studied in transgenic animal models, such as, for example, TNF-α transgenic mice (Taconic). These animals express human tumor necrosis factor (TNF-α), a cytokine which has been implicated in the pathogenesis of human rheumatoid arthritis. The expression of TNF-α in these mice results in severe chronic arthritis of the forepaws and hind paws, and provides a good mouse model for study of inflammatory arthritis. As shown in Examples 7 and 8, a representative NF-κB decoy molecule of the present invention showed significant efficacy in the collagen-induced and adjuvant-induced arthritis models.
- Skin Diseases and Related Conditions
- The efficacy of the NF-κB decoy molecules of the present invention can be tested in various animal models of inflammatory skin conditions. Such models are well known in the art and include Dustmite Ag (Dp) induced contact dermatitis in NC/Nga mice (Sasakawa, T et al., Int Arch Allergy Immunol 126:23947 (2001); Sasakawa et al., Int Arch Allergy Immunol 133:55-63 (2004)). Results of testing a representative NF-κB decoy of the invention in this model are described in Examples 3, 4, and 6.
- Since porcine skin is more similar to human skin than rodent skin, the NF-κB decoy molecules of the present invention can also be tested for efficacy in the treatment of inflammatory skin conditions, such as, for example, dermatitis, and eczema in pig skin inflammatory models. The NF-κB decoy molecules of the present invention effectively block NF-κB activity in this model, and block expression of key inflammatory genes.
- Existing therapies for the treatment of these conditions are inadequate, raising serious issues of side effects during long term application, especially in children. The NF-κB decoys are devoid of the known side effects of steroid therapy and involve limited systemic exposure.
- Skin is known for its functional role as a protective barrier. It is now clear that skin is also a very dynamic organ that can elicit immunological responses. However, not all immunological reactions in the skin are beneficial, some harmful reaction (inflammation) might result from reacting to invaders, such as allergens (contact dermatitis, atopic dermatitis an other kin inflammatory diseases) that require down-regulation/medication. Other reactions might occur from autoreactive lymphocytes being exposed to skin antigens, such as epithelia base membrane component type VII collage or cell surface components or keratinocytes, or still unknown cell components, which can lead to pemphigus vulgaris (Anhalt et al., N. Engl. J. Med. 323(25):1729-35 (1990)), or epidermyosis bullosa (Woodley et al., N. Engl. J. Med. 310(16):107-13 (1984)), orpsoriasis (Stern, Lancet 350(9074):349-53 (1997)). Most of these inflammatory skin responses involve mononuclear cells, in particular T cells. Observations of peri- and intrafollicular inflammation and infiltration of these follicles by T cells and other immune cells, such as macrophages and dendritic cells, point to a T cell mediated autoimmune syndrome in alopecia areata (AA) as well (McElwee et al., J. Invest. Dermatol. 119(6):1426-33 (2002)).
- A number of studies have demonstrated the crucial role of cytokines released from immune cells infiltrating the affected sites for initiating and maintaining fibrosis in the skin of scleroderma patients (Fagundus et al., Clin. Dermatol. 12(3):407-17 (1994); Postlethwaite, Current Opin. Rheumatol. 7(6):535-40 (1995)). Thus, drugs that target immune competent cells, such as T cells, should be very successful in treating a broad spectrum of inflammatory conditions of the skin.
- Inflammatory Bowel Disease (IBD)
- The term “inflammatory bowel disease” or “IBD” is commonly used to ulcerative colitis and Crohn's disease, which are chronic inflammatory diseases of the gastrointestinal tract of unknown etiology. Traditional treatment is based on corticosteroid therapy and the administration of salazopyrine. More recently, other therapeutics, such as an anti-TNF-α antibody, have been developed. However, there is a great need for new therapies, partly due to the known side effects of steroid therapy, and since in a significant subgroup of patients current therapies fail to induce remission. See, e.g. Mee et al., Gut 2:1-5 (1979). Mouse models are described by Matsumoto, et al., Gut 43:71-78 (1998); and Strober et al., J Clin Invest 107:667-670 (2001).
- Similarly to certain skin diseases, inflammatory disease of the gastrointestinal tract involves immune competent cells. For example, in inflammatory bowel disease (ulcerative colitis and Crohn's disease), T cells are the main culprit of the inflammation. The balance between pro- and anti-inflammatory cytokines secreted by T cells regulates both the initiation and perpetuation of inflammatory bowel disease. Most of these secreted factors are regulated directly or indirectly by NF-κB (Neurath et al., Natl. Med. 8(6):567-73 (2002); Strober et al., J. Gastroenterol. 38 Suppl 15:55-8 (2003)). Other diseases of the gastrointestinal tract, such as irritable bowel disease (IBS), gastritis, Barrett syndrome, peptide lulcer, reflux disease, acute and chronic pancreatitis, cholecystitis, result from similar, albeit more chronic dysregulated mucosal immune systems and thus are expected to be responsive to treated with NF-κB inhibitors.
- Other Therapeutic Utilities
- Since NF-κB plays a pivotal role in the coordinated transactivation of cytokine and adhesion molecule genes involved in atherosclerosis and lesion formation after vascular injury (Yoshimura et al., Gene Therapy 8: 1635-1642 (2001)); neuronal damage after cerebral ischemia (Ueno et al., J. Thoracic and Cardiovascular Surgery 122(4): 720-727 (2001)); chronic airway inflammation (Griesenbach et al.,
Gene Therapy 7, 306-313 (2000)); progression of autoimmune myocarditis (Yokoseki et al., Circ. Res. 89: 899-906 (2001)); acute rejection and graft arteriopathy in cardiac transplantation (Suzuki et al., Gene Therapy 7: 1847-1852 (2000)); and myocardial infarction (Morishita et al., Nature Medicine 3(8): 894-899 (1997)), NF-κB decoy molecules also find utility in the treatment of such diseases and conditions. - Recent evidence indicates that NF-κB and the signaling pathways that are involved in its activation are also important for tumor development. See, e.g. Karin et al., Nat. Rev. Cancer 2(4):301-10 (2002). Therefore, blocking NF-κB by the decoy molecules of the present invention finds utility in the prevention and treatment of cancer, offering a new anti-cancer strategy, either alone or in combination with other treatment options.
- Delivery of the NF-κB dsODN Molecules
- The route of delivery of the NF-κB decoys of the present invention depends on the disease or pathological condition the prevention and/or treatment is targeted. For certain indications, a preferred mode of delivering the NF-κB decoys of the present invention is pressure-mediated transfection, as described, for example, in U.S. Pat. Nos. 5,922,687 and 6,395,550, the entire disclosures of which are hereby expressly incorporated by reference. In brief, the NF-κB decoy molecules are delivered to cells in a tissue by placing the decoy nucleic acid in an extracellular environment of the cells, and establishing an incubation pressure around the cells and the extracellular environment. The establishment of the incubation pressure facilitates the uptake of the nucleic acid by the cells, and enhances localization to the cell nuclei.
- More specifically, a sealed enclosure containing the tissue and the extracellular environment is defined, and the incubation pressure is established within the sealed enclosure. In a preferred embodiment, the boundary of the enclosure is defined substantially by an enclosing means, so that target tissue (tissue comprising the target cell) is subjected to isotropic pressure, and does not distend or experience trauma. In another embodiment, part of the enclosure boundary is defined by a tissue. A protective means such as an inelastic sheath is then placed around the tissue to prevent distension and trauma in the tissue. While the incubation pressure depends on the application, incubation pressures about 300 mmHg-1500 mmHg above atmospheric pressure, or at least about 100 mmHg above atmospheric pressure are generally suitable for many applications.
- The incubation period necessary for achieving maximal transfection efficiency depends on parameters such as the incubation pressure and the target tissue type. For some tissue, such as human vein tissue, an incubation period on the order of minutes (>10 minute) at low pressure (about 0.5 atm) is sufficient for achieving a transfection efficiency of 80-90%. For other tissue, such as rat aorta tissue, an incubation period on the order of hours (>1 hour) at high pressure (about 2 atm) is necessary for achieving a transfection efficiency of 80-90%.
- Suitable mammalian target tissue for this type of delivery includes blood vessel tissue (in particular veins used as grafts in arteries), heart, bone marrow, and normal and tumor connective tissue, liver, genital-urinary system, bones, muscles, gastrointestinal organs, endocrine and exocrine organs, synovial tissue and skin. A method of the present invention can be applied to parts of an organ, to a whole organ, or to a whole organism. In one embodiment a nucleic acid solution can be perfused into a target region (e.g. a kidney) of a patient, and the patient is subject to pressure in a pressurization chamber.
- For other applications, the NF-κB decoys of the present invention can be administered by other conventional techniques. For example, retrovial transfection, transfection in the form of liposomes are among the known methods suitable for transfection. For details see also Dzau et al., Trends in Biotech 11:205-210 (1993); or Morishita et al., Proc. Natl. Acad. Sci. USA 90:8474-8478 (1993). When administered in liposomes, the decoy concentration in the lumen will generally be in the range of about 0.1 μM to about 50 μM per decoy, more usually about 1 μM to about 10 μM, most usually about 3 μM.
- Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides. In general, an effective dose is from 0.01 μg to 100 g per kg of body weight. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. In addition to the potency of the specific decoy molecule delivered, the effective dose will depend on the target disease, the route of delivery, the formulation used, the severity of the disease, the age, sex, and overall condition of the patient to be treated, and other similar considerations.
- For treatment of rheumatoid arthritis and inflammatory bowel disease (IBD), murine experiments typically use about 25-100 μg decoy in 50 to 100 μl injectable formulation. Based on these dose regimens, determination of the proper dosage for other species, including humans, can be assisted by mathematical calculations that have been developed for inter-species scaling. See, for example, Mordenti et al., Pharm Res 8:1351-9 (1991).
- For topical application, the decoys of the present invention are administered in the form of conventional topical formulations, such as, for example, creams, ointments, gels, suspensions, and the like. Preferably, such topical formulations will contain one or more penetration enhancers and/or surfactants to assure efficient delivery through the skin. Topical formulations for delivery of dsODN molecules are described in co-pending application U.S. Provisional Application Ser. No. 60/612,046, filed on Sep. 21, 2004, the entire disclosure of which is hereby expressly incorporated by reference. Topical formulations specifically include aqueous, emulsion-based and liposome formulations. For the treatment of dermatitis/eczema, a typical formulation may be a topical cream containing about 0.1 to 5% by weight, or about 0.2 to 3% by weight, or about 0.25 to 1% by weight of active ingredient. In order to increase half-life, for dermatological applications, at least one and preferably both strands of the NF-κB decoy molecules of the present invention are fully phosphorothioated.
- For other delivery routes, the most suitable concentration can be determined empirically. The determination of the appropriate concentrations and doses is well within the competence of one skilled in the art. Optimal treatment parameters will vary depending on the indication, decoy, clinical status of the patient, etc., and can be determined empirically based on the instructions provided herein and general knowledge in the art.
- The decoys may be administered as compositions comprising individual decoys or mixtures of decoys. Usually, a mixture contains up to 6, more usually up to 4, more usually up to 2 decoy molecules.
- Many anti-inflammatory and anti-rheumatic drugs, including glucocorticoids, aspirin, sodium salicylate, and sulfosalazine, are inhibitors of NF-κB activation. For the treatment of inflammatory and autoimmune diseases and conditions, the NF-κB decoy molecules of the present invention can optionally be administered in combination with such drug treatments. Combination treatment includes simultaneous administration as well as consecutive administration of two or more drugs in any order. Thus, for example, the topical anti-inflammatory applications, the NF-κB decoys of the invention can be administered in combination with betamethasone or similar therapeutic agents.
- In cancer therapy, the administration of the NF-κB decoy molecules can be combined with other treatment options, including treatment with chemotherapeutic anticancer agents and/or radiation therapy.
- Further details of the invention will be apparent from the following non-limiting Examples.
- Design and Testing of NF-κB Decoy Molecules
- Design
- NF-κB dsODN decoy molecules were designed and tested for their ability to bind and/or compete for binding of NF-κB. In a particular aspect, the goal of the invention was to design NF-κB decoy molecules that preferentially bind p65/p50 and/or cRel/p50 heterodimers over p50/p50 homodimers. As a result of not blocking p50/p50 homodimers, the selective decoy molecules of the invention allow these homodimers to block the promoters of NF-κB regulated genes, which provides an additional level of negative regulation of gene transcription.
- In designing the oligonucleotide decoys, information available from crystal structure studies and computational analysis of the known NF-κB binding sites were utilized.
- As discussed above, based on study of the crystal structure of the p50/p65 heterodimer bound to the immunoglobulin light-chain gene, which contains the consensus sequence of 5′-GGGACTTTCC-3′ (SEQ ID NO: 2), it has been shown that p50 contacts the 5-base-
pair subsite 5′-GGGAC-3′ (SEQ ID NO: 3) and that p65 contacts the 4-base-pair subsite 5′TTCC-3′ (SEQ ID NO: 4). A series of NF-κB oligonucleotide decoys were designed, which contained fewer numbers of G's at the 5′ end of the consensus binding site with the aim to prepare decoy molecules that would have lower affinity for the p50/p50 homodimer but still bind the p65/p50 heterodimer. These oligonucleotide decoys were assigned “core” and “flank” letter codes for ease of identification and presentation. The cores were assigned letter codes “A” through “L” and the flanks “T” through “Z′”. The decoys were tested in the gel shift assay to determine their ability to compete with a high affinity radiolabeled oligonucleotide for NF-κB binding The NF-κB-binding DNA consensus sequences were selected from publications of NF-κB related DNA-protein interactions, including: Blank et al., EMBO J. 10:4159-4167 (1991); Bours et al. Mol. Cell. Biol. 12:685-695 (1992); Bours et al. U. Cell 72:729-739 (1993); Duckett et al. Mol. Cell. Biol. 13:1315-1322 (1993); Fan C. -M., Maniatis T., Nature 354:395-398 (1991); Fujita et al., Genes Dev. 6:775-787 (1992); Fujita et al. Genes Dev. 7:1354-1363 (1993); Ghosh et al., Nature 373:303-310 (1995); Ghosh et al., Cell 62:1019-1029 (1990); Grumont et al., Mol. Cell. Biol. 14:8460-8470 (1994); Henkel et al., Cell 68:1121-1133 (1992); Ikeda et al. Gene 138:193-196 (1994); Kunsch et al., Mol. Cell. Biol. 12:4412-4421 (1992); LeClair et al., Proc. Natl. Acad. Sci. USA 89:8145-8149 (1992); Li C. -C. et al., J. Biol. Chem. 269:30089-30092 (1994); - Matthews et al., Nucleic Acids Res. 21:1727-1734 (1993); Mueller et al., Nature 373:311-317 (1995); Neri et al., Cell 67:1075-1087 (1991); Nolan et al., Cell 64:961-969 (1991); Paya et al., Proc. Natl. Acad. Sci. USA 89:7826-7830 (1992); Plaksin et al., J. Exp. Med. 177:1651-1662 (1993); Schmid et al., Nature 352:733-736 (1991); Schmitz M. L., Baeuerle P. A. EMBO J. 10:3805-3817 (1991); Ten et al., EMBO J. 11:195-203 (1992); Toledano et al., J. Mol. Cell. Biol. 13:852-860 (1993); Urban et al., EMBO J. 10:1817-1825 (1991).
- Based on this available information, a set of decoys was generated for initial screening. These decoys include a “mutation decoy”, the scrambled decoys, decoys with different length at their 5′ or 3′ end, and decoys with alternative base composition within the core region and/or in the flanking sequences.
- To better understand the base-composition near the core binding sites of NF-κB, the core binding sites were computationally aligned (forward strand only) with known binding sequences. Based on this alignment, several major groups of decoys with slightly different core binding sites were created.
- The major core and flanking sequences are listed in Table 1.
TABLE 1 LETTER SEQ LETTER CODE CORE ID CODE FLANK A GGGACTTTCC 5 T CCTTGAA . . . TCC (SEQ ID NO:6 and SEQ ID NO:8) B GGGGACTTTCC 7 U AT . . . GT (SEQ ID NO:12 and SEQ ID NO:14) C GGGGACTTTCCC 9 V TC . . . TC (SEQ ID NO:16 and SEQ ID NO:18) D GGGATTTCC 11 W CTC . . . TGT (SEQ ID NO:20 and SEQ ID NO:22) E GGACTTTCC 13 W′ CTC . . . TCA (SEQ ID NO:82 and SEQ ID NO:83) F GACTTTCC 15 X CT . . . TC (SEQ ID NO:84 and SEQ ID NO:85) G GACTTTCCC 17 Y TC . . . CA (SEQ ID NO:86 and SEQ ID NO:87) H GGATTTCC 19 Z AGTTGA . . . AGGC (SEQ ID NO:79 and SEQ ID NO:88) I GGATTTCCC 21 Z′ TTGA . . . AGGC (SEQ ID NO:80 and SEQ ID NO:89) J GATTTCC 23 Z-4 TTGA . . . AG (SEQ ID NO:90 and SEQ ID NO:91) K GATTTCCC 24 Z-2 GTTGA . . . AGG (SEQ ID NO:81 and SEQ ID NO:92) L GGACTTTCCC 25 - Oligonucleotide Synthesis
- The sequences of the NF-κB decoys used in the Examples herein include 5′AGTTGAGGACTTTCCAGGC-3′ (SEQ ID NO: 30) and 5′-GCCTGGAAAGTCCTCAACT-3′ (SEQ ID NO: 95). The scrambled ODN sequence was 5′-CAGTAGTATGTGAGCCTGC-3′ (SEQ ID NO: 46) and 5′-GCAGGCTCACATACTACTG-3′ (SEQ ID NO: 96). After synthesis, the ODNs were purified using ion exchange chromatography (Avecia Biotechnology). All ODNs used were phosphorothioates and were annealed by combining equal molarities of each strand at room temperature. Concentrations of ODNs were determined by spectrophotometry.
- Electrophoretic Mobility Shift Assay (EMSA)
- The EMSA assay was employed to characterize oligonucleotide decoys for the NF-κB transcription factor. Using a radiolabeled oligonucleotide probe (non-mammalian, based on NF-κB promoter from HIV, sequence 113/114, SEQ ID NO: 48, and its complement), which exhibits high affinity for relevant members of the NF-κB family, binding of p65/p50, cRel/p50 and p50/p50 was tested using a nuclear extract from an activated monocyte cell line. Using the above modified oligonucleotides to compete for binding for the above-mentioned NF-κB family members, it was possible to compare the binding affinity of these oligonucleotides against the high affinity radiolabeled probe and each other. This assay has also enabled the design of a decoy which selectively binds particular members of the NF-κB family. By using increasing concentrations of various oligonucleotides, it was observed that, by deleting or changing targeted residues in the binding site, it was possible to specifically decrease the binding of the decoy molecule to p50/p50 homodimers, while retaining the affinity for p65/p50 and cRel/p50 heterodimers.
- The NF-κB gel shift assays (EMSA) were performed as follows. A double-stranded oligonucleotide containing a consensus NF-κB binding site (5′
AGTTGAGGGGACTTTCCCAGGC 3′) (SEQ ID NO: 78) was end-labeled with γ32P-ATP using T4 Polynucleotide Kinase (Promega). Alternatively, a double-stranded ODN containing a consensus NF-κB binding site from the IL-6 promoter (5′TGTGGGATTTTCCCATGACTC 3′) (SEQ ID NO: 94) was end-labeled with γ32P-ATP using T4 Polynucleotide Kinase (Promega). One microgram of a nuclear extract prepared from LPS stimulated THP-1 cells (human monocyte cell line) was incubated with 35 fmol of radiolabeled probe in the presence or absence of competing unlabeled NF-κB double-stranded oligonucleotides (dsODN) or scrambled dsODN. The incubations were carried out at room temperature for 30 minutes in a 20 μl reaction volume composed of 10 mM Tris-HCl pH - In Vitro Serum Stability Assay
- To increase ODN stability, the normal phosphodiester backbone was modified to contain phosphorothioate linkages. Stability enhancement from the phosphorothioate backbone was verified by incubating NF-κB decoy containing either a phosphodiester or phosphorothioate backbone in serum for different time intervals and assessing degradation by gel electrophoresis.
- Mouse serum (United States Biologicals) was diluted to a final working concentration of 70% using Phosphate Buffered Saline (PBS). NF-κB decoy containing either a phoshodiester (PO) or phosphorothioate (PS) backbone was diluted into serum for a final concentration of 4 μM. Gentamycin was included to prevent bacterial growth. The reactions were allowed to incubate at 37° C. and 10 μl aliquots were removed at 0, 30, 75 and 120 minutes. The reactions were stopped by the addition of 1 μl 0.5M EDTA and quickly frozen on dry ice. The samples were loaded onto a 20% polyacrylamide gel and subjected to electrophoresis. The gels were imaged and quantitated using a Typhoon 8600 PhosphorImager (Amersham) and ImageQuant software.
- The results show that as a phosphorothioate, the NF-κB decoy was very stable in mouse serum (
FIG. 17 ). Although some degradation was observed by 30 minutes incubation, only minimal degradation was observed in subsequent time points. In contrast, the phosphodiester NF-κB decoy was degraded relatively quickly and completely degraded at 120 min. -
FIG. 18 shows that nuclear extracts from a human monocytic cell line has 2 strong DNA-protein complexes when incubated with an NF-κB-containing consensus sequence from the IL-6 promoter. A competitive reduction in the density of these bands was observed with NF-κB decoy addition that was concentration dependent. The band densities remained unchanged in samples treated with a negative control ODN containing a scrambled sequence (scramble ODN) at up to 10-fold excess over the radiolabeled probe. The NF-κB complexes, identified by antibody supershifts, were shown to either contain a p65/p50 complex (top band) or a combination of p50/cRel/p52 complexes (lower band). This verifies that the NF-κB decoy binds the proinflammatory NF-κB heterodimeric complexes in a dose- and sequence-specific manner and has improved stability due to the chemically-modified backbone. - Nuclease Degradation and Chemistry Modifications
- Native DNA is subject to rapid degradation inside of a cell, primarily through the action of 3′ exonucleases, but also as a result of endonuclease attack. Therefore, oligonucleotide decoys are designed, they are modified to enhance their stability. Replacing one of the non-bridging oxygen atoms of the internucleotide linkage with a sulfur group, creating what is referred to as a phosphorothioate (PS) oligodeoxynucleotide, has been highly successful. The molecules are relatively nuclease resistant; however, they have been shown to exhibit nonspecific protein binding relative to 3′-terminally modified and unmodified oligonucleotide decoys (Brown et al, J. Biol. Chem. 269(43):26801-5 (1994)). Therefore, a set of experiments was performed to determine how many sulfurs were required at the 3′, 5′ or an internal site to provide nuclease resistance to our oligonucleotide decoys while maintaining the achieved specificity.
- The Analysis of the EMSA Results
- As discussed earlier, one goal of the work disclosed herein has been to develop NF-κB oligonucleotide decoy molecules that preferentially bind to the NF-κB p65/p50 and/or cRel/p50 heterodimer relative to the p50/p50 homodimer. The experimental results showed that the binding to p65/p50 and cRel/p50 were generally equivalent, therefore, only the p65/p50 bands were quantitated in our analysis.
-
FIG. 1 shows the p65/p50 binding of certain NF-κB decoy molecules.FIG. 2 shows the p50/p50 binding of certain NF-κB decoy molecules. - Preferential binding was quantified using the specificity/affinity factor, calculated as follows:
Specificity/affinity factor=(S p50/p50 −S p65/p50)×S p50/p50 /S p65/p50
where Sp50/p50 equals the molar excess of decoy required to compete 50% of the binding of p50/p50 to the non-mammalian NF-κB promoter from HIV (sequence 113/114) and Sp65/p50 equals the molar excess of decoy required to compete 50% of the binding of p65/p50 to the non-mammalian NF-κB promoter from HIV (sequence 113/114, where the reverse strand corresponding to sequence 113 is designated as “114”). The score (S) is assigned as 100 if the decoy is unable to compete at least 50% of the binding at any molar ratio tested. - A preferred decoy molecule will have a lower score for the p65/p50 heterodimer and a higher score for the p50/p50 homodimer. The specificity of the decoy to p65/p50 heterodimer versus p50/p50 homodimer is proportional to their difference of score (score p50/p50-score p65/50). The results of the EMSA competition binding experiments, performed as described above, are summarized in Table 2A, where the decoy molecules are listed starting with the most specific decoys (highest specificity/affinity factor).
TABLE 2A Core- Specificity/ SEQ Flank (p50- (p50- affinity ID ID Sequences Alias p65 p50 p65)*p50 p65)/p65 factor NO 173 TTGAGGACTTTCCAG E-Z-4 55 100 4500 0.82 81.82 26 177 CTCGGACTTTCCTGT E-W 57.5 100 4250 0.74 73.9 27 151 AGTTGAGGGATTTCCAGGC D-Z 36 69 2277 0.92 63.25 28 207 AGTTGAGGACTTTCCCAGGC L-Z 20 45 1125 1.25 56.25 29 153 AGTTGAGGACTTTCCAGGC E-Z 62.4 96 3225.6 0.54 51.69 30 265 AGTTGAGGATTTCCCAGGC I-Z 54 84 2520 0.56 46.67 31 235 TCGGACTTTCCCTC L-V 37 62.5 1593.75 0.69 43.07 32 117 ATGGACTTTCCGT E-U 72.5 100 2750 0.38 37.93 33 227 TCGGATTTCCTC H-V 74 100 2600 0.35 35.14 34 155 TCGGACTTTCCTC E-V 81 97 1552 0.20 19.16 35 281 TTGAGGACTTTCCAGGC E-Z 87 100 1300 0.15 14.94 36 EVEN 121 TCGGGACTTTCCTC A-V 25 34 306 0.36 12.24 37 263 AGTTGAGGATTTCCAGGC H-Z 73 82 738 0.12 10.11 38 295 TGAGGACTTTCCAGGCTC 92 100 800 0.09 8.70 39 289 TGAGGACTTTCCAGGC 93 100 700 0.08 7.53 40 309 CCTTGAAGGGATTTCCCTCC M-T 45 50 250 11 5.56 10 279 TTGCGGACTTTCCAGGC E-Z A->C 48 52 208 0.08 4.33 41 EVEN 191 CTGGGACTTTCCTC A-X 19 22.5 78.75 0.18 4.14 42 141 GTTGAGGGACTTTCCAGG A-Z-2 7.5 10 25 0.33 3.33 43 123 CTCGGGACTTTCCTGT A-W 8 10 20 0.25 2.50 44 195 TCGGGGACTTTCCCTC C-V 8.5 9 4.5 0.06 0.53 45 103 CAGTAGTATGTGAGCCTGC 100 100 0 0.00 0.00 46 107 TTGCCGTACCTGACTTAGCC SCRAMBLED 100 100 0 0.00 0.00 47 113 AGTTGAGGGGACTTTCCCAGGC C-Z 5 5 0 0.00 0.00 48 129 TCGGGATTTCCTC D-V 37.5 37.5 0 0.00 0.00 49 145 AGTTGAGGGACTTTCCAGGC A-Z 8 8 0 0.00 0.00 50 157 AGTTGAGACTTTCCAGGC F-Z 100 100 0 0.00 0.00 51 159 AGTTGAGACTTTCCCAGGC G-Z 100 100 0 0.00 0.00 52 169 GGACTTTCC E 100 100 0 0.00 0.00 53 171 AGGACTTTCCA E-A 100 100 0 0.00 0.00 54 FLANK 179 CTGGACTTTCCTC E-X 100 100 0 0.00 0.00 55 183 AAGAGGACTTTCCAGAG E-AG 100 100 0 0.00 0.00 56 FLANK 185 ATATGGACTTTCCTTAA E-AT 100 100 0 0.00 0.00 57 FLANK 187 CAACGGACTTTCCACAC E-CA 100 100 0 0.00 0.00 58 189 CAGTGGACTTTCCACTG E-CAGT 100 100 0 0.00 0.00 59 FLANK 213 TCGACTTTCCCTC G-V 100 100 0 0.00 0.00 60 221 CTGGGGACTTTCCCTC C-X 25 25 0 0.00 0.00 61 229 TCGGATTTCCCTC I-V 100 100 0 0.00 0.00 62 231 TCGATTTCCTC J-V 100 100 0 0.00 0.00 63 233 TCGATTTCCCTC K-V 100 100 0 0.00 0.00 64 239 CTCGGGGACTTTCCCTCA C-W′ 9 9 0 0.00 0.00 65 241 CTCGGACTTTCCTCA E-W′ 100 100 0 0.00 0.00 66 273 TTGAGGATTTCCAGGC H-Z′ 100 100 0 0.00 0.00 67 (−3′2BP) 275 TTGAGGATTTCCAGGCT H-Z′ 100 100 0 0.00 0.00 68 (−3′1BP) 277 TTGAGGATTTCCAGGCTC H-Z′ 100 100 0 0.00 0.00 69 283 TGAGGACTTTCCAGG E-Z-3 100 100 0 0.00 0.00 70 285 GAGGACTTTCCAG E-Z-6 100 100 0 0.00 0.00 71 287 GTTGAGGACTTTCCAGGC 100 100 0 0.00 0.00 72 291 GAGGACTTTCCAGGC 100 100 0 0.00 0.00 73 293 AGGACTTTCCAGGC 100 100 0 0.00 0.00 74 297 AGGACTTTCCAGGCTC 100 100 0 0.00 0.00 75 259 TTGAGGACTTTCCAGGCTC E-Z′ 87 85 −170 −0.02 −1.95 76 197 CTCGGGGACTTTCCCTGT C-W 26 17.5 −148.75 −0.33 −5.72 77
E-Z minus 4 is E-Z with the two 5′ and 3′ bases deleted
E-Z even is E-Z minus the two 5′ bases
E-Z a to C Even is E-Z with the A inposition 6 changed to a C
A-Z-2 is A-Z with the 5′ and 3′ bases deleted
E-A is the E core with an A added to the 5′ and 3′ ends
E-AG Flank is E core with AAGA as the 5′ flank and AGAG as the 3′ flank
E-AT Flank is E core with ATAT as the 5′ flank and TTAA as the 3′ flank
E-CA Flank is E core with CAAC as the 5′ flank and ACAC as the 3′ flank
E-CAGT Flank is E core with CAGT as the 5′ flank and ACTG as the 3′ flank
H-Z′ (−3′2BP) is H-Z with the two 5′ bases deleted
H-Z′ (−3′1BP) is H-Z with two 5′ bases deleted and a T added at the 3′ end
E-Z-3 is E-Z with AGT deleted from the 5′ end with C deleted from the 3′ end
E-Z-6 is E-Z with AGTT deleted from the 5′ end and GC deleted from the 3′ end
- The data set forth in Table 2A suggest that the decoys with better p65/p50 specificity most likely share the “E” or “D” or “H” or “L” or “I” core sequence and “Z” or “W” or “V” or “U” or “Z-4” flanking sequences. In a more preferred group, the core sequence is “E” or “D” and the flanking sequence is “Z.” The decoy designated 153/154 was chosen as best from the top few candidates with the consideration of other parameters (see below).
- As discussed earlier, for certain uses of the NF-κB decoys herein specificity is not a requirement. For such applications, it is advantageous to select NF-κB decoy molecules with high binding affinity for p65. The following Table 2B shows the p65 binding affinity for some NF-κB decoy molecules tested.
TABLE 2B Core-Flank SEQ ID ID Sequences Alias p65 NO 113 AGTTGAGGGGACTTTCCCAGGC C-Z 5 48 141 GTTGAGGGACTTTCCAGG A-Z-2 7.5 43 123 CTCGGGACTTTCCTGT A-W 8 44 145 AGTTGAGGGACTTTCCAGGC A-Z 8 50 195 TCGGGGACTTTCCCTC C-V 8.5 45 239 CTCGGGGACTTTCCCTCA C-W′ 9 65 191 CTGGGACTTTCCTG A-X 19 42 207 AGTTGAGGACTTTCCCAGGC L-Z 20 29 121 TCGGGACTTTCCTC A-V 25 37 221 CTGGGGACTTTCCCTC C-X 25 61 197 CTCGGGGACTTTCCCTGT C-W 26 77 151 AGTTGAGGGATTTCCAGGC D-Z 36 28 235 TCGGACTTTCCCTC L-V 37 32 129 TCGGGATTTCCTC D-V 37.5 49 309 CCTTGAAGGGATTTCCCTCC M-T 45 279 TTGCGGACTTTCCAGGC E-Z A->C 48 41 EVEN 265 AGTTGAGGATTTCCCAGGC I-Z 54 31 173 TTGAGGACTTTCCAG E-Z-4 55 26 177 CTCGGACTTTCCTGT E-W 57.5 27 153 AGTTGAGGACTTTCCAGGC E-Z 62.4 30 117 ATGGACTTTCCGT E-U 72.5 33 263 AGTTGAGGATTTCCAGGC H-Z 73 38 227 TCGGATTTCCTC H-V 74 34 155 TCGGACTTTCCTC E-V 81 35 281 TTGAGGACTTTCCAGGG E-Z EVEN 87 36 259 TTGAGGACTTTCCAGGCTC E-Z′ 87 76 295 TGAGGACTTTCCAGGCTC 92 39 289 TGAGGAGTTTCCAGGC 93 40 103 CAGTAGTATGTGAGCCTGC 100 46 107 TTGCCGTACGTGACTTAGCC SCRAMBLED 100 47 157 AGTTGAGACTTTCCAGGC F-Z 100 51 159 AGTTGAGACTTTCCCAGGC G-Z 100 52 169 GGACTTTCC E 100 53 171 AGGACTTTCCA E-A FLANK 100 54 179 CTGGACTTTCCTC E-X 100 55 183 AAGAGGACTTTCCAGAG E-AG FLANK 100 56 185 ATATGGACTTTCCTTAA E-AT FLANK 100 57 187 CAACGGACTTTCCACAC E-CA FLANK 100 58 189 CAGTGGACTTTCCACTG E-CAGT 100 59 FLANK 213 TCGACTTTCCCTG G-V 100 60 229 TCGGATTTCCCTC I-V 100 62 231 TCGATTTCCTC J-V 100 63 233 TCGATTTCCCTC K-V 100 64 241 CTCGGACTTTCCTCA E-W′ 100 66 273 TTGAGGATTTCCAGGC H-Z′ 100 67 275 TTGAGGATTTCCAGGCT H-Z′ 100 68 277 TTGAGGATTTCCAGGCTC H-Z′ 100 69 283 TGAGGACTTTCCAGG E-Z-3 100 70 285 GAGGACTTTCCAG E-Z-6 100 71 287 GTTGAGGACTTTCCAGGC 100 72 291 GAGGACTTTCCAGGC 100 73 293 AGGACTTTCCAGGC 100 74 297 AGGACTTTCCAGGCTC 100 75 - A similar analysis was applied to evaluate the chemical modification of DNA backbone for tested decoys.
TABLE 3A Sp50/p50/Sp65/p50 and specificity/affinity factor for 153/154 with various DNA backbones Specificity/Affinity backbone p65 p50 p50-p65 (p50-p65) * p50 (p50 -p65)/p65 Factor PO/H11 7.5 40 32.5 1300 4.33 173.33 H7/H7 39 100 61 6100 1.56 156.41 H6/ H6 40 100 60 6000 1.50 150.00 H3/ H3 45 100 55 5500 1.22 122.22 H11/PO 7.5 33 25.5 841.5 3.40 112.20 H5/ H5 50 100 50 5000 1.00 100.00 PO 58 92 34 3128 0.59 53.93 PO/ H5 65 100 35 3500 0.54 53.85 H8/ H8 29 53 24 1272 0.83 43.86 H10/ H10 21 42 21 882 1.00 42.00 H5/PO 59 83 24 1992 0.41 33.76 H10/H8 9 21 12 252 1.33 28.00 H9/ H9 17 30 13 390 0.76 22.94 H4/ H4 85 100 15 1500 0.18 17.65 H8/H10 33 39 6 234 0.18 7.09 H11/ H11 24 27 3 81 0.13 3.38 PS/ PO 5 5 0 0 0.00 0.00 PO/ PS 5 5 0 0 0.00 0.00 - In the foregoing Table 3A, where there are two designations for the backbone chemistry, the first one indicates the chemistry of strand 153 and the second the chemistry of strand 154. Fully phosphodiester bonds are designated “PO,” fully phosphorothioate backbones are designated “PS.” Hybrid backbones are designated with an “H” followed by the number of phosphorothioate backbone linkages, starting from the 3′ end. Thus, H3 means that the three most 3′ linkages are phosphorothioate and the rest of the backbone linkages are phosphodiester. If only one designation is shown (such as just PO), both strands have the same backbone chemistry.
- The data set forth in Table 3A indicate that if either strand or both strands are fully phosphothioated (e.g. PS/PO or PO.PS) then the decoy has a high affinity for both p65/p50 and p50/p50, and therefore lacks the specificity desired. Generally, although not always, a higher number of phosphorothioate linkages resulted in reduced specificity. Generally, hybrid strands with more than 8 phosphorothioate linkages lacked specificity, whereas those with fewer than 7 retained acceptable affinity and specificity. However, H4/H4 has extremely low affinity, while H3/H3 and H5/H5 were both in the acceptable range. H11/PO and PO/H11 has good affinity and specificity. Based on half-life, specificity and affinity, H3/H3, H5/H5, H6/H6, and H7/H7 were identified as the optimal backbone for the 153/154 decoy. Optimal backbone chemistries for other decoys can be tested and determined in an analogous manner.
- The effect of backbone chemistry on the p65 binding affinity is illustrated by the data set forth in Table 3B below.
TABLE 3B backbone p65 PS/ PO 5 PO/ PS 5 PS/ PS 5 PO/H11 7.5 H11/PO 7.5 H10/H8 9 H9/ H9 17 H10/ H10 21 H11/ H11 24 H8/ H8 29 H8/H10 33 H7/H7 39 H6/ H6 40 H3/ H3 45 H5/ H5 50 PO 58 H5/PO 59 PO/ H5 65 H4/ H4 85 - Just as before, if increased p65 binding affinity is the goal, preferably decoys with an affinity score below 40, or below 35, or below 30, or below 25, or below 20 are selected. Since this data was generated in a competitive binding assay, smaller scores indicate better binding affinity, as they represent the amount of competing material left binding after the competition. The results set forth in Table 3B show that, with a few exceptions, such as H4 on both strands or H5 on one strand, which decreases p65 binding affinity, increasing the level of phosphorothioate substitutions generally increases p65 binding affinity.
- Specificity Relative to Other Transcription Factors
- Decoy molecules must also specifically block only the target transcription factor and not non-specifically bind and block unrelated transcription factors. It has also been established that it is possible to design NF-κB decoy molecules which do not exhibit any non-specific effects on unrelated promoters using EMSA. Specifically, using radiolabeled oligonucleotide probes corresponding to the promoter sequences for the ubiquitous transcription factor Oct-1, it demonstrated that 153/154 (wherein “154” designates the reverse sequence corresponding to the sequence “153”) PO and H3 NF-κB decoy did not show any binding affinity for the promoter (data not provided). This is important because any non-specific effects of an oligonucleotide to other important proteins in the cell could result in unwanted toxicity of the decoy for the treatment individual.
- Half-Life
- Native DNA is subject to rapid degradation inside a cell, primarily through the action of 3′ exonucleases, but also as a result of endonuclease attack. Therefore, when oligonucleotide decoys are designed, they are modified to enhance their stability. Replacing one of the non-bridging oxygen atoms of the internucleotide linkage with a sulfur group, creating what is referred to as a phosphorothioate oligodeoxynucleotide, has been highly successful. The molecules are relatively nuclease resistant; however, they have been shown to exhibit non-specific protein binding relative to 3′-terminally modified and unmodified oligonucleotide decoys (Brown et al., J. Biol. Chem. 269:26801-5 (1994)). Therefore, a set of experiments were performed to determine how many sulfurs were required at the 3′- or 5′-end, or at an internal site to provide nuclease resistance to the oligonucleotide decoys herein, while maintaining specificity.
- Binding specificity was assessed by the gel shift assay described above. 3′-exonuclease resistance was assessed using a standard snake venom assay (Cummins et al., Nucleic Acids Res. 23:2019-24 (1995)). To assess the resistance of the decoys to more relevant mammalian nuclease activity, as assay was adapted in which cytoplasmic and nuclear extracts were prepared from activated macrophages. (Hoke et al., Nucl. Acids Res. 19(20):5743-8 (1991)). The activity of the extracts was confirmed with positive controls in each assay. It was determined that capping the 3′-ends of each strand of the decoy with a few sulfur groups was sufficient to protect it from nuclease degradation.
- Together these data indicate that for a p50/p65-selective NF-κB decoy 3-5 sulfurs at the 3′ ends of a 19-mer oligonucleotide duplex are sufficient to protect the decoy from nuclease degradation. Additionally, it was able to maintain specific subunit binding within the transcription factor family as well as lack of binding to irrelevant transcription factors. These data demonstrate that the present invention provides methods and means for designing specific and long-lasting oligonucleotide decoys targeting transcription factors, in particular NF-κB.
- NF-κB Decoy Molecules Comprising a Nuclear Localization Signal
- In order to determine the ability of a nuclear localization signal (NLS) containing peptide to improve the entry of an oligonucleotide decoy into the nucleus, a peptide with the NLS sequence based on the
simian virus 40 large tumor antigen (PKKKRKVEDPYC) (SEQ ID NO: 93) was synthesized by Sigma Genosys and conjugated to the NF-κB 153 H3 oligonucleotide as follows. Briefly, 6.5 nmols of oligonucleotide was first incubated with 40-fold molar excess of the linker Sulfo-SMCC (Pierce) at room temperature for 2 hours. After removal of excess linker from the reaction by a NAP-10 column (Pharmacia Biotech), the activated oligonucleotide was incubated with 5-fold molar excess of the NLS peptide at room temperature overnight. To assess the percentage of oligonucleotide successfully conjugated to the NLS peptide, the reaction was analyzed by loading 1 μl onto a 20% PAGE gel (non-denaturing). The gel was stained with SYBR Gold (Molecular Probes) and visualized on a Typhoon Phosphorimager (Amersham). The concentration of the NLS-peptide conjugated single strand 153 H3 was determined by OD absorbance. The conjugate was then annealed to its complemetary strand 154 H3 (in equal molar amounts) containing a biotin molecule at its 5′ end. The presence of the biotin molecule on the now double stranded NLS decoy was to enable visualization (via streptavidin) of the localization through the use of microscopy. - The following examples describe results obtained by the administration of the NF-kB decoy “153/154.” In the dermatological models, both strands of the NF-kB decoy 153/154 are fully phosphorothioated, i.e. the 153/154 molecule is “PS/PS.”
- NF-κB Decoy Reduces Ear Swelling in Murine Atopic Dermatitis
- To determine the efficacy and effective dose range of NF-kB decoy in Dustmite Ag (Dp) induced contact dermatitis in NC/Nga mice.
- Method
- Dp Ag induced dermatitis was induced as previously described (Sasakawa, T et al., Int Arch Allergy Immunol 126:239-47 (2001); Sasakawa et al., Int Arch Allergy Immunol 133:55-63 (2004)). Briefly, Six week old male NC/Nga mice were injected intradermally with 5 μg of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on
days - Results
- To examine the effect of NF-κB decoy treatment on established atopic dermatitis, the ear swelling/inflammation, as measured by ear thickness of Dp-injected NC/Nga mice with or without NF-κB decoy treatment, was examined. Dp extract was injected on the ventral side of the right ear on
days FIG. 4 , topical 0.25% NF-κB decoy or betamethasone (BID) treatment resulted in a rapid decrease in ear thickness while the 0.1% NF-κB decoy treatment group resulted in little to no decrease in ear thickness similar to the vehicle control. - Conclusion
- Topical application of NF-κB decoy suppresses inflammation in a dose dependent manner in this mouse model of atopic dermatitis.
- Cessation of NF-κB Decoy Treatment Does Not Result in a Rebound of Ear Swelling and Inflammation in the Dp Injected Ear
- The purpose of this experiment was to determine whether or not NF-κB decoy efficacy is maintained when treatment is stopped.
- Method
- Dp Ag-induced dermatitis was induced as previously described (Sasakawa et al, supra). Briefly, six-week old male NC/Nga mice were injected intradermally with 5 μg of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on
days - Results
- The ability of NF-κB decoy treatment to maintain the decrease in ear thickness after discontinuation of treatment was examined. As shown in
FIG. 5 , discontinuation of the NF-κB decoy treatment resulted in no increase in ear swelling, while the cessation of betamethasone in the Dp injected ears resulted in a significant increase of ear swelling. - Conclusion
- Cessation of the betamethasone, but not NF-κB decoy treatment results in a rebound of ear swelling and inflammation in the Dp injected ear.
- NF-κB Decoy Treatment Reduces Expression of Key Pro-Inflammatory Genes in Dp Injected NC/Nga Mice
- The goal of this study was to evaluate the effect of NF-κB decoy treatment on elevated pro-inflammatory cytokine expression in Dp injected NC/Nga mice.
- Method
- Right ears of Dp-injected mice were removed 1 day after the final decoy treatment. Part of the ear was flash frozen in liquid nitrogen and store at −80° C. Total RNA was isolated from the ears using Qiazol (Qiagen) according to manufacturer's instruction. The expression of the mouse genes were assayed by real-time quantitative PCR with an ABI PRISM 7900 Sequence Detector System (Applied Biosystems, Foster City, Calif.). All procedures were carried out as previously described (Hurst et al., Immunol 169:443-53 (2002)). Briefly, Dnase-treated total RNAs were mixed with random hexamers (Gibco-BRL), Oligo dt (Boehringer), and the first strand cDNAs were synthesized with SurperScript II reverse transcriptase. Primers for the respective genes were designed using the primer design software Primer Express (Applied Biosystems). Primers were synthesized by Sigma Genosys (Woodlands, Tex.). The quantitative PCR was performed using TaqMan PCR reagent kits according to the manufacturer's protool (Applied Biosystems). Sample cDNAs equivalent to 25 ng of RNA were examined in each reaction in a 384-well PCR plate. Levels of ubiquitin were measured for each sample, and used as internal standard. Cytokine levels are expressed as relative expression to ubiquitin levels.
- Results
- The effects of NF-κB decoy treatment on pro-inflammatory gene expression in the skin was analyzes by real-time quantitative PCR. As shown in
FIG. 6 , vehicle or non treated Dp injected mice showed a marked increase in expression levels of both IL-1β and IL-6, while NF-κB decoy treatment decreased the expression levels of both cytokines similar to that of protopic and betamethasone. - Conclusion
- Topical NF-κB decoy treatment decreases the expression of pro-inflammatory cytokines (IL-1β and IL-6) in Dp induced murine atopic dermatitis.
- The Efficacy of NF-κB Decoy Therapy in Dustmite Ag (Dp) Induced Contact Dermatitis in NC/Nga Mice
- This experiment investigates the efficacy of NF-κB decoy in Dustmite Ag (Dp) induced contact dermatitis in NC/Nga mice.
- Method
- Right ears of Dp-injected mice were removed 1 day after the final decoy treatment. Part of the ear was fixed in 10% phosphate buffered formalin (pH 7.2) and embedded in paraffin, and 3 micron sections were cut. Then the samples were stained with hematoxylin and eosin for histology and toluidine blue for detection of degranulated mast cells.
- Results
- Histological examination of the skin lesions was performed on
day 26. H&E staining showed severe epidermal hyperplasia and cellular infiltration into the dermis of vehicle treated ears injected with Dp, and treatment with NF-κB decoy or betamethasone produced both a decrease in epidermal hyperplasia and cellular infiltrate. As shown inFIG. 7 , most of the mast cells in the Dp-injected, vehicle treated mice were degranulated while treatment with NF-κB decoy or betamethasone demonstrated a decrease in degranulated mast cells. - Conclusion
- Topical application of NF-κB decoy suppresses inflammation and the infiltration of inflammatory cells (i.e mast cells) responsible for atopic dermatitis. Also, NF-κB decoy treatment decreased epidermal hyperproliferation, cellular infiltration and degranulation of mast cells.
- NF-κB Decoy Molecules Reduces Ear Swelling in Acute and Chronic Inflammation
- The following studies further examine the use of topical NF-κB decoy for targeting Th1/Th2 driven skin inflammation in experimental atopic dermatitis.
- Method
- Oligonucleotide Synthesis: The NF-κB decoy is a 19 base pair (molecular weight of 13 kDa) double-stranded deoxyribonucleic acid comprised of a random mixture of R- and S-chiral forms of oligonucleotides. The sequence of the NF-κB decoy used in this study was: 5′AGTTGAGGACTTTCCAGGC-3′ (SEQ ID NO: 30) and 5′-GCCTGGAAAGTCCTCAACT-3′ (SEQ ID NO: 95). The scrambled oligonucleotides (ODN) sequence was 5′-CAGTAGTATGTGAGCCTGC-3′ (SEQ ID NO: 46) and 5′-GCAGGCTCACATACTACTG-3′ (SEQ ID NO: 96). All oligonucleotides used were phosphorothioates and were annealed by combining equal molarities of each strand at room temperature.
- The oligonucleotides described above are also used in Examples 8-14 described below.
- Indicated concentrations of ODN were added to Corgentech's gel based formulation, for topical application (U.S. patent application Ser. No. 11/233,511).
- Animal Models:
- In order to demonstrate that topical NF-κB decoy is effective in reducing skin inflammation in a mouse model of chronic inflammation, dustmite Ag (Dp)-induced dermatitis was induced in six week old male NC/Nga mice (Charles River Lab). Animals were injected intradermally with 5 μg of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on
days day 12, the Dp injected ear was topically treated 2 times a day for 11-14 days with 20 μl of vehicle, vehicle containing 0.25% or 1% NF-κB decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control. The ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment. - 2. In order to demonstrate that topical NF-κB decoy is effective in reducing skin inflammation in an acute mouse treatment model, 12-O-tetradecanoylphorbol 13-acetate (TPA, phorbol 12-tetradecanoate 13-acetate) (TPA)-induced dermatitis was initiated by topical application of 2 μg of TPA on 7-8 week old female Balb/C mice ears. Six hours after induction, mice were treated topically with 20 μl of vehicle, vehicle containing 1% of scramble ODN, 0.1%, 0.25% or 0.5% NF-κB, or topical 0.1% BMV as the positive control. The ear thickness was measured with ear thickness gauge (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after induction.
- Results
- For the chronic atopic dermatitis model, a dose-dependent inhibition of inflammation following NF-κB Decoy treatment was observed (
FIG. 19 ). The highest topical dose of 1% NF-κB decoy inhibited inflammation by 74%, similar to topical BMV. Ears treated with scrambled ODN, vehicle only, or ears left untreated maintained severe ear thickness (FIG. 19 ). - For the acute atopic dermatitis model, TPA-induced ear swelling was reduced following application of topical NF-κB decoy; the highest dose (1%) showed similar efficacy to BMV treatment, with over 70% inhibition of ear swelling (
FIG. 20 ) - Conclusion
- This data demonstrate that topical NF-κB decoy is effective in reducing skin inflammation in both the chronic and the acute mouse treatment models.
- NF-κB Decoy Molecules Inhibits p65-DNA Binding Activity
- The purpose of this experiment was to determine whether NF-κB decoy competitively inhibits NF-κB protein.
- Method
- Animal Model: Dustmite Ag (Dp)-induced dermatitis was induced in six week old male NC/Nga mice (Charles River Lab). Animals were injected intradermally with 5 μg of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on
days day 12, the Dp injected ear was topically treated 2 times a day for 11-14 days with 20 μl of vehicle, vehicle containing 0.25% or 1% NF-κB decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control. The ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment. - EMSA: The NF-κB gel shift assays were performed as follows. A double-stranded ODN containing a consensus NF-κB binding site from the IL-6 promoter (5′
TGTGGGATTTTCCCATGACTC 3′ (SEQ ID NO: 97)) was end-labeled with γ32P-ATP using T4 Polynucleotide Kinase (Promega). 5 μg of a nuclear extract prepared from Dp-Ag injected ears was incubated with 35 fmol of radiolabeled probe in the presence or absence of indicated antibodies. The identity of NF-κB proteins contained in complexes bound to the radiolabeled ODN probe were identified by pre-incubating the reactions for 10 minutes with antibodies specific for each member of the NF-κB family prior to the addition of the radiolabeled probe (all antibodies were purchased from Active Motif (p65 and p50) (Carlsbad, Calif.) or Santa Cruz Biotechnology (p52, RelB, cRel). - NF-YA TransAM Assay: To assess the relative affinities of NF-κB decoy for a NF-YA/SP1 containing complex, the NF-YA TransAM assay (Active Motif, Carlsbad, Calif.) was utilized. The assay was performed according to manufacturer's instructions. A double-stranded ODN containing the consensus NF-YA binding sequence was immobilized on a 96-well plate. A nuclear extract prepared from NC/Nga ears/activated THP-1 cells were incubated and allowed to bind to the immobilized ODN. The unbound material was washed away and the bound NF-YA/
SP 1 detected using an antibody that specifically recognizes NF-YA/SP1. The NF-YA/SP1 antibody was detected by a secondary antibody labeled with horseradish peroxidase (HRP), and the amount of HRP in each well was measured using a colorimetric substrate reaction and read using a microplate spectrophotometer. - Results
- Gel shift assay was performed with labeled probe and nuclear extracts of inflamed Dp-injected ears to determine NF-κB decoy-dependent competitive inhibition to NF-κB protein. Nuclear extracts from inflamed ears of NC/Nga mice showed 3 strong DNA-protein complexes with low mobility (
FIG. 21 , indicated by the arrows). A reduction in the density of the three bands was observed in samples treated with topical BMV or 1% NF-κB decoy, while band densities remaining unchanged in samples treated with scrambled ODN. The identity of the p50 and p65 NF-κB sub-units was confirmed by a reduction in mobility following incubation of the sample extracts with specific antibodies (FIG. 21 ; right panel denoted by *). Nuclear extract quality and equal gel loading was confirmed by normalizing the band intensity from the gel shift analysis to the values obtained from a TransAM assay for the ubiquitously expressed transcription factor, nuclear factor-YA (NF-YA) (FIG. 22 ). The DNA-binding specificity of the NF-κB decoy was tested through competitive inhibition of NF-κB protein. - Conclusion
- NF-κB decoy demonstrates a dose-dependent inhibition of p65-DNA binding activity. Further, NF-κB decoy failed to block the binding activity of other known ubiquitously expressed transcription factors including SP1 or NF-YA.
- Topical NF-κB Decoy Suppresses Inflammation
- Method
- Animal Model: Dustmite Ag (Dp)-induced dermatitis was induced in six week old male NC/Nga mice (Charles River Lab). Animals were injected intradermally with 5 μg of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on
days day 12, the Dp injected ear was topically treated 2 times a day for 11 -14 days with 20 μl of vehicle, vehicle containing 0.25% or 1% NF-κB decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control. The ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment. - Hematoxylin and Eosin Staining: Dp injected mice ears were formalin-fixed, paraffin-embedded and 5-μM sections were then stained with hematoxylin and eosin. Mast Cells Staining: Deparaffinized and rehydrated sections were stained in toluidine blue working solution (1% Toluidine blue stock solution). Eosinophils Staining: Formalin-fixed, paraffin-embedded tissue samples were stained with congo red for detection of eosionophiis.
- Results
- Histological analyses showed that topical NF-κB Decoy decreased edema and inflammatory cell infiltrate in skin lesions induced by Dp injection into ears of NC/Nga mice. Hematoxylin and eosin (H&E)-stained sections of untreated lesions at
day 25 reveal a hyperplastic epidermis and edematous dermis, with an increase in lymphocyte infiltration, clinically resembling human AD (FIG. 23A ). In contrast, topical NF-κB decoy or BMV treatment produced a similar and significant decrease in epidermal hyperplasia and cellular infiltration (FIG. 23A ). Toludine blue stained ear sections of both untreated and scrambled ODN treated lesions showed an increased number of mast cells (FIG. 23B ), while inflamed skin treated with topical NF-κB decoy or BMV showed fewer mast cells (FIG. 23B ). In addition, congo red staining revealed a decrease in eosinophil infiltration in skin treated with topical NF-κB decoy or BMV, (FIG. 23C ). CD4+ T cells were also decreased with topical NF-κB decoy and BMV treatment (FIG. 23D ). Mice treated with either vehicle control or scrambled-sequence ODN fail to reduce such inflammatory response. A quantitative representation of the decrease in mast cells (60%), eosinophils (70%) and CD4+ T cells (60%), upon topical NF-κB decoy and BMV treatment was performed (FIG. 24 ). - Conclusion
- Topical application of NF-κB decoy suppresses inflammation and the infiltration of inflammatory cells (i.e. mast cells) responsible for atopic dermatitis.
- Cellular Uptake of Topical NF-κB Decoy
- The purpose of this experiment is to examine the specific cellular uptake of topical NF-κB decoy.
- Method
- Animal Model: Dustmite Ag (Dp)-induced dermatitis was induced in six week old male NC/Nga mice (Charles River Lab). Animals were injected intradermally with 5 μg of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on
days day 12, the Dp injected ear was topically treated 2 times a day for 11-14 days with 20 μl of vehicle, vehicle containing 0.25% or 1% NF-κB decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control. The ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment. - NF-κB Decoy Localization: Cryosections were used for co-localization of 1% biotinylated NF-κB decoy with various cells in inflamed skin. After fixation in 2% paraformaldehyde, sections were blocked with Goat Ig (Sigma, Atlanta, Ga.). Primary antibodies include rat anti-mouse CD4 (R&D Systems, Minneapolis, Minn.), rat anti-mouse CD117 (BD, San Diego, Calif.), rabbit anti-mouse CD207-Langerin (Imgenex, San Diego, Calif.), rat anti-mouse MCP-1 (Abcam, Cambridge, UK), rat IgG2b Iso. (BD), rabbit Ig Iso (
Sigma 10 mg/ml). Secondary antibodies include Alexa 546 SAV (Molecular Probes, Eugene, Oreg.), goat anti-rat Alexa 546, goat anti-rabbit Alexa 546 (Molecular Probes). Images were taken at 60× magnification, using laser scanning confocal microscopy. - Results
- To examine the specific cellular uptake of topical NF- To examine the specific cellular uptake of topical NF-κB decoy, topical biotinylated-NF-κB decoy was applied to Dp Ag-induced inflamed ears for 2 days (B.I.D). NF-κB decoy distribution in the epidermal cells and throughout the papillary dermis was observed (
FIG. 25 ). Immunohistological analysis revealed an uptake of NF-κB decoy by several key inflammatory cells. The co-localization of NF-κB decoy was detected in langerin-positive, resident antigen-presenting cells (APC)-Langerhans cells (LC), CD117 positive mast cells, CD4+ T cells and MCP-1 positive macrophages (FIG. 25 ). - Conclusion
- The results show efficient drug delivery to inflamed mouse skin by immunohistological analysis as revealed by the presence of NF-κB decoy in cells pivotal for disease progression and maintenance, including keratinocytes, resident APC-Langerhans cell LCs, mast cells, CD4+ T cells and macrophages.
- Topical NF-κB Decoy Uptake in Porcine Skin
- The purpose of this experiment is to demonstrate effective topical NF-κB decoy delivery into porcine skin tissue.
- Method
- For pig skin, 0.5% biotinylated NF-κB decoy was applied at 30 μl/cm2 area on the back of a light skinned female Yorkshire pig for 24 hrs. Skin was washed thoroughly with PBS to remove any remaining formulation. Duct tape from Intertape Polymer Group (Sarasota, Fla.) was used and the skin was tape-stripped 20 times. The biotinylated-NF-κB decoy was visualized using AlexaFluor488-streptavidin (Molecular Probes) and counterstained with Hoechst stain for nuclear co-localization.
- Results
- The results show an excellent delivery of topical NF-κB decoy into the porcine epidermis and dermis (
FIG. 26 ). Semi-quantitative analyses using Image-Pro software indicates that over 80% cells in treated pig skin are NF-κB decoy positive. This observation was further confirmed using a quantitative real-time PCR-based analytical method to detect the decoy (FIG. 27 ). Uptake and retention of topical NF-κB decoy by pig skin following application of a 1% decoy topical formulation was 10 ng/mg of tissue processed at 24 hours post-application. Prior tape-stripping of the skin, to model the compromised barrier in atopic dermatitis, increased the uptake of an equivalent application to 20 ng decoy/mg of tissue (FIG. 27 ). Overall, these observations confirm effective NF-κB decoy delivery into both compromised and uncompromised skin tissue. - Conclusion
- The results demonstrate effective topical NF-κB decoy delivery into porcine skin tissue.
- NF-κB Decoy Effects on Inflammation, Apoptosis and Proliferation
- The purpose of this experiment is to evaluate the anti-inflammatory effects of NF-κB decoy through the inhibition of essential regulators of inflammation and by induction of apoptosis of key immune cells.
- Method
- Animal Model: Dustmite Ag (Dp)-induced dermatitis was induced in six week old male NC/Nga mice (Charles River Lab). Animals were injected intradermally with 5 μg of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on
days day 12, the Dp injected ear was topically treated 2 times a day for 11-14 days with 20 μl of vehicle, vehicle containing 0.25% or 1% NF-κB decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control. The ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment. - Apoptosis and Mitotic Index: Formalin-fixed, paraffin-embedded tissue samples were used to identify apoptotic cells by the TUNEL assay. All the reagents were provided in the “In Situ Cell Death Detection Kit” (Roche, Indianapolis, Ind., Cat. No. 1 684 795). Formalin-fixed, paraffin-embedded tissue samples were also used to identify proliferating cells using Ki67 rabbit monoclonal antibody (NeoMarkers Cat. No. RM-9106, Lab Vision Corp., Fremont, Calif.).
- Immunoflourescence: Cryosections were used for IL-1β, TNFα, MIP2α and ICAM localization. Primary antibodies include PE-rat anti-mouse IL-1β (R&D Systems, Minneapolis, Minn.), PE-rat anti-mouse TNF (BD), rat anti-mouse MIP2α (R&D Systems, Minneapolis, Minn.), rat anti-mouse ICAM (Serotec, Raleigh, N.C.), rat IgG2b isotype control (BD) (Sigma, Atlanta, Ga.). Secondary antibodies include goat anti-rat Alexa 546 (Molecular Probes, Eugene, Oreg.).
- RNA Analysis: Total RNA was isolated from the ears using Qiazol (Qiagen, Valencia, Calif.). The first strand cDNA was synthesized using Reverse Transcriptase II (Invitrogen, Carlsbad, Calif.). The expression of the mouse genes was assayed by real-time quantitative PCR with an ABI PRISM 7900 Sequence Detector System (Applied Biosystems, Foster City, Calif.). Primers were designed to cross at least one intron based on the most current genome sequences using software Primer3 (Whitehead Institute for Biomedical Research, MIT). The quantitative PCR was performed using TaqMan PCR reagent kits according to the manufacturer's protocol (Applied Biosystems, Foster City, Calif.). ECM genes and cytokine mRNA levels were normalized to ubiquitin mRNA levels and expressed relative to normal untreated samples.
- Results
- Immunohistological analysis of skin lesions showed an increase in inflammatory cytokine expression IL-1β, TNF-α, macrophage inflammatory protein 2-alpha precursor (Mip2α) and a key adhesion molecule, intercellular adhesion molecule 1 (ICAM-1) in the inflamed ears (
FIG. 28 ). Both topical NF-κB decoy and BMV treatment decreased the expression of IL-1β, TNF-α Mip2α and ICAM-1. Tissues treated with the scrambled ODN showed no alteration in the expression of these molecules. These observations indicate that inflamed skin cells readily take up NF-κB decoy and topical NF-κB decoy, similar to BMV, suppresses expression of key regulatory proteins. - For a quantitative measure of the anti-inflammatory effects of topical NF-κB decoy and BMV treatment in the Dp Ag-inflamed ears, real time RTPCR analysis was performed. NF-κB decoy and BMV treatment inhibits mRNA levels of both Th1 and Th2 related proinflammatory genes including chemokine (C-C motif) receptor 3 (CCR3), IL-4, ICAM, thymic stromal lymphopoietin (TSLP), IL-13, IFNγ, IL-1β and TNF-α (
FIG. 29 ). These results confirm the above immunohistochemistry data that NF-κB decoy downregulated important inflammatory related genes and has a similar efficacy profile compared to BMV. - Since blockade of NF-κB function is associated with induction of apoptosis as well as inhibition of proliferation, NF-κB decoy treated Dp Ag-inflamed ears was analyzed by Tunnel assay and by Ki67 staining (
FIG. 30 ). Enhanced apoptosis mediated by BMV and topical NF-κB decoy application on inflammed ears was observed, in both the skin epidermis and dermis (FIG. 30 ). In contrast, the scramble ODN failed to elicit a similar response. Positive Ki67 staining showed increased proliferation in the epidermal and dermal layers of inflamed ears (FIG. 30 ; lower panel). Comparative quantitative analyses of both topical NF-κB decoy and BMV treated inflamed tissue revealed that each treatment resulted in a similar outcome: 50-70% apoptotic cells and a 50% decrease in the mitotic index (FIG. 31 ). The number of Ki67-positive cells with scrambled ODN treatment remained unaffected (FIG. 31 ). Together, these observations indicate that NF-κB decoy exerts its anti-inflammatory action through the effective inhibition of essential regulators of inflammation and by induction of apoptosis of key immune cells. - Conclusion
- Topical NF-κB decoy, similar to BMV, exerts its anti-inflammatory action by blocking expression of major inflammatory regulators and by inducing apoptosis of inflamed skin cells.
- Lack of Skin Atrophy With NF-κB Decoy Treatment
- The purpose of this experiment was to test the local skin-thinning effects of topical application of NF-κB decoy.
- Method
- Animal Model: Dustmite Ag (Dp)-induced dermatitis was induced in six week old male NC/Nga mice (Charles River Lab). Animals were injected intradermally with 5 μg of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on
days day 12, the Dp injected ear was topically treated 2 times a day for 11 -14 days with 20 μl of vehicle, vehicle containing 0.25% or 1% NF-κB decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control. The ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment. - Collagen Staining: Formalin-fixed, paraffin-embedded tissue samples were used to stain collagen using sirius red F3B dye. In the dermis this stain specifically detects collagen type III. Sections are stained with Alcian blue pH=2.5, to delineate cartilage prior to picro-sirius red staining (0.1%).
- Results
- Ear thickness measurements of normal ears treated with BMV and 1% NF-κB decoy for 14 days application twice-a-day (BID) were performed. Notably, dramatic decrease in ear thickness was observed in response to BMV treatment (
FIG. 32 ). NF-κB decoy failed to show any such side effects of skin atrophy (FIG. 32 ). Collagen I and III stain was performed on drug treated ear sections, which further confirmed skin-thinning effects of BMV (FIG. 33 ). - Further, topical NF-κB decoy did not cause skin atrophy in a 4-week dermal pig and a 21-week mouse carcinogenicity study.
- Gene expression of key extra-cellular matrix (ECM) components, including collagen I and III, tenacin C and elastin are decreased over 50% by BMV, without much effect by NF-κB decoy (
FIG. 34 ). - Conclusion
- Long-term treatment of topical NF-κB decoy does not cause breakdown of connective tissue genes associated with skin atrophy.
- Withdrawal of Topical NF-κB Decoy Treatment Does Not Cause Disease Rebound and Restores Epidermal Permeability
- The purpose of this experiment was to test whether the cessation of NF-κB decoy treatment causes rebound of swelling and inflammation.
- Method
- Animal Model: Dustmite Ag (Dp)-induced dermatitis was induced in six week old male NC/Nga mice (Charles River Lab). Animals were injected intradermally with 5 μg of Dp extract (Greer Laboratories, Lenoir, N.C.) dissolved in saline on the ventral side of their right ears on
days day 12, the Dp injected ear was topically treated 2 times a day for 11-14 days with 20 μl of vehicle, vehicle containing 0.25% or 1% NF-κB decoy, non-specific scramble ODN, or topical 0.1% betamethasone valerate (BMV) as the positive control. The ear thickness was measured with snap caliper (Oditest, Dyer, Inc., Lancaster, Pa.) 24 hr after each intradermal injection or treatment. - TEWL Measurements: Transepidermal water loss in Dp-induced inflamed ears was measured using a Tewameter water analyzer (Courage and Khazaka, Cologne, Germany). Inflamed ears were treated with scramble ODN, 1% NF-κB decoy or BMV for 14 days twice-a-day (BID). Ears were analyzed 16-18 hrs after the last application of either scramble ODN, 1% NF-κB decoy or BMV.
- PCRPK Analysis: The amount of NF-κB decoy in skin tissue was determined by using in-house developed method. Simply, the method is based on real-time quantitative PCR based assay with specific primer design and reagent modifications. The skin samples undergo alkaline lysis (using P2 buffer of Qiagen Miniprep Kit). Quantitative measure of NF-κB decoy in samples is obtained by comparing with the standard curve that is prepared by spiking known amounts of NF-κB decoy to the same biological matrix (or sample without NF-κB decoy treatment). The final value of NF-κB decoy in tissue was normalized to the net tissue weight.
- Results
- The abilities of NF-κB decoy and steroid treatment to cause rebound of disease after discontinuation of drug application were compared. Unlike NF-κB decoy, cessation of BMV resulted in an immediate and severe rebound of swelling and inflammation.
- Polymerase Chain Reaction Pharmacokinetics (PCRPK) study was performed to determine the presence of NF-κB decoy after treatment withdrawal. Rapid clearance of NF-κB decoy to minimal levels within 3 days of withdrawal was observed (
FIG. 35 ). Furthermore, the absence of therapeutic effective doses of decoy in the skin was confirmed by cutaneous Dp-Ag rechallenge experiments, in which the decoy treated group, showed a similar response to injected dust-mite antigen as the non-treated or scramble group (FIG. 36 ). These observations indicate that there is no significant accumulation of decoy in the treated tissue and no impaired immune response after 15 days of BID application. - BMV treatment withdrawal causing rebound is known to be associated with barrier disruption; therefore the effects of BMV and topical NF-κB decoy on integrity of mouse stratum corneum (SC) were determined by measuring the rate of Transepidemal Water Loss (TEWL). Increase of TEWL in inflamed ears was restored to normal levels by topical NF-κB Decoy application for 14 days (BID) (
FIG. 37 ). In contrast, BMV treatment failed to achieve complete reduction of TEWL, indicative of the lack of normal restoration of epidermal permeability. Next, the likelihood of topical NF-κB decoy or BMV application (BID for 14 days) on normal ears to exert adverse effects on SC function was assessed. Neither BMV nor NF-κB decoy produced any changes in basal TEWL. However, unlike NF-κB decoy that shows normal kinetics of barrier recovery after acute barrier disruption with acetone, BMV treatment showed a significant delay of barrier recovery at 3 hrs, 6 hrs and 24 hrs (FIG. 38 ). - Increase in TEWL is associated with dysregulation of several key regulators of SC integrity. NF-κB decoy treatment does not increase expression of inflammation-associated genes like skin-derived antileucoproteinase (SKALP), cytokeratin 6 (CK6), and cytokeratin 16 (CK16) levels, as observed in inflamed skin (
FIG. 39 ). However, BMV treatment further augments this expression (FIG. 39 ). The inflammation-associated cytokeratin 17 (CK17) mRNA levels were not induced in this inflammation model (data not shown). These data indicate that topical NF-κB decoy treatment restored inflammation-induced compromised barrier function and does not induce inflammation-associated cytokeratin genes. - Conclusion
- There is no significant accumulation of decoy in the treated tissue and no impaired immune response after 15 days of BID application.
- Further, topical NF-κB decoy treatment restored inflammation-induced compromised barrier function and does not induce inflammation-associated cytokeratin genes.
- Administration of NF-κB Decoy Into Arthritic Joints Led to Amelioration of Collagen-Induced Arthritis
- In rheumatoid arthritis (RA) NF-κB plays a pivotal role in the development of arthritis. In the present experiment, it has been investigated whether local administration of an NF-κB decoy could suppress the severity of joint inflammation.
- Method
- Collagen Induced Arthritis (CIA) was induced using a method previously described by Trentham et al., Arthritis Rheum 25:911-6 (1982). Briefly, 6 week old female DA rats (Charles Rivers) were immunized intradermally with 1 mg of bovine type II collagen (Chondrex) dissolved in 0.5 ml of 0.1M acetic acid at 4° C. and emulsified in 0.5 ml of cold Freund's incomplete adjuvant (Difco, Detroit, Mich.). Onset of arthritis in the ankle joints could be seen between 10 and 12 days. All rats whose onset of arthritis could not be recognized visually by
day 13 were excluded from the study. Onday 14 after immunization, the rats were anesthetized with isoflurane. Next 50 μl of a 100 μg solution of NF-κB decoy was injected into the articular space of the hind ankle with a 27 gauge needle. As a control, 0.5 mg of prednisolone was injected into the articular space of the hind ankle. Footpad swelling was measured with a caliper every other day for the first 2 weeks then 1× week there after. - Results
- Hindpaw swelling in CIA rats injected with NF-κB decoy was measured daily for the first week and then twice a week thereafter. As shown in
FIG. 8 , one-time injection of NF-κB decoy markedly reduced footpad swelling starting onday 23 and continued to resolve at a faster rate while the inflammation in the scramble control gradually decreased over time. Prednisolone treated animals significantly decreased hindpaw swelling almost immediately after injection and continued to suppress swelling throughout the experiment. - Conclusion
- Administration of NF-κB decoy into the arthritic joints of CIA rats led to an amelioration of arthritis.
- NF-κB Decoy Efficacy Studies in an Adjuvant Induced Arthritis (AIA) Model
- The efficacy of NF-κB decoy in the prevention and treatment arthritis was further studied in the adjuvant induced arthritis (AIA) model of arthritis.
- Method
- AIA was induced using a method previously described by Taurog et al. (Cell Immunol 75:271-82 (1983); Cell Immunol 80:198-204 (1983)). Briefly, 7-8 -week old female Lewis rats (Charles Rivers) were immunized intradermally at the base of the tail with 0.2 ml of a 10 mg/ml solution of Freund's adjuvant containing heat-killed mycobacterium tuberculosus H37Ra (Difco, Detroi, Mich.). Onset of arthritis in the ankle joints could be seen between 10 and 12 days. All rats whose unset of arthritis could not be recognized visually by
day 12 were excluded from the study. Onday 13 after immunization, the rats were anesthetized with isoflurane. Next 50 μl of a 100 μg solution of NF-κB decoy was injected into the articular space of the hind ankle with a 27 gauge needle. As a control, 0.5 mg of prednisolone was injected into the articular space of the hind ankle. Footpad swelling was measured with a caliper daily for the first week and 2 times a week thereafter. - Results
- The results shown in
FIG. 9 show that local injection of the NF-κB decoy into the inflamed joint in this arthritis model markedly reduced footpad swelling and continued to ameliorate the swelling while in the footpad treated with the scramble decoy, swelling was greatly increased and maintained throughout the study. Prednisolone treatment severely inhibited the footpad swelling compared to that of the scramble decoy control. - NF-κB Decoy Efficacy Studies in the TNBS-Induced Colitis Model
- Trinitrobenzene sulfonic acid (TNBS)-induced colitis in the mouse is one of the most relevant animal models that resembles the etiology of Crohn's disease (CD) in humans. In this colitis model, intestinal inflammation develops as a result of the covalent binding of the haptenizing agent to autologous host proteins with subsequent stimulation of a delayed-type hypersensitivity to TNBS-modified self antigens. Although the relationship of this model to human disease is imperfect, the hapten-induced colitis displays CD-like features, notably transmural mononuclear inflammation and predominant Th-1 activity of the resident mucosal leukocytes. Inflammation and cytokine production in TNBS-treated mice, as well as in CD patients, is associated with activation of transcription factors such as nuclear factor NF-κB.
- The procedures used for setting up the TNBS colitis model are very similar to that described in the following publications: Neurath et al., Int Rev Immunol 19:51-62 (2000); Bouma et al., Gastroenterol 123:554-565 (2002), and Bouma and Strober, Nat Rev Immunol 3:521-533 (2003).
- In brief, according to this protocol under general anesthesia with isoflurane, colitis is induced in SJL/J mice by intrarectal administration of 2 mg TNBS in a 45% ethanol solution. Intrarectal injection is administered with a 3.5F polyurethane umbilical catheter equipped with a 1 -ml syringe. The catheter is inserted so that the tip is 3 cm proximal to the anal verge and the TNBS was injected with a total volume of 100 μl. To ensure distribution of the TNBS within the entire colon and cecum, mice are held in a vertical position for 30 s after the injection. Changes in body weight are monitored daily, which typically amount to weight losses of 15-30% occurring over a period of approximately 1-4 weeks after TNBS administration. The mice are treated with decoy in the same intrarectal manner with a single administration either prior to TNBS (prophylactic) or at various time points post TNBS induction (therapeutic). In some instances a second decoy treatment may be administered to prolong therapeutic effects if deemed necessary. In addition to body weight measurements, in certain experiments animals are sacrificed at different time points to harvest tissues for mRNA and/or protein expression and histological analysis.
- Following this protocol, a single administration of NF-κB decoy given two days post disease induction can substantially reverse the weight loss associated with TNBS colitis (
FIG. 10 ). Weight loss in this model is closely correlated with inflammation and disease severity. Byday 2 post induction the mice have generally lost 15-20% body weight indicating disease onset. When vehicle alone was administered at this point, no ameliorative effects were seen and the mice in this group continued to lose weight and suffer from a high mortality rate. In treatment groups receiving either 50 or 100 μg NF-κB decoy onday 2, the disease associated weight loss was reversed very rapidly with almost complete recovery achieved byday 7. There was also a much higher survival rate in the decoy treated groups. The efficacy of NF-κB decoy was corroborated at the histopathological level in colons harvested from mice in both treatment groups at theday 7 post induction time point (FIG. 11 ). The TNBS-induced animals treated with vehicle alone showed localized inflammation, loss of the mucosal epithelium, an increase in crypt depth (with some sign of crypt branching), dissolution of the muscularis mucosae, and thickening of the muscularis layer (localized to the site of the inflammation). All these features are consistent with human inflammatory bowel disease (IBD) and the animal models presented in the literature. A single treatment with NF-κB decoy onday 2 post induction was able to reverse many of these pathological hallmarks of IBD. - NF-κB Decoy Efficacy Studies in the Oxazolone Colitis Model
- A series of preclinical experiments have been initiated to evaluate the therapeutic potential of an NF-κB decoy of the present invention in inflammatory bowel disease. Oxazolone induced colitis in the mouse is a relevant model for studying disease pathology related to ulcerative colitis (UC) in humans. In this colitis model, intestinal inflammation develops as a result of covalent binding of the haptenizing agent to autologous host proteins with subsequent stimulation of a delayed-type hypersensitivity to oxazolone-mediated self antigens. Using the “classical” haptenazing agent, oxazolone elicits an inflammatory bowel disease involving the distal half of the colon, and has histologic features resembling UC rather than Crohn's disease. In addition, oxazolone colitis is driven by a Th2 as opposed to Th1 response. NF-κB regulates many of the cytokines, chemokines, and cell adhesion molecules contributing to this response.
- The procedures used to set up this oxazolone colitis model were similar to those described by Neurath et al., Int Rev Immunol 19:51-62 (2000); Bouma et al., Gastroenterol 123:554-565 (2002), and Bouma and Strober, Nat Rev Immunol 3:521-533 (2003).
- In brief, under general anesthesia with isoflurane, mice were presensitized by applying 200 μl of a 3% (w/v) solution of oxazolone (ethoxymethylene-2-phenyl-2-oxazolin-5-one) in 100% ethanol to a 2×2 cm field of shaved abdominal skin. Five days after presensitization, mice were rechallenged intrarectally with 150 μl of 1.5% oxazolone in 50% ethanol or only 50% ethanol, again under general anesthesia with isoflurane. Intrarectal injection was administered with a 3.5F polyurethane umbilical catheter equipped with a 1-ml syringe. The catheter was inserted so that the tip was 3 cm proximal to the anal verge and the oxazolone was injected with a total volume of 150 μl. To ensure distribution of the oxazolone within the entire colon and cecum, mice were held in a vertical position for 30 seconds after the injection. Changes in body weight were monitored daily. Typically 15-20% weight losses were observed over a period of approximately 5-7 days after oxazolone administration. The oxazolone colitis model has an accurate disease progression from which the animals fully recover within 7-10 days.
- The mice were treated with the NF-κB decoy in the same intrarectal manner with a single administration either prior to intrarectal oxazolone challenge (prophylactic) or at various time points post oxazolone challenge (therapeutic). In some instances, a second decoy treatment may be administered to prolong therapeutic effects if deemed necessary. In addition to body weight measurements, in certain experiments animals were sacrificed at various time points to harvest tissues for mRNA expression and histological analysis.
- It has been found that a single administration of the NF-κB decoy given two days post disease induction could substantially reverse the weight loss associated with oxazolone colitis (
FIG. 12 ). Weight loss in this model is closely associated with inflammation and disease severity. Byday 2 post induction, the mice have generally lost 15-20% body weight indicating disease onset. When vehicle alone was administered at this point, no ameliorative effects were see, and the mice in this group continued to lose weight and suffer from a high mortality rate. In treatment groups receiving either 50 or 100 μg NF-κB decoy onday 2, the disease associated weight loss was reversed very rapidly with complete recovery observed in the 100 μg decoy group within 3 days of treatment. There was also a much higher survival rate in the decoy treatment groups (FIG. 13 ). Byday 3, there was 60-70% mortality rate in the vehicle treated group. In contrast, in the treated groups there was only a 20-30% mortality rate. - Additional Studies on TNBS-Induced Colitis Model
- To further establish the therapeutic efficacy of locally administered NF-κB decoy in inflammatory bowl disease (IBD), Examples 19, 20 and 21 show additional studies in three different mouse models of acute colitis that display unique features related to human IBD.
- The NF-κB decoy used in the experiments described in Examples 19, 20 and 21 was a 19 base pair (molecular weight of 13 kDa) double-stranded deoxyribonucleic acid comprised of a random mixture of R- and S-chiral forms of oligonucleotides. The sequence of the NF-κB decoy used in this study was: 5′AGTTGAGGACTTTCCAGGC-3′ (SEQ ID NO: 30) and 5′-GCCTGGAAAGTCCTCAACT-3′ (SEQ ID NO: 95). The scrambled oligonucleotides (ODN) sequence was 5′-CAGTAGTATGTGAGCCTGC-3′ (SEQ ID NO: 46) and 5′-GCAGGCTCACATACTACTG-3′ (SEQ ID NO: 96). All oligonucleotides used were phosphorothioates and were annealed by combining equal molarities of each strand at room temperature.
- Trinitrobenzene sulfonic acid (TNBS) colitis was induced in 5-6 week old male SJL/J mice. 2.5 mg TNBS (Sigma, Atlanta, Ga.) dissolved in 45% ethanol was administered intrarectally on
day 0 with a 3.5F polyurethane umbilical catheter (Supplier) equipped with a 1-ml syringe. The catheter is inserted so that the tip is 4 cm proximal to the anal verge and the TNBS is injected with a total volume of 150 μl. To ensure distribution of the TNBS within the entire colon and cecum, mice are held in a vertical position for 30 s after the injection. Changes in body weight are monitored daily. Ondays - Histological Analysis
- Harvested colons were formalin-fixed in a Swiss-roll orientation, embedded in paraffin, sectioned longitudinally and stained with hematoxylin-and-eosin, Peroidic acid-Schiff (PAS) or Alcian blue stains. Crypt loss and inflammation were assessed based on severity of lesions and the extent of tissue damage. The colon sections were scored in a blinded fashion by an independent veterinary pathologist using previously described criteria. Fort M M, et al., J Immunol 2005;174:6416-23.
- Immunohistochemistry
- In addition to assessing the ability of NF-κB decoy treatment to mitigate pro-inflammatory responses in colitis discussed below, the ability of NF-κB decoy treatment to affect mucosal repair processes was evaluated. Mucosal healing in the gastrointestinal tract requires both restitution and regeneration of the epithelium. (See Okamoto and Watanabe, Dig Dis Sci, 50 Suppl 1:S34-8 (2005); Taupin and Podolsky, Nat Rev Mol Cell Biol, 4:721-32 (2003)). Restitution promotes epithelial-cell migration to reseal lesions and re-establish surface-cell continuity. The trefoil factor family of secreted peptides play an essential role in protecting the mucosal epithelium from a range of insults and contribute to restitution and repair. NF-κB activation has been specifically associated with decreased intestinal trefoil factor (ITF) expression in inflamed epithelium. (See Loncar et al., Gut 52:1297-303 (2003); Dossinger et al., Cell Physiol Biochem 12:197-206 (2002)).
- Formalin-fixed paraffin-embedded sections were used for immunohistochemstry following heat-induced epitope retrieval using a modified citrate buffer, pH=6.1 (Target retrieval solution, DAKO, Carpinteria, Calif.) in a pressure cooker (Retrever 2100, EM Sciences, Hatfield, Pa.). The immunohistochemical staining was carried out with Autostainer (DAKO, Carpinteria, Calif.) using rabbit monoclonal anti-Ki67 (LabVision, Freemont, Calif.), peroxidase-conjugated mouse anti-smooth muscle actin, EPOS-SMA (DAKO, Carpinteria, Calif.), goat anti ITF (intestinal trefoil factor) (Santa Cruz Biotechnologies, Inc., Santa Cruz Calif.). The primary antibodies were localized by anti-rabbit SuperPicture-HRP reagent (ZYMED, South San Francisco, Calif.), biotinylated anti-goat IgG, biotinylated anti-rat IgG and ABC-HRP (Vector Laboratories, Inc., Burlingame, Calif.). Peroxidase activity was revealed using DAB substrate. The sections were counterstained with hematoxylin before coverslipping.
- Immunohistochemical assessment of ITF levels revealed very low levels of staining in the inflamed vehicle-treated control mice (
FIG. 40A ). After two treatments of 1.5 mg/kg NF-κB decoy, the production of ITF by goblet cells was pronounced in the mucosal epithelium atday 7 post TNBS induction (FIG. 40B ). Regeneration, on the other hand, involves epithelial proliferation and differentiation to restore normal function. Reduced goblet cell function is a classic pathological hallmark of disease in murine and human colitis. Re-emergence of secretory granules from goblet cells is evident in the H&E stained sections from mice treated with NF-κB decoy (FIG. 41 ). The ability of these highly differentiated cells to produce mucopolysaccharides was determined by PAS (FIGS. 40C and 40D ) and Alcian blue (FIGS. 40E and 40F ) staining of colonic tissues. In both cases, the colons from mice treated with NF-κB decoy demonstrated a dramatic increase in the levels of mucopolysaccharide production in the tissue as compared to saline controls. - To assess changes in cell proliferation due to NF-κB decoy treatment, colons from TNBS-induced mice were stained for Ki67. In the inflamed colons of vehicle treated mice high levels of proliferation were observed not only in the mucosal epithelium lining the crypts, but also throughout the lamina propria and muscularis layers (
FIGS. 42A and 42C ). In NF-κB decoy treated mice, normal levels of proliferation were observed in the lymphoid follicles (FIG. 42D ) suggesting a return to homeostatic conditions. To further evaluate the condition of the colonic muscularis, smooth muscle actin levels were examined. While inflamed colons showed very disrupted actin patterns associated with increased intercellular space, the muscularis of NF-κB decoy treated mice was uniform and well compacted (FIG. 42E versus 42F). These findings suggest the ability of NF-κB decoy to aid the repair of damaged intestinal epithelium and restore colon function. - Laser Scanning Confocal Microscopy
- In order to assess NF-κB decoy uptake into the inflamed colon, fluorescently labeled decoy (HEX-NFκB decoy) was intrarectally administered into mice with TNBS-induced colitis as discussed below.
- For decoy localization studies, 6-carboxy-2′,4,4′,5′,7,7′-hexachlorofluorescein, succinimidyl ester labeled NF-κB decoy (HEX-NFκB decoy) was applied in an enema form in TNBS-treated mice. Colon harvested after 6 hours was embedded and frozen in Tissue-Tek OTC following formalin fixation. The whole colon of HEX-NFκB decoy treated animals was embedded and frozen in Tissue-Tek OTC following formalin fixation. Frozen sections (10 micrometer thickness) were stained with Sytox Green (Molecular Probes, Inc., Eugene, Oreg.) and mounted in glycergel (DAKO, Carpinteria, Calif.). The frozen sections were photographed using a NIKON laser scanning confocal microscope (NIKON USA, NJ). A NIKON Eclipse E800 light microscope was fitted with the
PCM 2000 confocal system. The fluorochromes were sequentially excited with a HeNe laser followed by an Argon laser (using the 488 line for excitation). The confocal images were captured with Simple PCI software, v. 4.0.6 (Compix Inc., Cranberry Township, Pa.). - Throughout the distal colon, the HEX-NFκB decoy concentrated specifically at sites of inflammation, with little to no decoy accumulation observed in non-inflamed areas where the mucosal epithelium is intact. HEX-NFκB decoy uptake and /or accumulation were not seen in the cells of intact mucosal epithelium or in cells in the underlying lamina propria (
FIG. 43A ). In the inflamed areas with evidence of ulceration, HEX-NFκB decoy accumulation was detected not only in the luminal inflammatory cells but also in cells throughout the lamina propria all the way to the muscularis mucosae (FIG. 43B ). Co-localization studies with Sytox green nuclear counterstain revealed that HEX-decoy delivered to cells within the inflamed lesions is in fact primarily localized in the cell nuclei after 6 hours, the site of drug action. Although NFκB decoy was found distributed throughout the colon, from the cecum to the rectum, with this route of administration it was found in a majority but not all lesions after only two applications. The nuclear localization and the restriction to highly inflamed regions indicate a selective delivery of the therapeutic agent to important tissue target sites, i.e. inflamed areas with ulcerative lesions. Co-localization studies with cell-type specific markers revealed uptake by neutrophils, macrophages, and CD4+ T-cells (data not shown). In order to assess the amount of drug delivered, NFκB decoy levels were measured in the colonic tissue using a quantitative pharmacokinetic-PCR (PCRPK) assay discussed below. - Pharmacokinetic-PCR Assay
- The amount of NF-κB decoy in tissue was determined using an in-house developed pharmacokinetic-PCR (PCRPK) method based on a real-time quantitative PCR assay with specifically designed primers and modified reaction mixture.
- Six hours after the first intrarectal treatment of 1.5 mg/kg NF-κB decoy on
day 2, the mean level of NF-κB decoy detected was 420±90 pg per mg of tissue (FIG. 44 ). This amounts to approximately 0.27% of the original 1.5 mg/kg dose being retained in the tissue. The detectable level of NF-κB decoy remained constant over 24 hrs (450±130 pg/mg at day 3) and then showed a 45% decline at day 4 (250±80 pg/mg) despite the application of asecond dose 6 hrs prior to this harvest time point. Byday - NF-κB TransAM Assay
- To verify the targeted blockade of NF-κB function upon NF-κB decoy treatment, colons from TNBS-induced mice were analyzed for tissue NF-κB levels at various time points post treatment using an electrophoretic mobility shift assay.
- Nuclear extracts prepared from colon tissue were evaluated for transcription factor levels using the NF-κB TransAM assay (Active Motif, Carlsbad, Calif.) according to manufacturer's instructions.
- As expected during an inflammatory response, increased binding to a radiolabeled ODN containing NF-κB-binding sites was observed in tissue extracts from vehicle treated mice indicating elevated transcription factor levels (
FIG. 45 ). A reduction in the density of the p65/p50 band was observed in tissues treated with 1.5 mg/kg NF-κB decoy. The identity of the p65, RelB and p50 NF-κB sub-units was confirmed by a reduction in mobility following incubation of the sample extracts with specific antibodies. Kinetic analysis of p65 levels in the TNBS model was carried out using an ELISA-based TransAM assay. p65 binding in the vehicle treated animals increased throughday 6 reaching a peak level of 0.82±0.02 A450 units and remaining elevated through day 8 (FIG. 46 ). In contrast, the amount of p65 available for binding was mitigated upon treatment with 1.5 mg/kg NF-κB decoy beginning onday 2, and after a second dose atday 4 p65 levels remained substantially lower than vehicle controls through day 7 (0.61±0.09 A450 units). Regression analysis of the curve fits for each of these data sets revealed the differences in p65 activation to be statistically significant (p=0.03), thus indicating that a naked phosphorothioated NF-κB decoy is able to significantly reduce levels of this key transcription factor in vivo. - Myeloperoxidase Assay
- Infiltration of leukocytes is a hallmark of colitis pathology. Using CD45 as a pan-leukocyte marker, the level of inflammatory cell accumulation by immunohistochemistry was evaluated (
FIG. 47 ). - Myeloperoxidase (MPO) activity can be used as a quantitative measure of the extent of neutrophil infiltration into inflamed tissue. To measure myeloperoxidase (MPO) activity, frozen colonic tissue was pulverized then homogenized in T-PER protein extraction reagent (Pierce, Rockford, Ill.). Homogenates were centrifuged at 16,000×g for 15 min then MPO activity was measured by adding 50 ml of supernatant to 250 ml of an assay reaction mixture containing 0.5% hexadecyltrimethylammonium bromide (in 50 mM potassium phosphate, pH 6.4), 0.17 mg/ml o-dianisidine dihydrochloride, and 0.0015% hydrogen peroxide. After a 30 min incubation period at room temperature, absorbance at 450 nm was measured. Absolute MPO activity was determined based on the generation of a standard curve and normalized with protein concentration as determined by BCA assay (Pierce, Rockford, Ill.).
- Seven days after TNBS-induced colitis, the amount of inflammatory cell infiltration was clearly reduced in mice treated intrarectally with 1.5 mg/kg NF-κB decoy as compared to saline vehicle controls (
FIG. 47A versus 47B). Using a specific immunohistochemical marker for murine neutrophils the experiment showed that a large proportion of the inflammatory infiltrates are in fact, neutrophils (FIGS. 47C and 47D ). Neutrophil accumulation was predominant not only in the ulcerated areas but also in the expanded lamina propria between the colonic crypts. The TNBS-induced acute inflammatory response in the colon is specifically associated with an increase in the infiltration of activated neutrophils into the gut mucosa. (See Buell and Berin, Dig Dis Sci, 39:2575-88 (1994); Yamada et al., Gastroenterology, 102:1524-34 (1992)). - Colitis induction with TNBS followed by vehicle treatment resulted in substantially increased MPO activity levels that peaked at
post induction day 2 but remained elevated at theday 7 endpoint. Treatment with 1.5 mg/kg NF-κB decoy ondays FIG. 48 ). The scramble ODN had no protective effect, ruling out non-specific inhibitory mechanisms. In summary, this data indicates the ability of NF-κB decoy to reduce infiltration and activity of inflammatory cells in colonic tissue and that the effectiveness of NF-κB decoy was sequence dependent and superior to budesonide. - Cytokine mRNA Quantification
- Cytokines and chemokines play a central role in the modulation of the intestinal immune system and there is extensive evidence illustrating their dysregulation in inflammatory bowel disease. Therefore, key inflammatory mediators in the colon were examined to assess the efficacy of NF-κB decoy treatment at the molecular level.
- At the time of sacrifice, the colon was removed from the colo-caecal junction to the anal verge. Harvested colons were flushed to remove fecal material and flash-frozen in liquid nitrogen and stored at −80° C. Total RNA was isolated from the colons using Qiazol (Qiagen; Valencia, Calif.). The expression of the mouse genes was assayed by real-time quantitative PCR with an ABI PRISM 7900 Sequence Detector System (Applied Biosystems, Foster City, Calif.). Primers were synthesized at Sigma Genosys. The quantitative PCR was performed using TaqMan PCR reagent kits according to the manufacturer's protocol (Applied Biosystems, Foster City, Calif.). Cytokine mRNA levels are expressed relative to ubiquitin mRNA levels.
- As determined by real-time PCR, TNBS-induced inflammation resulted in upregulation of TNFα, IL-1β, IL-6, IL-12 and MCP-1 mRNA levels (
FIG. 49 ). Treatment with 1.5 mg/kg NF-κB decoy resulted in a 5-fold reduction in TNFα levels as compared to vehicle controls at theday 7 endpoint (1.1±0.4 versus 5.1±1.3, respectively; p<0.05). The highly expressed cytokines IL-6 and IL-1β were reduced by NF-κB decoy treatment 2- and 4-fold (P<0.05); respectively. IL-12, a key Th1-inducing cytokine, was down-regulated nearly 4-fold in NF-κB decoy treated mice (data not shown). The monocyte chemoattract protein, MCP-1, decreased approximately 3-fold after NF-κB decoy treatment (p<0.05). In the cases of TNFα and IL-1β, NF-κB decoy treatment demonstrated even greater inhibition than the steroid treated group. The scramble ODN (1.5 mg/kg) had little to no effect on mRNA levels. These important mediators of the inflammatory response are all controlled by NF-κB and affect the differentiation and activation of key immune cells, including macrophages, lymphocytes and polymorphonuclear neutrophils. The ability of NF-κB decoy to down-regulate these important inflammatory mediators indicates one of the mechanisms by which efficacy is achieved in ameloriating colitis. - Statistics
- Data are presented as mean values±S.E.M. Statistical significance was determined using the Student's unpaired t-test for two group analysis and by ANOVA with post hoc comparisons by Dunnett's Multiple Comparison Test for multiple group analysis (GraphPad Software, San Diego Calif.).
- Additional Studies on Oxazolone-Induced Colitis Model
- The purpose of this experiment was to determine the therapeutic potential of our NF-κB decoy to treat a Th2 cytokine-mediated colitis model.
- Oxazolone-induced colitis was initiated by presensitizing C57BL/10 mice with a 3% (w/v) solution of oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one; Sigma, Atlanta, Ga.) in 100% ethanol applied topically to a 2×2 cm field of shaved abdominal skin. 5-7 days after presensitization mice are rechallenged intrarectally with 150 ul of 1.5% oxazolone in 50% ethanol or 50% ethanol alone under general anesthesia with isoflurane. The mice are treated with 1.5 or 5 mg/kg NF-κB decoy or 0.3 mg/kg budesonide in the same intrarectal manner with a single administration either prior to intrarectal oxazolone challenge (prophylactic) or at various time points post oxazolone challenge (therapeutic).
- Animals receiving saline vehicle demonstrated a 17% weight loss two days after disease induction, which was followed by a steady recovery in body weight that returned to the original starting value by day 5-6 (
FIG. 50 ). While neither budesonide nor NF-κB decoy was able to completely prevent disease onset, presumably as a result of the ethanol damage caused during induction, these two treatment groups recovered much more rapidly than vehicle controls. Byday 2, both the NF-κB decoy and budesonide treatment groups began recovering body weight, while the vehicle group remained non-responsive. A significant difference between treated and vehicle groups was observed atday 3, at which point the NF-κB decoy and budesonide treated groups had returned to their approximate starting weights while the vehicle group was still down 12% from its original mean weight (p<0.01). There was a moderate but non-statistically significant increase in survival associated with NF-κB decoy and budesonide (62% and 69%, respectively) when compared with the 35% survival in vehicle controls (data not shown). At theday 6 endpoint, despite what appeared to be a full recovery in body weight, there was a remarkable amount of damage still present throughout the vehicle treated colons (FIG. 5 1). However, in the NF-κB decoy treated group colonic damage was minimal at this time point and limited to the most distal portion of the colon. Quantitative analysis of the histopathological scores indicated over 70% reduction in the level of colitic damage between NF-κB decoy and vehicle treated controls (7.2±2.6 versus 26.7±7.3, respectively) (FIG. 52 ). Histological scores in the budesonide-treated group were also improved but to a lesser degree than the NF-κB decoy treated mice. Animals receiving NF-κB decoy treatment showed greater improvement than those given budesonide in a majority of the pathological parameters evaluated; including mucoid crypt cysts and abscesses, goblet cell depletion, edema, mononuclear cell infiltration and transmural inflammation. Overall, this data shows that topical delivery of naked NF-κB decoy has a better efficacy profile than budesonide in a Th2-mediated disease model. - Dextran Sulfate Sodium (DSS)-Induced Colitis Model
- The purpose of this experiment was to examine NF-κB decoy efficacy in acute and chronic dextran sodium sulphate (DSS)-induced colitis models which recapitulate epithelial injury conditions and have been characterized by a mixed Th1/Th2 cytokine response.
- To induce DSS colitis, female BALB/C mice were fed 5% dextran sodium sulfate (DSS; 35-45 kDa; MP Biomedicals) dissolved in drinking water for 10 days. Animals were administered 2.5 mg/kg NF-κB decoy, scramble ODN (negative control ODN), or vehicle every other day by intrarectal administration from
day 0 to day 9. A disease activity index (DAI) was calculated onday 10 based on the summation of scores evaluating weight loss, blood in stool, and stool consistency. Each parameter was graded on a scale of 0 to 4, and the combined scores were divided by 3 to obtain the final disease activity index. The presence of blood in the stool was evaluated with Hemoccult test strips (Supplier). Colon lengths were also measured when mice were sacrificed. Chronic colitis was induced by giving themice 4% DSS in their drinking water for two cycles. The first cycle of DSS administration was followed by 14 days of plain drinking water. The second cycle of DSS was followed by 3 days of plain drinking water, after which the mice were sacrificed. NF-κB decoy (5 mg/kg) was intrarectally administered every other day for a total of 5 treatments beginning the first day of each DSS cycle. - Animals receiving vehicle only or scramble ODN control treatment achieved mean disease activity index scores of 1.6±0.2 and 1.5±0.3, respectively (
FIG. 53 ). Remarkably, the disease activity index was reduced over 50% in the NF-κB decoy treatment group compared to vehicle and scramble controls, reaching a statistically significant value of 0.78±0.2 (p<0.05). Surprisingly, the steroid treatment was ineffective and in some cases even exacerbating in this model (data not shown). At theday 10 endpoint, in the acute DSS model, crypt elongation, severe lymphocytic infiltration, goblet cell loss, and a high frequency of lymphoid aggregates in the submucosum of vehicle treated animals were observed (FIG. 54 ). Similar to the quantitative difference in DAI scores in this model, the NF-κB decoy treated colons had significantly reduced histopathology scores, decreased over 55% as compared to vehicle controls (21.5±5.0 versus 47.9±5.6, respectively) (FIG. 55 ). The recovery of colonic morphology was apparent with resolution of crypt length, return of goblet cells, and reduced number and size of lymphoid aggregates. - A repeated inflammation cycle protocol for the DSS model was used to assess the effectiveness of NF-κB decoy treatment under more clinically-related chronic inflammatory conditions. Treatment in this model was given therapeutically, beginning at the start of the 2nd cycle. Ten days into the second DSS cycle, the NF-κB decoy treated group had a significantly lower DAI score as compared to the vehicle control (
FIG. 56 ) (p<0.0015). The decreased DAI score in the NF-κB decoy treated mice comprised reductions of over 30% in weight loss (1.9±0.3 versus 2.9±0.2) and stool consistency scores (1.6±0.2 versus 2.4±0.2), and a reduction of over 80% in the amount of fecal occult blood (0.1±0.1 versus 0.6±0.2) observed in this group. No effect was observed with the scramble ODN. Histologically, the NF-κB decoy treated colons still displayed some intermittent areas of inflammation but overall the colitic damage was substantially reduced compared to vehicle treated controls which had very high levels of infiltrates, lamina propria edema, disrupted crypt morphology, loss of goblet cells, and large well-developed lymphoid aggregates (data not shown). The amelioration of disease in the DSS induced colitis model shows the therapeutic potential of NF-κB decoy in a mixed Th1/Th2 mediated disease. These findings in the chronic colitis model further show that therapeutic treatment with NF-κB decoy is also efficacious under chronic inflammatory conditions. - All references cited throughout this disclosure are hereby expressly incorporated by reference.
- Although the present invention is illustrated with reference to certain specific embodiments, it is not so limited. Modifications and variations are possible without diverting from the idea of the invention, and will be apparent to those skilled in the art. All such modifications and variations are specifically within the scope herein.
Claims (23)
1. A method for the treatment of an inflammatory bowel disease (IBD), comprising administering to a mammalian subject in need an effective amount of an NF-κB double-stranded decoy oligodeoxynucleotide (dsODN) molecule.
2. The method of claim 1 wherein said dsODN comprises in its sense strand, in 5′ to 3′ direction, the sequence of SEQ ID NO:30.
3. The method of claim 2 wherein the antisense strand of said dsODN molecule is at least partially complementary to said sense strand.
4. The method of claim 3 wherein the dsODN molecule further comprises at least one single-stranded overhang.
5. The method of claim 3 wherein the two strands of the dsODN are linked at the 5′ and/or 3′ end by a covalent bond, other than a peptide bond.
6. The method of claim 3 wherein the dsODN molecule comprises modified nucleotides.
7. The method of claim 3 wherein the dsODN molecule has a phosphodiester backbone.
8. The method of claim 3 wherein the dsODN molecule has a phosphorothioate backbone.
9. The method of claim 3 wherein the dsODN molecule has a mixed phosphodiester-phosphorothioate backbone.
10. The method of claim 2 wherein the antisense strand of said dsODN molecule is fully complementary to said sense strand.
11. The method of claim 2 wherein said dsODN molecule has a phosphodiesterate backbone.
12. The method of claim 2 wherein said dsODN molecule has a phosphorothioate backbone.
13. The method of claim 2 wherein said dsODN molecule has a mixed phosphodiesterate-phosphorothioate backbone.
14. The method of claim 2 wherein the sense and antisense strands are connected to each other solely by Watson-Crick base pairing.
15. The method of claim 2 wherein the sense and antisense strands are connected, completely or partially, by cross-links other than Watson-Crick base pairing.
16. The method of claim 2 wherein the sense and antisense strands are covalently linked to each other at their 3′ and/or 5′ end.
17. The method of claim 2 wherein the dsODN molecule comprises modified nucleotides.
18. The method of claim 1 wherein said mammalian subject is human.
19. The method of claim 1 wherein said dsODN molecule is administered by pressure mediated transfection.
20. The method of claim 1 wherein said dsODN molecule is administered by retroviral transfection.
21. The method of claim 1 wherein said dsODN molecule is administered in liposomes.
22. The method of claim 1 wherein said dsODN molecule is administered as a topical formulation.
23. The method of claim 1 wherein said dsODN molecule is administered as an oral formulation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/521,714 US20070010474A1 (en) | 2003-12-02 | 2006-09-14 | NF-kappaB oligonucleotide decoy molecules |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52662303P | 2003-12-02 | 2003-12-02 | |
US61202904P | 2004-09-21 | 2004-09-21 | |
US11/004,512 US7378509B2 (en) | 2003-12-02 | 2004-12-02 | NF-kappaB oligonucleotide decoy molecules |
US11/368,060 US20070078102A1 (en) | 2003-12-02 | 2006-03-03 | NF-kB oligonucleotide decoy molecules |
US11/521,714 US20070010474A1 (en) | 2003-12-02 | 2006-09-14 | NF-kappaB oligonucleotide decoy molecules |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/368,060 Continuation US20070078102A1 (en) | 2003-12-02 | 2006-03-03 | NF-kB oligonucleotide decoy molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070010474A1 true US20070010474A1 (en) | 2007-01-11 |
Family
ID=34681509
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/004,512 Expired - Fee Related US7378509B2 (en) | 2003-12-02 | 2004-12-02 | NF-kappaB oligonucleotide decoy molecules |
US11/368,060 Abandoned US20070078102A1 (en) | 2003-12-02 | 2006-03-03 | NF-kB oligonucleotide decoy molecules |
US11/521,714 Abandoned US20070010474A1 (en) | 2003-12-02 | 2006-09-14 | NF-kappaB oligonucleotide decoy molecules |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/004,512 Expired - Fee Related US7378509B2 (en) | 2003-12-02 | 2004-12-02 | NF-kappaB oligonucleotide decoy molecules |
US11/368,060 Abandoned US20070078102A1 (en) | 2003-12-02 | 2006-03-03 | NF-kB oligonucleotide decoy molecules |
Country Status (4)
Country | Link |
---|---|
US (3) | US7378509B2 (en) |
EP (1) | EP1691817A2 (en) |
JP (1) | JP2007512845A (en) |
WO (1) | WO2005056020A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090143319A1 (en) * | 2005-06-06 | 2009-06-04 | Angesmg, Inc. | Transcription factor decoy |
US20100167390A1 (en) * | 2005-12-22 | 2010-07-01 | Toshohiro Nakajima | Novel Oligonucleotide and NF-kB Decoy Comprising the Same |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1340505A3 (en) * | 1993-10-29 | 2004-07-14 | The Brigham And Women's Hospital, Inc. | Therapeutic use of cis-element decoys in vivo |
JP2005160464A (en) * | 2003-12-02 | 2005-06-23 | Corgentech Inc | NF-kappaB OLIGONUCLEOTIDE DECOY MOLECULE |
EP1691817A2 (en) * | 2003-12-02 | 2006-08-23 | Corgentech, Inc. | NF-kB OLIGONUCLEOTIDE DECOY MOLECULES |
WO2005080567A1 (en) * | 2004-02-20 | 2005-09-01 | Mologen Ag | Substituted, non-coding nucleic acid molecule used for the therapeutic and prophylactic immune stimulation in humans and higher animals |
US7482158B2 (en) | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
MX2007003167A (en) * | 2004-09-21 | 2007-05-16 | Anesiva Inc | Delivery of polynucleotides. |
US20080312145A1 (en) * | 2004-12-16 | 2008-12-18 | Anges Mg, Inc. | Agent for Regulating Bone Formation |
JPWO2006075776A1 (en) * | 2005-01-13 | 2008-06-12 | アンジェスMg株式会社 | Treatment for chronic obstructive pulmonary disease (COPD), cystic fibrosis (pulmonary hypertension) or pulmonary hypertension |
US20060258604A1 (en) * | 2005-05-10 | 2006-11-16 | Warren Strober | Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides |
EP2127681A4 (en) * | 2007-02-16 | 2011-10-12 | Anges Mg Inc | Therapeutic agent for periodontal disease and alveolar bone loss due to surgery |
GB0906130D0 (en) * | 2008-10-03 | 2009-05-20 | Procrata Biosystems Ltd | Transcription factor decoys |
US9994514B2 (en) | 2012-05-08 | 2018-06-12 | Aeromics, Inc. | Methods of treating cerebral edema and spinal cord edema |
RU2691951C2 (en) | 2013-11-06 | 2019-06-19 | Аэромикс, Инк. | Novel compounds |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262033B1 (en) * | 1995-02-11 | 2001-07-17 | Fujisawa Pharmaceutical Co., Ltd. | Remedy for diseases associated with NF-κB |
US20020177568A1 (en) * | 1992-12-07 | 2002-11-28 | Stinchcomb Dan T. | Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B |
US20030013669A1 (en) * | 1991-08-21 | 2003-01-16 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
US20040063614A1 (en) * | 1997-07-04 | 2004-04-01 | Fujisawa Pharmaceutical Co. Ltd. | Brain-protective agent |
US20040072726A1 (en) * | 2002-02-01 | 2004-04-15 | Ryuichi Morishita | Decoy-containing pharmaceutical compositions and method of using the same |
US20040162251A1 (en) * | 2001-02-20 | 2004-08-19 | Ryuichi Morishita | Pharmaceutical composition containing decoy and method of using the same |
US20040191779A1 (en) * | 2003-03-28 | 2004-09-30 | Jie Zhang | Statistical analysis of regulatory factor binding sites of differentially expressed genes |
US20040191328A1 (en) * | 2002-12-31 | 2004-09-30 | Warrell Raymond P. | Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia |
US20050125054A1 (en) * | 2000-12-22 | 2005-06-09 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
US20050175539A1 (en) * | 2001-11-22 | 2005-08-11 | Ryuichi Morishita | Compositions inhibiting rejection in organ transplantation and method of using the same |
US20050182012A1 (en) * | 2003-12-02 | 2005-08-18 | Mcevoy Leslie M. | NF-kappaB oligonucleotide decoy molecules |
US20050203612A1 (en) * | 2000-12-22 | 2005-09-15 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
US20060057154A1 (en) * | 2003-03-28 | 2006-03-16 | Universiteit Utrecht Holding B.V. | Compositions for inducing of immunotolerance |
US20060135449A1 (en) * | 2002-03-29 | 2006-06-22 | Yoshiki Sawa | Decoy compositions for treating and preventing brain diseases and disorders |
US20060153847A1 (en) * | 2005-01-11 | 2006-07-13 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
US20060241066A1 (en) * | 2002-05-29 | 2006-10-26 | Tetsuya Tomita | Decoy composition for treating and preventing inflammatory disease |
US20060258604A1 (en) * | 2005-05-10 | 2006-11-16 | Warren Strober | Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410516B1 (en) * | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
US6262022B1 (en) * | 1992-06-25 | 2001-07-17 | Novartis Ag | Pharmaceutical compositions containing cyclosporin as the active agent |
WO2002045659A2 (en) * | 2000-10-27 | 2002-06-13 | Baylor College Of Medicine | Novel therapeutics for heart failure and aging |
AU2003217649A1 (en) * | 2002-02-21 | 2003-09-09 | University Of Utah Research Foundation | COMPOSITIONS AND METHODS FOR INHIBITING NF-KappaB MEDIATED TUMORIGENICITY AND ADHESION-DEPENDENT SURVIVAL OF CANCER CELLS |
US20070014840A1 (en) * | 2002-04-26 | 2007-01-18 | In-Kyu Lee | Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription |
JP2005160464A (en) * | 2003-12-02 | 2005-06-23 | Corgentech Inc | NF-kappaB OLIGONUCLEOTIDE DECOY MOLECULE |
-
2004
- 2004-12-02 EP EP04813060A patent/EP1691817A2/en not_active Withdrawn
- 2004-12-02 US US11/004,512 patent/US7378509B2/en not_active Expired - Fee Related
- 2004-12-02 JP JP2006542829A patent/JP2007512845A/en active Pending
- 2004-12-02 WO PCT/US2004/040673 patent/WO2005056020A2/en active Application Filing
-
2006
- 2006-03-03 US US11/368,060 patent/US20070078102A1/en not_active Abandoned
- 2006-09-14 US US11/521,714 patent/US20070010474A1/en not_active Abandoned
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030013669A1 (en) * | 1991-08-21 | 2003-01-16 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
US20040138167A1 (en) * | 1991-08-21 | 2004-07-15 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
US20020177568A1 (en) * | 1992-12-07 | 2002-11-28 | Stinchcomb Dan T. | Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B |
US6262033B1 (en) * | 1995-02-11 | 2001-07-17 | Fujisawa Pharmaceutical Co., Ltd. | Remedy for diseases associated with NF-κB |
US20020098162A1 (en) * | 1995-05-12 | 2002-07-25 | Fujisawa Pharmaceutical Co., Ltd. | Remedy and preventive for diseases caused by NF-kappaB |
US20060116344A1 (en) * | 1995-05-12 | 2006-06-01 | Anges Mg, Inc. | Remedy and preventive for diseases caused by NF-kB |
US20040162250A1 (en) * | 1995-05-12 | 2004-08-19 | Fujisawa Pharmaceutical Co., Ltd. | Remedy and preventive for diseases caused by NF-kB |
US20040063614A1 (en) * | 1997-07-04 | 2004-04-01 | Fujisawa Pharmaceutical Co. Ltd. | Brain-protective agent |
US20050125054A1 (en) * | 2000-12-22 | 2005-06-09 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
US20050203612A1 (en) * | 2000-12-22 | 2005-09-15 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
US20040162251A1 (en) * | 2001-02-20 | 2004-08-19 | Ryuichi Morishita | Pharmaceutical composition containing decoy and method of using the same |
US20050175539A1 (en) * | 2001-11-22 | 2005-08-11 | Ryuichi Morishita | Compositions inhibiting rejection in organ transplantation and method of using the same |
US20040072726A1 (en) * | 2002-02-01 | 2004-04-15 | Ryuichi Morishita | Decoy-containing pharmaceutical compositions and method of using the same |
US20040109843A1 (en) * | 2002-02-01 | 2004-06-10 | Ryuichi Morishita | Pharmaceutical composition containing decoy and use of the same |
US20060135449A1 (en) * | 2002-03-29 | 2006-06-22 | Yoshiki Sawa | Decoy compositions for treating and preventing brain diseases and disorders |
US20060241066A1 (en) * | 2002-05-29 | 2006-10-26 | Tetsuya Tomita | Decoy composition for treating and preventing inflammatory disease |
US20040191328A1 (en) * | 2002-12-31 | 2004-09-30 | Warrell Raymond P. | Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia |
US20040191779A1 (en) * | 2003-03-28 | 2004-09-30 | Jie Zhang | Statistical analysis of regulatory factor binding sites of differentially expressed genes |
US20060057154A1 (en) * | 2003-03-28 | 2006-03-16 | Universiteit Utrecht Holding B.V. | Compositions for inducing of immunotolerance |
US20050182012A1 (en) * | 2003-12-02 | 2005-08-18 | Mcevoy Leslie M. | NF-kappaB oligonucleotide decoy molecules |
US20060153847A1 (en) * | 2005-01-11 | 2006-07-13 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
US20060258604A1 (en) * | 2005-05-10 | 2006-11-16 | Warren Strober | Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090143319A1 (en) * | 2005-06-06 | 2009-06-04 | Angesmg, Inc. | Transcription factor decoy |
US20100167390A1 (en) * | 2005-12-22 | 2010-07-01 | Toshohiro Nakajima | Novel Oligonucleotide and NF-kB Decoy Comprising the Same |
Also Published As
Publication number | Publication date |
---|---|
WO2005056020A8 (en) | 2006-08-31 |
US20070078102A1 (en) | 2007-04-05 |
EP1691817A2 (en) | 2006-08-23 |
WO2005056020A3 (en) | 2005-08-04 |
JP2007512845A (en) | 2007-05-24 |
US7378509B2 (en) | 2008-05-27 |
WO2005056020B1 (en) | 2005-09-22 |
US20050182012A1 (en) | 2005-08-18 |
WO2005056020A2 (en) | 2005-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070010474A1 (en) | NF-kappaB oligonucleotide decoy molecules | |
TWI784934B (en) | Compositions and methods for inhibiting gene expression of lpa | |
US8470796B2 (en) | Treatment of cancer by inhibition of IGFBPs and clusterin | |
US20030064945A1 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors | |
US20060069055A1 (en) | Delivery of polynucleotides | |
KR101605932B1 (en) | Organic compositions to treat hsf1-related diseases | |
EP3061824B1 (en) | Organic compositions to treat beta-enac-related diseases | |
US20060122136A1 (en) | Effective and stable DNA enzymes | |
KR20200023427A (en) | Compositions and Methods for Inhibiting HMGB1 Expression | |
KR101142080B1 (en) | Compositions and Methods for Treatment of Prostate and Other Cancers | |
EP3247716A2 (en) | Mir-92 inhibitors and uses thereof | |
JP2022517742A (en) | Compositions and Methods for Inhibiting HMGB1 Expression | |
WO2005056795A2 (en) | Hif oligonucleotide decoy molecules | |
JP7258362B2 (en) | Composition for anti-inflammatory | |
KR20200127211A (en) | Composition and method for inhibiting GYS2 expression | |
JP2005160464A (en) | NF-kappaB OLIGONUCLEOTIDE DECOY MOLECULE | |
EP3352765A1 (en) | MiR-19 MODULATORS AND USES THEREOF | |
Islam et al. | Increased 5-HT2A receptor expression and function following central glucocorticoid receptor knockdown in vivo | |
US20030073207A1 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors | |
US20030186909A1 (en) | Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors | |
EP2907874A1 (en) | MiR-21-3p inhibitors in skin disorders | |
CN114929336A (en) | Compounds and methods for modulating gene splicing | |
JP2024508069A (en) | Compositions and methods for inhibiting mitochondrial amidoxime reducing component 1 (MARC1) expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |